

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 November 2006 (09.11.2006)

PCT

(10) International Publication Number
WO 2006/119432 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/US2006/017157

(22) International Filing Date: 1 May 2006 (01.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/676,604 29 April 2005 (29.04.2005) US

(71) Applicant (for all designated States except US): THE GOVERNMENT OF THE U.S.A., AS REP. BY THE SEC., DEPT. OF HEALTH & HUMAN SERVICES [US/US]; NATIONAL INSTITUTE OF HEALTH, OFFICE OF TECHNOLOGY TRANSFER, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SCHMIDT, Michael [US/US]; 10209 Greenfield St., Kensington, Maryland 20895 (US). CHIORINI, John, A. [US/US]; 9611 Hillridge Dr., Kensington, Maryland 20895 (US).


(74) Agents: SPRATT, Gwendolyn, D. et al.; NEEDLE & ROSENBERG, P.C., SUITE 1000, 999 Peachtree Street, Atlanta, Georgia 30309-3915 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AI., AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GI, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: ISOLATION, CLONING AND CHARACTERIZATION OF NEW ADENO-ASSOCIATED VIRUS (AAV) SEROTYPES



(57) Abstract: The present invention provides new adeno-associated virus (AAV) viruses and vectors, and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV vectors and particles.



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

ISOLATION, CLONING AND CHARACTERIZATION OF NEW ADENO- ASSOCIATED VIRUS (AAV) SEROTYPES

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit of U.S. Provisional Application No. 60/676,604, filed April 29, 2005, which is hereby incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

Adeno-associated virus (AAV) is a member of the Parvoviridae, a virus family characterized by a single stranded linear DNA genome and a small icosahedral shaped capsid measuring about 20nm in diameter. AAV was first described as a contamination of tissue culture grown simian virus 15, a simian adenovirus and was found dependent on adenovirus for measurable replication. This led to its name, adeno-associated virus, and its classification in the genus *Dependovirus* (reviewed in Hoggan et al., 1970). AAV is a common contaminant of adenovirus samples and has been isolated from human virus samples (AAV2, AAV3, AAV5), from samples of simian virus-15 infected cells (AAV1, AAV4) as well as from stocks of avian (AAAV) (Bossis and Chiorini, 2003), bovine, canine and ovine adenovirus and laboratory adenovirus type 5 stock (AAV6). DNA spanning the entire rep-cap ORFs of AAV7 and AAV8 was amplified by PCR from heart tissue of rhesus monkeys (Gao et al., 2002). With the exception of AAVs 1 and 6, all cloned AAV isolates appear to be serologically distinct. Nine isolates have been cloned, and recombinant viral stocks have been generated from each isolated virus.

AAV appears to commonly infect humans. 50%-80% of adults in North America are seropositive for AAV. A steep rise in antibody response against AAV 1-3 was observed in the age group between 1-10 years (Blacklow et al., 1968). AAV 2 and 3 were readily isolated from anal and throat specimens from children (Blacklow et al., 1967) whereas isolation from adults was not observed. It appears that AAV spreads primarily in the young population (Hoggan, 1970). Prevalence of antibodies against AAV was found to be similar in Europe, Brazil and Japan, which suggests a global spread of AAV (Erles et al., 1999). Infection with AAV appears to be benign in man and laboratory animals. Currently, no disease has been associated with AAV infections.

AAV2 is the best characterized adeno-associated virus and will be discussed as an AAV prototype. The AAV2 genome consists of a linear single stranded DNA of 4,780 nucleotides. Both polarities of DNA are encapsulated by AAV with equal efficiency. The

AAV2 genome contains 2 open reading frames (ORF) named rep and cap. The rep ORF encodes the non-structural proteins that are essential for viral DNA replication, packaging and AAV integration. The cap ORF encodes the capsid proteins. The rep ORF is transcribed from promoters at map units P5 and P19. The rep transcripts contain an intron close to the 3' end of the rep ORF and can be alternatively spliced. The rep ORF is therefore expressed as 4 partially overlapping proteins, which were termed according to their molecular weight Rep78, 68, 52 and 40. The cap ORF is expressed from a single promoter at P40. By alternative splicing and utilization of an alternative ACG start codon, cap is expressed into the capsid proteins VP1-3 which range in size from 65-86 kDa. VP3 is the most abundant capsid protein and constitutes 80% of the AAV2 capsid. All viral transcripts terminate at a polyA signal at map unit 96.

During a productive AAV2 infection, unspliced mRNAs from the p5 promoter encoding Rep78 are the first detectable viral transcripts. In the course of infection; expression from P5, P19 and P40 increase to 1:3:18 levels respectively. The levels of spliced transcripts increased to 50% for P5, P19 products and 90% of P40 expressed RNA (Mouw and Pintel, 2000).

The AAV2 genome is terminated on both sides by inverted terminal repeats (ITRs) of 145 nucleotides (nt). 125 nt of the ITR constitute a palindrome which contains 2 internal palindromes of 21 nt each. The ITR can fold back on itself to generate a T-shaped hairpin with only 7 non-paired bases. The stem of the ITR contains a Rep binding site (RBS) and a sequence that is site and strand specifically cleaved by Rep – the terminal resolution site (TRS). The ITR is essential for AAV2 genome replication, integration and contains the packaging signals.

The single-stranded AAV2 genome is packaged into a non-enveloped icosahedral shaped capsid of about 20-25 nm diameter. The virion consists of 26% DNA and 74% protein and has a density of 1.41 g/cm³. AAV2 particles are extremely stable and can withstand heating to 60°C for 1 hour, extreme pH, and extraction with organic solvents.

Rep proteins are involved in almost every step of AAV2 replication including AAV2 genome replication, integration, and packaging. Rep78 and Rep68 possess ATPase, 3'-5' helicase, ligase and nicking activities and bind specifically to DNA. Rep52 and Rep40 appear to be involved in the encapsidation process and encode ATPase and 3'-5' helicase activities. Mutational analysis suggests a domain structure for Rep78. The N-terminal 225 aa are involved in DNA binding, DNA nicking and ligation. Rep78 and Rep68 recognize a GCTC repeat motif in the ITR as well as in a linear truncated form of the ITR (Chiorini et al., 1994)

with similar efficiencies. Rep78 and Rep68 possess a sequence and strand specific endonuclease activity, which cleaves the ITR at the terminal resolution site (TRS). Rep endonuclease activity is dependent on nucleoside triphosphate hydrolysis and presence of metal cations. Rep 78 and 68 can also bind and cleave single stranded DNA in a NTP independent manner. In addition, Rep78 catalyzes rejoining of single stranded DNA substrates originating from the AAV2 origin of replication – i.e., sequences containing a rep binding and terminal resolution element.

The central region of AAV2 Rep78, which represents the N-terminus of Rep52 and Rep40, contains the ATPase and 3'-5' helicase activities as well as nuclear localization signals. The helicase activity unwinds DNA-DNA and DNA-RNA duplexes, but not RNA-RNA. The ATPase activity is constitutive and independent of a DNA substrate. The C-terminus of Rep78 contains a potential zinc-finger domain and can inhibit the cellular serine/threonine kinase activity of PKA as well as its homolog PRKX by pseudosubstrate inhibition. Rep68 which is translated from a spliced mRNA that encodes the N-terminal 529 amino acids (aa) of Rep78 fused to 7 aa unique for Rep68, doesn't inhibit either PKA or PRKX. In addition to these biochemical activities, Rep can affect intracellular conditions by protein-protein interactions. Rep78 binds to a variety of cellular proteins including transcription factors like SP-1, high-mobility-group non-histone protein 1 (HMG-1) and the oncosuppressor p53. Overexpression of Rep results in pleiotrophic effects. Rep78 disrupts cell cycle progression and inhibits transformation by cellular and viral oncogenes. In susceptible cell lines, overexpression of Rep resulted in apoptosis and cell death. Several of Rep78 activities contribute to cytotoxicity, including its constitutive ATPase activity, interference with cellular gene expression and protein interactions.

The first step of an AAV infection is binding to the cell surface. Receptors and coreceptors for AAV2 include heparan sulfate proteoglycan, fibroblast growth factor receptor-1, and $\alpha_v\beta_5$ integrins whereas N-linked 2,3-linked sialic acid is required for AAV5 binding and transduction (Walters et al., 2001). In HeLa cells, fluorescently labeled AAV2 particles appear to enter the cell via receptor-mediated endocytosis in clathrin coated pits. More than 60% of bound virus was internalized within 10 min after infection. Labeled AAV particles are observed to have escaped from the endosome, been trafficked via the cytoplasm to the cell nucleus and accumulated perinuclear, before entering the nucleus, probably via nuclear pore complex (NPC). AAV2 particles have been detected in the nucleus, suggesting that uncoating takes place in the nucleus (Bartlett et al., 2000; Sanlioglu et al., 2000). AAV5 is internalized in

HeLa cells predominantly by clathrin coated vesicles, but to a lesser degree also in noncoated pits. AAV particles can also be trafficked intercellularly via the Golgi apparatus (Bantel-Schaal et al., 2002). At least partial uncoating of AAV5 was suggested to take place before entering the nucleus since intact AAV5 particles could not be detected in the nucleus (Bantel-Schaal et al., 2002). After uncoating, the single stranded genome is converted into duplex DNA either by leading strand synthesis or annealing of input DNA of opposite polarity. AAV replication takes place within the nucleus.

During a co-infection with a helper virus such as Adenovirus, herpes simplex virus or cytomegalovirus, AAV is capable of an efficient productive replication. The helper functions provided by Adenovirus have been studied in great detail. In human embryonic kidney 293 cells, which constitutively express the Adenovirus E1A and E1B genes, the early Adenovirus gene products of E2A, E4 and VA were found sufficient to allow replication of recombinant AAV. Allen et al. reported that efficient production of rAAV is possible in 293 cells transfected with only an E4orf6 expression plasmid (Allen et al., 2000). E1A stimulates S phase entry and induces unscheduled DNA synthesis by inactivating the pRB checkpoint at the G1/S border by interaction with pRB family proteins which results in the release of E2F (reviewed in (Ben-Israel and Kleinberger, 2002). This leads to either induction or activation of enzymes involved in nucleotide synthesis and DNA replication. Since unscheduled DNA synthesis is a strong apoptotic signal, anti-apoptotic functions are required. E1B-19k is a Bcl-2 homolog and E1B-55k is a p53 antagonist. Both proteins have anti-apoptotic functions. E4orf6 forms a complex with E1B-55k and results in degradation of p53. It is also reported to cause S-phase arrest (Ben-Israel and Kleinberger, 2002). E2A encodes a single strand DNA binding protein, which appears to be non-essential for DNA replication but effects gene expression (Chang and Shenk, 1990) (Fields 39, 40). The VA transcription unit affects AAV2 RNA stability and translation (Janik et al., 1989). E1A has a more direct effect on AAV2 gene expression. The cellular transcription factor YY-1 binds and inhibits the viral P5 promoter. E1A relieves this transcriptional block. None of the late Ad gene products have been found to be essential for AAV2 replication. The main function of the helper virus appears to be the generation of a cellular environment with active DNA replication machinery and blocked pro-apoptotic functions that allows high-level AAV replication rather than a direct involvement in AAV replication.

While AAV is usually dependent on a helper virus for efficient replication, low level AAV replication was observed under conditions of genotoxic stress (Yakinoglu et al., 1988;

Yakobson et al., 1989). AAV DNA replication and particle formation was also observed in differentiating keratinocytes in the absence of helper virus infection (Meyers et al., 2000). This demonstrates that AAV is not defective *per se* but rather depends on the helper virus to establish the favorable cellular condition and to provide factors for efficient replication

The ability of AAV vectors to infect dividing and non-dividing cells, establish long-term transgene expression, and the lack of pathogenicity has made them attractive for use in gene therapy applications. Lack of cross competition in binding experiments suggests that each AAV serotype may have a distinct mechanism of cell entry. Comparison of the cap ORFs from different serotypes has identified blocks of conserved and divergent sequence, with most of the latter residing on the exterior of the virion, thus explaining the altered tissue tropism among serotypes (19-21, 48, 56). Vectors based on new AAV serotypes may have different host range and different immunological properties, thus allowing for more efficient transduction in certain cell types. In addition, characterization of new serotypes will aid in identifying viral elements required for altered tissue tropism.

BRIEF SUMMARY OF THE INVENTION

Provided herein are adeno-associated viruses (AAV) and vectors derived therefrom. Thus, the present invention relates to AAV vectors for and methods of delivering nucleic acids to cells of subjects.

Additional advantages of the disclosed method and compositions will be set forth in part in the description which follows, and in part will be understood from the description, or may be learned by practice of the disclosed method and compositions. The advantages of the disclosed method and compositions will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the disclosed method and compositions and together with the description, serve to explain the principles of the disclosed method and compositions.

Figure 1 shows evolutionary relationship among human, non-human primate AAVs, and AAV contaminants detected in adenovirus stocks. The phylogenetic tree is based on

merged ClustalW alignments of VP1 sequences. VR numbers are identifiers of the ATCC virus collection.

Figure 2 shows rAAV6, rAAV(VR-195), and rAAV(VR-355) are neutralized by pooled human IgGs. COS cells were transduced with a pre-incubation mixture consisting of rAAV-6, rAAV(VR-195), and rAAV(VR-355) expressing GFP and human IgGs at the indicated concentrations. Twenty-four hours post-inoculation, transduction was analyzed by flow cytometry and graphed as percent transduction of the untreated control. Values are means from three experiments; error bars represent standard deviations.

Figure 3 shows inhibitory effect of heparin on of COS cell transduction. COS cells were transduced with a pre-incubation mixture consisting out of rAAV2, rAAV5, rAAV6, rAAV(VR-195), and rAAV(VR-355) expressing GFP and heparin at the indicated concentrations. 24 h post-inoculation, transduction was analyzed by flow cytometry. Values are means from three experiments; error bars represent standard deviations.

Figure 4 shows charge-dependency of AAV6, rAAV(VR-195), and rAAV(VR-355) transduction of COS cells. COS cells were transduced with rAAV6, rAAV(VR-195), and rAAV(VR-355) in medium containing the indicated concentrations of NaCl. Twenty-four hour postinoculation, transduction was analyzed by flow cytometry. Values are means from three experiments; error bars represent standard deviations

Figure 5 shows neuraminidase treatment blocks rAAV6, rAAV(VR-195), and rAAV(VR-355) transduction and cell binding. Figure 5A shows gene transfer mediated by rAAV6, rAAV(VR-195), and rAAV(VR-355) expressing GFP in COS cells, following neuraminidase pretreatment. Figure 5B shows binding. Values are means from three experiments; error bars represent standard deviations

Figure 6 shows effects of lectins on rAAV6, rAAV(VR-195), and rAAV(VR-355) transduction of COS cells. After pre-incubation with ECL, LCA, MalII or STL, COS cells were transduced with rAAV-6, rAAV(VR-195), and rAAV(VR-355) expressing GFP in the presence of the indicated lectin. Twenty-four hour post-inoculation, transduction was analyzed by flow cytometry. Values are means from two experiments done in duplicate; error bars represent standard deviations.

Figure 7 shows transduction efficiency in human cancer cell lines. The indicated cell lines were transduced with 1×10^8 particles of rAAV6, rAAV(VR-195), and rAAV(VR-355) expressing a nuclear localized GFP. Twenty-four hour post-inoculation, transduction was

analyzed by flow cytometry. Values are means from three experiments; error bars represent standard deviations. * COS cells transduction is given as transducing units/ 2×10^7 particles.

Figure 8 shows AAV6 competition. COS cells were transduced with a constant amount of rAAV6, rAAV(VR-195) or rAAV(VR-355) expressing GFP after 60 min pre-incubation with increasing titers of rAAV6-lacZ. Forty-eight hour post-inoculation, transduction was analyzed by flow cytometry. Values are means from three experiments; error bars represent standard deviations.

Figure 9 shows effects of sugars on rAAV mediated transduction. Cos cells were transduced with GFP encoding rAAVs that were pre-incubated with various sugar monomers and polymers. 24 h post-inoculation, transduction was analyzed by flow cytometry. Heparin is the attachment factor for AAV2 that mediates initial binding of AAV2 to the cell. Extracellular heparin binds to the virus and blocks the attachment of the virus to the cell. None of the sugars tested blocked transduction of AAV-X1, AAV-X5, AAV-X25 or AAV-X26.

Figure 10 shows effects of lectins on rAAV transduction of COS cells. After pre-incubation with various lectins, COS cells were transduced with rAAV-6, AAV-X1 and AAV-X25 expressing GFP in the presence of the indicated lectin. 24 h post-inoculation, transduction was analyzed by flow cytometry. All AAVs have a distinct profile on the lectin panel.

Figure 11 shows transduction efficiency of rAAVs in cell lines. Cells were transduced with various rAAV serotypes encoding GFP. Two days after inoculation, cells were analyzed for GFP expression by flow cytometry. The transduction profiles of AAV-X1, AAV-X5, AAV-X25 and AAV-X26 were different from that of known AAVs.

Figure 12 shows rAAV12 COS cell transduction is not inhibited by heparin. COS cells were transduced with a pre-incubation mixture consisting out of rAAV2-GFP, or rAAV12-GFP expressing GFP and heparin at the indicated concentrations. 24 h post-inoculation, transduction was analyzed by flow cytometry. Values are means from three experiments; error bars represent standard deviations.

Figure 13 shows rAAV12 transduction is independent of cell surface sialic acid. COS cells were pretreated with the *V. cholera* neuraminidase to remove exposed sialic acids groups before the cells were transduced with rAAV2, rAAV4, rAAV5 and rAAV12-GFP. Gene transfer was determined by flow cytometry. Values are means from three experiments; error bars represent standard deviations.

Figure 14 shows rAAV12 transduction is protease sensitive and does not require glycosphingolipids. COS cells were proteolytically digested with trypsin (A) or treated with

the glycosphingolipids synthesis inhibitors PPMP (B) prior to transduction with rAAV2-GFP, rAAV12-GFP and rBAAV-GFP. Gene transfer in these cells was compared to untreated cultures. Values are means from three experiments; error bars represent standard deviations.

Figure 15 shows extracellular mannosamine inhibits rAAV12 transduction. COS cells were transduced with a pre-incubation mixture of rAAV2-GFP, or rAAV12-GFP and mannosamine at the indicated concentrations. 24 h post-inoculation, transduction was analyzed by flow cytometry. Values are means from three experiments; error bars represent standard deviations.

Figure 16 shows rAAV12 has a broad tropism. Transduction efficiency of rAAV12 was compared to rAAV4 in 13 human cancer cell lines. Cells were transduced with particles of either rAAV12-GFP or rAAV4-GFP. Transduction was analyzed by flow cytometry 28 h after virus inoculation. Values are means from three experiments; error bars represent standard deviations.

Figure 17 shows rAAV12 is highly resistant to neutralization by human IgGs. rAAV2-GFP, rAAV6-GFP and rAAV12-GFP were incubated with pooled human IgGs prior to transduction of COS cells. 24 h post-inoculation, transduction was analyzed by flow cytometry. Transduction efficiencies relative to an untreated control were plotted. Values are means from three experiments; error bars represent standard deviations.

Figure 18 shows rAAV12 transduces salivary glands and skeletal muscles *in vivo*. Male Balb/c mice were administered 10^9 particles of either AAV2-hEPO or AAV12-hEPO by retrograde ductal delivery to both submandibular glands or in both their tibialis anterior (two injection sites per muscle). Secretion of hEPO in mouse serum was determined 4 weeks after transduction by an ELISA test. Error bars represent standard deviations.

DETAILED DESCRIPTION OF THE INVENTION

The disclosed method and compositions may be understood more readily by reference to the following detailed description of particular embodiments and the Example included therein and to the Figures and their previous and following description.

It is to be understood that the disclosed methods and compositions are not limited to specific synthetic methods, specific analytical techniques, or to particular reagents unless otherwise specified, and, as such, may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

Disclosed are materials, compositions, and components that can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed method and compositions. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a vector is disclosed and discussed and a number of modifications that can be made to a number of molecules including the promoters and ITRs are discussed, then each and every combination and permutation of the promoters and ITRs, and the modifications that are possible, are specifically contemplated unless specifically indicated to the contrary. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited, each is individually and collectively contemplated. Thus, in this example, each of the combinations A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. Likewise, any subset or combination of these is also specifically contemplated and disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. This concept applies to all aspects of this application including, but not limited to, steps in methods of making and using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the disclosed methods, and that each such combination is specifically contemplated and should be considered disclosed.

It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “a vector” includes a plurality of such vectors, reference to “the vector” is a reference to one or more vectors and equivalents thereof known to those skilled in the art, and so forth.

“Optional” or “optionally” means that the subsequently described event, circumstance, or material may or may not occur or be present, and that the description includes instances

where the event, circumstance, or material occurs or is present and instances where it does not occur or is not present.

Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, also specifically contemplated and considered disclosed is the range from the one particular value and/or to the other particular value unless the context specifically indicates otherwise. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another, specifically contemplated embodiment that should be considered disclosed unless the context specifically indicates otherwise. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint unless the context specifically indicates otherwise. Finally, it should be understood that all of the individual values and sub-ranges of values contained within an explicitly disclosed range are also specifically contemplated and should be considered disclosed unless the context specifically indicates otherwise. The foregoing applies regardless of whether in particular cases some or all of these embodiments are explicitly disclosed.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed method and compositions belong. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present method and compositions, the particularly useful methods, devices, and materials are as described. Publications cited herein and the material for which they are cited are hereby specifically incorporated by reference. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such disclosure by virtue of prior invention. No admission is made that any reference constitutes prior art. The discussion of references states what their authors assert, and applicants reserve the right to challenge the accuracy and pertinency of the cited documents. It will be clearly understood that, although a number of publications are referred to herein, such reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art.

Throughout the description and claims of this specification, the word “comprise” and variations of the word, such as “comprising” and “comprises,” means “including but not limited to,” and is not intended to exclude, for example, other additives, components, integers or steps.

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the method and compositions described herein. Such equivalents are intended to be encompassed by the following claims.

Provided herein are new recombinant adeno-associated viruses (AAVs) designated AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, and AAV-X26. The term AAVX is used herein to refer generally to the new AAVs disclosed herein. Thus, AAVX can refer to one or more or all of AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26. The application provides the isolation, subcloning, and sequencing of the disclosed AAVXs. These viruses have one or more of the characteristics described below. In one embodiment, the compositions provided herein do not include wild-type AAV. The methods provided herein can use either wild-type AAV or recombinant AAV-based delivery. Thus, in one embodiment, the methods provided herein do not use wild-type AAV.

Provided herein are recombinant AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, and AAV-X26 particles, recombinant AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, and AAV-X26 vectors and recombinant AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, and AAV-X26 virions. As used herein, "recombinant" refers to nucleic acids, vectors, polypeptides, or proteins that have been generated using DNA recombination (cloning) methods and are distinguishable from native or wild-type nucleic acids, vectors, polypeptides, or proteins. An AAVX particle is a viral particle comprising an AAVX capsid protein. A recombinant AAVX vector is a nucleic acid construct that comprises at least one unique, isolated nucleic acid of AAVX. The recombinant AAVX vector can further comprise at least one non-AAVX nucleic acid. As used herein, a "virion" refers to an infectious virus particle, and "infectious" refers to the ability of a virion to deliver genetic material to a cell. Thus, a recombinant AAVX virion is a particle containing a recombinant AAVX vector, wherein the particle can be either an AAVX particle as described herein or a non-AAVX particle. Alternatively, a recombinant AAVX virion can be an AAVX particle containing a recombinant vector, wherein the vector can be either an AAVX vector as described herein or a non-AAVX vector. An AAVX particle can further be an "empty particle", wherein the particle does not contain a nucleic acid, vector or plasmid, and is

therefore not infectious. These vectors, particles, virions, nucleic acids and polypeptides are described below.

Provided herein are nucleotide sequences of AAVX genomes and vectors and particles derived therefrom. Specifically provided is an AAVX nucleic acid vector. Thus, provided is a nucleic acid vector, comprising an AAVX-specific nucleic acid or a nucleic acid encoding an AAVX-specific protein. The AAVX-specific nucleic acid can be a pair of AAVX inverted terminal repeats (ITRs) or an AAVX promoter. The nucleic acid encoding an AAVX-specific protein can be an AAVX capsid protein or an AAVX Rep protein. Thus, the provided AAVX nucleic acid vector need only have an AAVX ITR, an AAVX promoter, an AAVX Rep or an AAVX capsid to be an AAVX nucleic acid vector.

The AAV ITR functions as an origin of replication for packaging of recombinant AAV particles. The minimum sequence necessary for this activity is the TRS site where Rep cleaves in order to replicate the virus. Minor modifications in an ITR are contemplated and are those that will not interfere with the hairpin structure formed by the ITR as described herein and known in the art. Furthermore, to be considered within the term it must retain the Rep binding site described herein. For example, the D- region of the AAV2 ITR, a single stranded region of the ITR (the D+ region is the reverse complement of the D- region), inboard of the TRS site, has been shown to bind a factor, which, depending on its phosphorylation state, correlates with the conversion of the AAV2 from a single stranded genome to a transcriptionally active form that allows for expression of the viral DNA. For example, this region is conserved between AAV2, AAV3, AAV4, and AAV6 but is divergent in AAV5 and BAAV. Further, as disclosed herein, the TRS signal (e.g., aa 176-181 of SEQ ID NO:40) and Rep Binding site (e.g., aa 195-210 of SEQ ID NO:40) is conserved between AAV2 and AAV-X26.

In one aspect, the AAVX nucleic acid vector comprises an AAVX ITR. Thus, the AAVX nucleic acid vector can comprise an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 ITR. In another aspect, the AAVX nucleic acid vector comprises an ITR from any AAV serotype. Thus, the AAVX nucleic acid vector can comprise an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, or BAAV ITR.

In one aspect, the AAVX nucleic acid vector comprises an AAVX promoter. Thus, the promoter can be an AAVX p5, p19 or p40 promoter. Thus, the promoter can be an AAV-X1 p5 promoter, an AAV-X1b p5 promoter, an AAV-X5 p5 promoter, an AAV-X19 p5 promoter,

n AAV-X21 p5 promoter, an AAV-X22 p5 promoter, an AAV-X23 p5 promoter, an AAV-X24 p5 promoter, an AAV-X25 p5 promoter, or an AAV-X26 p5 promoter.

In another aspect, the promoter can be a promoter from any of the AAV serotypes. Thus, the promoter can be an AAV1 p5 promoter, an AAV2 p5 promoter, an AAV3 p5 promoter, an AAV4 p5 promoter, AAV5 p5 promoter, an AAV6 p5 promoter, an AAV p5 promoter, a BAAV p5 promoter, or an AAVX p5 promoter.

Furthermore, smaller fragments of an AAV p5 promoter that retain promoter activity can readily be determined by standard procedures including, for example, constructing a series of deletions in the p5 promoter, linking the deletion to a reporter gene, and determining whether the reporter gene is expressed, *i.e.*, transcribed and/or translated.

In yet another aspect, the promoter of the AAVX nucleic acid vector can be any desired promoter, selected by known considerations, such as the level of expression of a nucleic acid functionally linked to the promoter and the cell type in which the vector is to be used. That is, the promoter can be tissue/cell-specific. Promoters can be prokaryotic, eukaryotic, fungal, nuclear, mitochondrial, viral or plant promoters. Promoters can be exogenous or endogenous to the cell type being transduced by the vector. Promoters can include, for example, bacterial promoters, or known strong promoters such as SV40 or the inducible metallothionein promoter. Additionally, chimeric regulatory promoters for targeted gene expression can be utilized. Examples of these regulatory systems, which are known in the art, include the tetracycline based regulatory system which utilizes the tet transactivator protein (tTA), a chimeric protein containing the VP16 activation domain fused to the tet repressor of *Escherichia coli*, the IPTG based regulatory system, the CID based regulatory system, and the Ecdysone based regulatory system (No, D., *et al.*, Proc Natl Acad Sci U S A. 93(8):3346-3351 (1996)). Other promoters include promoters derived from actin genes, immunoglobulin genes, cytomegalovirus (CMV), adenovirus, bovine papilloma virus, adenoviral promoters, such as the adenoviral major late promoter, an inducible heat shock promoter, respiratory syncytial virus, Rous sarcomas virus (RSV), etc.

In one aspect, the AAVX nucleic acid vector comprises a nucleic acid encoding an AAVX Rep protein. Thus, the Rep protein can be an AAV-X1 Rep protein, an AAV-X1b Rep protein, an AAV-X5 Rep protein, an AAV-X19 Rep protein, n AAV-X21 Rep protein, an AAV-X22 Rep protein, an AAV-X23 Rep protein, an AAV-X24 Rep protein, an AAV-X25 Rep protein, or an AAV-X26 Rep protein. In another aspect, the AAVX nucleic acid vector comprises a nucleic acid encoding a Rep protein from any AAV serotype. Thus, the AAVX

nucleic acid vector can comprise a nucleic acid encoding an AAV1 Rep protein, an AAV2 Rep protein, an AAV3 Rep protein, an AAV4 Rep protein, an AAV5 Rep protein, an AAV6 Rep protein, an AAV7 Rep protein, an AAV8 Rep protein, an AAV9 Rep protein, an AAV10 Rep protein, an AAV11 Rep protein, an AAV Rep protein, or an BAAV Rep protein. For all AAV serotypes, the AAV Rep proteins can be selected from a group consisting of Rep78, Rep68, Rep52 and Rep40.

The AAV-X1 Rep protein of an AAV-X1 nucleic acid vector can be encoded by a nucleic acid sequence comprising nucleotides 1-743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 752, 754, 755, 756, 757, 758, 759, 760, 761, 762, or 763 of SEQ ID NO:1. The AAV-X1 Rep protein can be encoded by a nucleic acid sequence of SEQ ID NO:48. The AAV-X1 Rep protein can comprise the amino acid sequence of SEQ ID NO:49. The AAV-X1b Rep protein of an AAV-X1b nucleic acid vector can be encoded by a nucleic acid sequence comprising nucleotides 1-2016, 2017, 2018, 2019, 2020, 2021, 2022, 23 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, or 2036 of SEQ ID NO:2. The AAV-X5 Rep protein of an AAV-X5 nucleic acid vector can be encoded by a nucleic acid sequence comprising nucleotides 1-1926, 1927, 1928, 1929, 1930, 1931, 1932, 1933, 1934, 1935, 1936, 1937, 1938, 1939, 1940, 1941, 1942, 1943, 1944, 1945, or 1946 of SEQ ID NO:3. The AAV-X19 Rep protein of an AAV-X19 nucleic acid vector can be encoded by a nucleic acid sequence comprising nucleotides 1-743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 752, 754, 755, 756, 757, 758, 759, 760, 761, 762, or 763 of SEQ ID NO:4. The AAV-X21 Rep protein of an AAV-X21 nucleic acid vector can be encoded by a nucleic acid sequence comprising nucleotides 1-752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, or 772 of SEQ ID NO:5. The AAV-X22 Rep protein of an AAV-X22 nucleic acid vector can be encoded by a nucleic acid sequence comprising nucleotides 1-748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, or 768 of SEQ ID NO:6. The AAV-X23 Rep protein of an AAV-X23 nucleic acid vector can be encoded by a nucleic acid sequence comprising nucleotides 1-746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, or 766 of SEQ ID NOS:7. The AAV-X24 Rep protein of an AAV-X24 nucleic acid vector can be encoded by a nucleic acid sequence comprising nucleotides 1-752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, or 772 of SEQ ID NO:8. The AAV-X25 Rep protein of an AAV-X25 nucleic acid vector can be encoded by the a nucleic acid sequence comprising nucleotides 1-974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987,

988, 989, 990, 991, 992, 993, or 994 of SEQ ID NO:9. The AAV-X25 Rep protein can be encoded by a nucleic acid sequence of SEQ ID NO:50. The AAV-X25 Rep protein can comprise the amino acid sequence of SEQ ID NO:51. The AAV-X26 Rep protein of an AAV-X26 nucleic acid vector can be encoded by the a nucleic acid sequence comprising nucleotides 1-789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, or 809 of SEQ ID NO:10. The AAV-X26 Rep protein can be encoded by a nucleic acid sequence of SEQ ID NO:52. The AAV-X26 Rep protein can comprise the amino acid sequence of SEQ ID NO:53.

In one aspect, the AAVX nucleic acid vector comprises a nucleic acid encoding an AAVX capsid protein. Thus, the capsid protein can be an AAV-X1 capsid protein, an AAV-X1b capsid protein, an AAV-X5 capsid protein, an AAV-X19 capsid protein, an AAV-X21 capsid protein, an AAV-X22 capsid protein, an AAV-X23 capsid protein, an AAV-X24 capsid protein, an AAV-X25 capsid protein, or an AAV-X26 capsid protein. In another aspect, the AAVX nucleic acid vector comprises a nucleic acid encoding a capsid protein from any AAV serotype. Thus, the AAVX nucleic acid vector can comprise a nucleic acid encoding an AAV1 capsid protein, an AAV2 capsid protein, an AAV3 capsid protein, an AAV4 capsid protein, an AAV5 capsid protein, an AAV6 capsid protein, an AAV7 capsid protein, an AAV8 capsid protein, an AAV9 capsid protein, an AAV10 capsid protein, an AAV11 capsid protein, an AAV capsid protein, or an BAAV capsid protein. For all AAV serotypes, the AAV capsid proteins can be selected from a group consisting of VP1, VP2 and VP3.

As an example, the AAV-X1 VP1 capsid protein of an AAV-X1 particle can have the amino acid sequence of SEQ ID NO:21. The AAV-X1b VP1 capsid protein of an AAV-X1b particle can have the amino acid sequence of SEQ ID NOS:22. The AAV-X5 VP1 capsid protein of an AAV-X5 particle can have the amino acid sequence of SEQ ID NO:23. The AAV-X19 VP1 capsid protein of an AAV-X19 particle can have the amino acid sequence of SEQ ID NO:24. The AAV-X21 VP1 capsid protein of an AAV-X21 particle can have the amino acid sequence of SEQ ID NO:25. The AAV-X22 VP1 capsid protein of an AAV-X22 particle can have the amino acid sequence of SEQ ID NO:26. The AAV-X23 VP1 capsid protein of an AAV-X23 particle can have the amino acid sequence of SEQ ID NO:27. The AAV-X24 VP1 capsid protein of an AAV-X24 particle can have the amino acid sequence of SEQ ID NO:28. The AAV-X25 capsid protein of an AAV-X25 particle can have the amino acid sequence of SEQ ID NO:29. The AAV-X26 capsid protein of an AAV-X26 particle can have the amino acid sequence of SEQ ID NO:30.

The AAV-X1 VP1 capsid protein of an AAV-X1 particle can be encoded by the nucleic acid sequence of SEQ ID NO:11. The AAV-X1b VP1 capsid protein of an AAV-X1b particle can be encoded by the nucleic acid sequence of SEQ ID NO:12. The AAV-X5 VP1 capsid protein of an AAV-X5 particle can be encoded by the nucleic acid sequence of SEQ ID NO:13. The AAV-X19 VP1 capsid protein of an AAV-X19 particle can be encoded by the nucleic acid sequence of SEQ ID NO:14. The AAV-X21 VP1 capsid protein of an AAV-X21 particle can be encoded by the nucleic acid sequence of SEQ ID NO:15. The AAV-X22 VP1 capsid protein of an AAV-X22 particle can be encoded by the nucleic acid sequence of SEQ ID NO:16. The AAV-X23 VP1 capsid protein of an AAV-X23 particle can be encoded by the nucleic acid sequence of SEQ ID NOS:17. The AAV-X24 VP1 capsid protein of an AAV-X24 particle can be encoded by the nucleic acid sequence of SEQ ID NO:18. The AAV-X25 VP1 capsid protein of an AAV-X25 particle can be encoded by the nucleic acid sequence of SEQ ID NO:19. The AAV-X26 VP1 capsid protein of an AAV-X26 particle can be encoded by the nucleic acid sequence of SEQ ID NO:20.

It should be recognized that any errors in any of the nucleotide sequences disclosed herein can be corrected, for example, by using the hybridization procedure described below with various probes derived from the described sequences such that the coding sequence can be re-isolated and re-sequenced. Rapid screening for point mutations can also be achieved with the use of polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP). The corresponding amino acid sequence can then be corrected accordingly. Also, since the disclosed AAV serotypes AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, and AAV-X26 are disclosed herein to be present in defined ATCC cultures, the whole virus sequence is provided by reference to the deposit.

The AAVX-derived vector provided herein can further comprise an exogenous nucleic acid functionally linked to the promoter. By "exogenous" nucleic acid is meant any nucleic acid that is not normally found in wild-type AAVX that can be inserted into a vector for transfer into a cell, tissue or organism. The exogenous nucleic acid can be a nucleic acid not normally found in the target cell, or it can be an extra copy or copies of a nucleic acid normally found in the target cell. The terms "exogenous" and "heterologous" are used herein interchangeably.

By "functionally linked" is meant that the promoter can promote expression of the exogenous nucleic acid, as is known in the art, and can include the appropriate orientation of the promoter relative to the exogenous nucleic acid. Furthermore, the exogenous nucleic acid

preferably has all appropriate sequences for expression of the nucleic acid. The nucleic acid can include, for example, expression control sequences, such as an enhancer, and necessary information processing sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences.

The exogenous nucleic acid can encode beneficial proteins or polypeptides that replace missing or defective proteins required by the cell or subject into which the vector is transferred or can encode a cytotoxic polypeptide that can be directed, *e.g.*, to cancer cells or other cells whose death would be beneficial to the subject. The exogenous nucleic acid can also encode antisense RNAs that can bind to, and thereby inactivate, mRNAs made by the subject that encode harmful proteins. The exogenous nucleic acid can also encode ribozymes that can effect the sequence-specific inhibition of gene expression by the cleavage of mRNAs. In one aspect, antisense polynucleotides can be produced from an exogenous expression cassette in an AAV5 vector construct where the expression cassette contains a sequence that promotes cell-type specific expression (Wirak *et al.*, *EMBO* 10:289 (1991)). For general methods relating to antisense polynucleotides, see *Antisense RNA and DNA*, D. A. Melton, Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1988).

Examples of exogenous nucleic acids which can be administered to a cell or subject as part of the present AAVX vector can include, but are not limited to the following: nucleic acids encoding secretory and nonsecretory proteins, nucleic acids encoding therapeutic agents, such as tumor necrosis factors (TNF), such as TNF- α ; interferons, such as interferon- α , interferon- β , and interferon- γ ; interleukins, such as IL-1, IL-1 β , and ILs -2 through -14; GM-CSF; adenosine deaminase; cellular growth factors, such as lymphokines; soluble CD4; Factor VIII; Factor IX; T-cell receptors; LDL receptor; ApoE; ApoC; alpha-1 antitrypsin; ornithine transcarbamylase (OTC); cystic fibrosis transmembrane receptor (CFTR); insulin; Fc receptors for antigen binding domains of antibodies, such as immunoglobulins; anti-HIV decoy tar elements; and antisense sequences which inhibit viral replication, such as antisense sequences which inhibit replication of hepatitis B or hepatitis non-A, non-B virus. The nucleic acid is chosen considering several factors, including the cell to be transfected. Where the target cell is a blood cell, for example, particularly useful nucleic acids to use are those which allow the blood cells to exert a therapeutic effect, such as a gene encoding a clotting factor for use in treatment of hemophilia. Another target cell is the lung airway cell, which can be used to administer nucleic acids, such as those coding for the cystic fibrosis transmembrane receptor, which could provide a gene therapeutic treatment for cystic fibrosis. Other target cells include muscle cells

where useful nucleic acids, such as those encoding cytokines and growth factors, can be transduced and the protein the nucleic acid encodes can be expressed and secreted to exert its effects on other cells, tissues and organs, such as the liver. Furthermore, the nucleic acid can encode more than one gene product, limited only, if the nucleic acid is to be packaged in a capsid, by the size of nucleic acid that can be packaged.

Furthermore, suitable nucleic acids can include those that, when transferred into a primary cell, such as a blood cell, cause the transferred cell to target a site in the body where that cell's presence would be beneficial. For example, blood cells such as TIL cells can be modified, such as by transfer into the cell of a Fab portion of a monoclonal antibody, to recognize a selected antigen. Another example would be to introduce a nucleic acid that would target a therapeutic blood cell to tumor cells. Nucleic acids useful in treating cancer cells include those encoding chemotactic factors which cause an inflammatory response at a specific site, thereby having a therapeutic effect.

Cells, particularly blood cells, muscle cells, airway epithelial cells, brain cells and endothelial cells having such nucleic acids transferred into them can be useful in a variety of diseases, syndromes and conditions. For example, suitable nucleic acids include nucleic acids encoding soluble CD4, used in the treatment of AIDS and α -antitrypsin, used in the treatment of emphysema caused by α -antitrypsin deficiency. Other diseases, syndromes and conditions in which such cells can be useful include, for example, adenosine deaminase deficiency, sickle cell deficiency, brain disorders such as Alzheimer's disease, thalassemia, hemophilia, diabetes, phenylketonuria, growth disorders and heart diseases, such as those caused by alterations in cholesterol metabolism, and defects of the immune system.

Other cells in which a gene of interest can be expressed include, but are not limited to, fibroblasts, neurons, retinal cells, kidney cells, lung cells, bone marrow stem cells, hematopoietic stem cells, retinal cells and neurons. The cells in which the gene of interest can be expressed can be dividing cells such as MDCK cells, BHK cells, HeLa cells, 3T3 cells, CV1 cells, COS7 cells, HOS cells and 293 cells. The cells can also be embryonic stem cells of mouse, rhesus, human, bovine or sheep origin, as well as stem cells of neural, hematopoietic, muscle, cardiac, immune or other origin. Non-dividing cells can also be contacted with a particle provided herein to express a gene of interest. Such cells include, but are not limited to hematopoietic stem cells and embryonic stem cells that have been rendered non-dividing.

As another example, hepatocytes can be transfected with the present vectors having useful nucleic acids to treat liver disease. For example, a nucleic acid encoding OTC can be

used to transfect hepatocytes (*ex vivo* and returned to the liver or *in vivo*) to treat congenital hyperammonemia, caused by an inherited deficiency in OTC. Another example is to use a nucleic acid encoding LDL to target hepatocytes *ex vivo* or *in vivo* to treat inherited LDL receptor deficiency. Such transfected hepatocytes can also be used to treat acquired infectious diseases, such as diseases resulting from a viral infection. For example, transduced hepatocyte precursors can be used to treat viral hepatitis, such as hepatitis B and non-A, non-B hepatitis, for example by transducing the hepatocyte precursor with a nucleic acid encoding an antisense RNA that inhibits viral replication. Another example includes transferring a vector provided herein having a nucleic acid encoding a protein, such as γ -interferon, which can confer resistance to the hepatitis virus.

For a procedure using transfected hepatocytes or hepatocyte precursors, hepatocyte precursors having a vector provided herein transferred in can be grown in tissue culture, removed from the tissue culture vessel, and introduced to the body, such as by a surgical method. In this example, the tissue would be placed directly into the liver, or into the body cavity in proximity to the liver, as in a transplant or graft. Alternatively, the cells can simply be directly injected into the liver, into the portal circulatory system, or into the spleen, from which the cells can be transported to the liver via the circulatory system. Furthermore, the cells can be attached to a support, such as microcarrier beads, which can then be introduced, such as by injection, into the peritoneal cavity. Once the cells are in the liver, by whatever means, the cells can then express the nucleic acid and/or differentiate into mature hepatocytes which can express the nucleic acid.

The provided viral particles can be administered to cells, as described herein, with a Multiplicity of Infection (MOI) of 10. The MOI is the ratio of infectious virus particles to the number of cells being infected. Thus, an MOI of 0.1 results in the average inoculation of 1 virus particle for every 10 cells. The general theory behind MOI is to introduce one infectious virus particle to every host cell that is present in the culture. However, more than one virus may infect the same cell which leaves a percentage of cells uninfected. This occurrence can be reduced by using a higher MOI to ensure that every cell is infected. The provided viral particles can therefore be administered to cells, as described herein, with a MOI of 0.01 to 100, such as for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100.

The AAVX-derived vector can include any normally occurring AAVX nucleic acid sequences. The AAVX-derived vector can also include sequences that are at least 80%, 81%,

82%, 83%, 84%, 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99%, 99.5% or 99.9% identical to the AAVX nucleic acids set forth herein. Examples of vector constructs are provided below.

The present AAVX vector or AAVX particle or recombinant AAVX virion can utilize any unique nucleic acid fragment of the AAVX disclosed herein, including the AAVX nucleic acids set forth in SEQ ID NOS:1-20. A unique fragment consists of a sequence that is not present anywhere else on a genome. A fragment is a subpart of the reference sequence, and thus is identical in sequence to the region of the parent nucleic acid of which it is a fragment. To be unique, the fragment must be of sufficient size to distinguish it from other known sequences, which is most readily determined by comparing any nucleic acid fragment to the nucleotide sequences of nucleic acids in computer databases, such as GenBank. Such comparative searches are standard in the art. Typically, a unique fragment useful as a primer or probe will be at least about 8 or 10, preferable at least 20 or 25 nucleotides in length, depending upon the specific nucleotide content of the sequence. Additionally, fragments can be, for example, at least about 30, 40, 50, 75, 100, 200 or 500 nucleotides in length and can encode polypeptides or be probes. The nucleic acid can be single or double stranded, depending upon the purpose for which it is intended. Where desired, the nucleic acid can be RNA.

It is understood that as discussed herein the use of the terms "homology" and "identity" mean the same thing as similarity. Thus, for example, if the use of the word homology is used to refer to two non-natural sequences, it is understood that this is not necessarily indicating an evolutionary relationship between these two sequences, but rather is looking at the similarity or relatedness between their nucleic acid sequences. Many of the methods for determining homology between two evolutionarily related molecules are routinely applied to any two or more nucleic acids or proteins for the purpose of measuring sequence similarity regardless of whether they are evolutionarily related.

In general, it is understood that one way to define any known variants and derivatives or those that might arise, of the disclosed nucleic acids and polypeptides herein, is through defining the variants and derivatives in terms of homology to specific known sequences. In general, variants of nucleic acids and polypeptides herein disclosed typically have at least, about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99%, 99.5% or 99.9% homology to the stated sequence or the native sequence. Those of skill in the art readily understand how to determine the homology of two

polypeptides or nucleic acids. For example, the homology can be calculated after aligning the two sequences so that the homology is at its highest level.

Another way of calculating homology can be performed by published algorithms. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman *Adv. Appl. Math.* 2: 482 (1981), by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48: 443 (1970), by the search for similarity method of Pearson and Lipman, *Proc. Natl. Acad. Sci. U.S.A.* 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI; the BLAST algorithm of Tatusova and Madden *FEMS Microbiol. Lett.* 174: 247-250 (1999) available from the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html>), or by inspection.

The same types of homology can be obtained for nucleic acids by for example the algorithms disclosed in Zuker, *M. Science* 244:48-52, 1989, Jaeger et al. *Proc. Natl. Acad. Sci. USA* 86:7706-7710, 1989, Jaeger et al. *Methods Enzymol.* 183:281-306, 1989, which are herein incorporated by reference for at least material related to nucleic acid alignment. It is understood that any of the methods typically can be used and that in certain instances the results of these various methods may differ, but the skilled artisan understands if identity is found with at least one of these methods, the sequences would be said to have the stated identity.

For example, as used herein, a sequence recited as having a particular percent homology to another sequence refers to sequences that have the recited homology as calculated by any one or more of the calculation methods described above. For example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using the Zuker calculation method even if the first sequence does not have 80 percent homology to the second sequence as calculated by any of the other calculation methods. As another example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using both the Zuker calculation method and the Pearson and Lipman calculation method even if the first sequence does not have 80 percent homology to the second sequence as calculated by the Smith and Waterman calculation method, the Needleman and Wunsch calculation method, the Jaeger calculation methods, or any of the other calculation methods. As yet another example, a first

sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using each of calculation methods (although, in practice, the different calculation methods will often result in different calculated homology percentages).

Further provided herein is an AAVX capsid protein that can combine with other capsid proteins to form an AAVX particle to contain the disclosed vectors. Also provided herein is an AAVX particle, comprising an AAVX capsid protein. The capsid protein can be selected from a group consisting of VP1, VP2 and VP3.

The AAV-X1 VP1 capsid protein of an AAV-X1 particle can have the amino acid sequence of SEQ ID NO:21. The AAV-X1b VP1 capsid protein of an AAV-X1b particle can have the amino acid sequence of SEQ ID NO:22. The AAV-X5 VP1 capsid protein of an AAV-X5 particle can have the amino acid sequence of SEQ ID NO:23. The AAV-X19 VP1 capsid protein of an AAV-X19 particle can have the amino acid sequence of SEQ ID NO:24. The AAV-X21 VP1 capsid protein of an AAV-X21 particle can have the amino acid sequence of SEQ ID NO:25. The AAV-X22 VP1 capsid protein of an AAV-X22 particle can have the amino acid sequence of SEQ ID NO:26. The AAV-X23 VP1 capsid protein of an AAV-X23 particle can have the amino acid sequence of SEQ ID NO:27. The AAV-X24 VP1 capsid protein of an AAV-X24 particle can have the amino acid sequence of SEQ ID NO:28. The AAV-X25 capsid protein of an AAV-X25 particle can have the amino acid sequence of SEQ ID NO:29. The AAV-X26 capsid protein of an AAV-X26 particle can have the amino acid sequence of SEQ ID NO:30.

The AAV-X1 VP1 capsid protein of an AAV-X1 particle can be encoded by the nucleic acid sequence of SEQ ID NO:11. The AAV-X1b VP1 capsid protein of an AAV-X1b particle can be encoded by the nucleic acid sequence of SEQ ID NO:12. The AAV-X5 VP1 capsid protein of an AAV-X5 particle can be encoded by the nucleic acid sequence of SEQ ID NO:13. The AAV-X19 VP1 capsid protein of an AAV-X19 particle can be encoded by the nucleic acid sequence of SEQ ID NO:14. The AAV-X21 VP1 capsid protein of an AAV-X21 particle can be encoded by the nucleic acid sequence of SEQ ID NO:15. The AAV-X22 VP1 capsid protein of an AAV-X22 particle can be encoded by the nucleic acid sequence of SEQ ID NO:16. The AAV-X23 VP1 capsid protein of an AAV-X23 particle can be encoded by the nucleic acid sequence of SEQ ID NO:17. The AAV-X24 VP1 capsid protein of an AAV-X24 particle can be encoded by the nucleic acid sequence of SEQ ID NO:18. The AAV-X25 VP1 capsid protein of an AAV-X25 particle can be encoded by the nucleic acid sequence of SEQ ID NO:19. The

AAV-X26 VP1 capsid protein of an AAV-X26 particle can be encoded by the nucleic acid sequence of SEQ ID NO:20.

For example, provided is an AAVX particle, comprising all three AAVX capsid proteins, *i.e.*, VP1, VP2 and VP3. Also provided is an AAVX particle, comprising each AAVX capsid protein individually or in combination. Also provided is an AAVX particle comprising VP1 and VP3 capsid proteins, *i.e.*, lacking any VP2 capsid proteins. Thus, an AAVX particle comprising an AAVX capsid protein comprises at least one AAVX capsid protein (VP1, VP2 or VP3) or a functional fragment thereof. One of skill in the art understands that it is the non-conserved amino acids that are contributing to the properties of AAVX that make it distinct from the other serotypes. Provided therefore is a capsid protein comprising a mutation, deletion or substitution in the conserved regions, including, for example, a substitution with a homologous region from another AAV serotype.

An AAVX particle comprising an AAVX capsid protein can be utilized to deliver a nucleic acid vector to a cell, tissue or subject. For example, the herein described AAVX vectors can be encapsidated in an AAVX capsid-derived particle and utilized in a gene delivery method. Furthermore, other viral nucleic acids can be encapsidated in the AAVX particle and utilized in such delivery methods. For example, an AAV1-11, AAV, or BAAV vector (e.g. AAV1-11, AAV, BAAV or AAVX ITR and nucleic acid of interest) can be encapsidated in an AAVX particle and administered. Furthermore, an AAVX chimeric capsid incorporating AAV1-11, AAV, BAAV or AAVX capsid sequences and a different AAVX capsid sequences can be generated, by standard cloning methods, selecting regions from the known sequences of each protein as desired. For example, particularly antigenic regions of the AAVX capsid protein can be replaced with the corresponding region of the AAV2 capsid protein. In addition to chimeric capsids incorporating AAV2 capsid sequences, chimeric capsids incorporating AAV1, 3-8, AAV, BAAV or AAVX capsid sequences can be generated, by standard cloning methods, selecting regions from the known sequences of each protein as desired. Alternatively a chimeric capsid can be made by the addition of a plasmid that expresses AAV1-11, AAV, BAAV or AAVX capsid proteins at a ratio with the AAVX capsid expression plasmid that allows only a few capsid proteins to be incorporated into the AAVX particle. Thus, for example, a chimeric particle may be constructed that contains 6 AAV2 capsid proteins and 54 AAVX capsid proteins if the complete capsid contains 60 capsid proteins. Methods for generating chimeric AAVs are known in the art and can be found in Rabinowitz JE, et al. J Virol. 2004 May;78(9):4421-32, herein incorporated by reference for

these methods. Examples of chimeric capsids would be to combine the VP1, 2, 3 proteins of AAVX and the VP1, 2, 3 proteins of AAV5 such that a new tropism would arise. The capsids can also be modified to alter their specific tropism by genetically altering the capsid to encode a specific ligand to a cell surface receptor.

Alternatively, the capsid can be chemically modified by conjugating a ligand to a cell surface receptor. By genetically or chemically altering the capsids, the tropism can be modified to direct AAVX to a particular cell or population of cells. The capsids can also be altered immunologically by conjugating the capsid to an antibody that recognizes a specific protein on the target cell or population of cells.

Provided are three regions in the capsid of AAVX that are on the virus surface and could tolerate substitution. These three regions in AAV-X1, AAV-X1b, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, and AAV-X25 are aa 261-271, aa 450-476, and aa 546-559. These three regions in AAV-X5 are aa 259-268, aa 448-473, and aa 543-554. These three regions in AAV-X26 are aa 260-274, aa 445-477, and aa 550-565. Thus, provided is an AAVX VP1 capsid, comprising amino acid substitutions in aa 261-271, aa 450-476, or aa 546-559 of SEQ ID NOS:21, 22, 24, 25, 26, 27, 28, or 29. Thus, also provided is an AAVX VP1 capsid, comprising amino acid substitutions in aa 259-268, aa 448-473, and aa 543-554 of SEQ ID NO:23. Thus, also provided is an AAVX VP1 capsid, comprising amino acid substitutions in aa 260-274, aa 445-477, and aa 550-565 of SEQ ID NO:30.

Other regions of the AAVX capsid could also accommodate the substitution of amino acids that would allow for epitope presentation on the surface of the virus. All of these regions would have surface exposure and the ability to support a substitution of sequence to insert the epitope while still allowing for capsid assembly. The substitutions can include non-AAVX epitopes and non-AAVX ligands.

Because of the symmetry of the AAV particles, a substitution in one subunit of the capsid will appear multiple times on the capsid surface. For example the capsid is made of approximately 50 VP3 proteins, 5 VP1 and 5 VP2. Therefore an epitope incorporated in the VP3 protein could be expressed 55 times on the surface of each particle increasing the likelihood of the epitope forming a stable interaction with its target. In some cases this may be too high of a ligand density for functional binding or this high density of epitope may interfere with capsid formation. The epitope density could be lowered by introducing another plasmid into the packaging system for production of recombinant particles and the ratio between the packaging plasmid with the modified VP3 protein and the wt VP3 protein altered to balance

the epitope density on the virus surface. Thus, the ratio between the modified VP3 and the wt VP3 can be 0:50 to 50:0, including, for example, 1:49, 2:48, 3:47, 4:46, 5:45, 6:44, 7:43, 8:42, 9:41, 10:40, 11:39, 12:38, 13:37, 14:36, 15:35, 16:34, 17:33, 18:32, 19:31, 20:30, 21:29, 22:28, 23:27, 24:27, 25:25, 26:24, 27:23, 28:22, 29:21, 30:20, 31:19, 32:18, 33:17, 34:16, 35:15, 36:14, 37:13, 38:12, 39:11, 40:10, 41:9, 42:8, 43:7, 44:6, 45:5, 46:4, 47:3, 48:2, or 49:1.

Epitopes could be incorporated into the virus capsid for the purpose of 1) altering the tropism of the virus 2) blocking an immune response directed at the virus 3) developing a host immune response to the epitope for the purpose of vaccination.

Examples of epitopes that could be added to AAVX capsids include but are not limited to:

LH receptor binding epitope

RGD integrin binding epitope

CD13 binding epitope NGRAHA SEQ ID NO:35

The Retanef polyprotein vaccine candidate for HIV-1

single chain antibody fragments directed against tumor cells

Endothelial cell binding epitope SIGYPLP SEQ ID NO:36

serpin receptor ligand, KFNKPFVFLI SEQ ID NO:37

protective B-cell epitope hemagglutinin (HA) 91-108 from influenza HA

NDV B-cell immunodominant epitope (IDE) spanning residues 447 to 455

Major immunogenic epitope for parvovirus B19 (NISLDNPLENPSSLFDLVARIK SEQ ID NO:38) that can elicit protective antibody titers.

The capsids can also be assembled into empty particles by expression in mammalian, bacterial, fungal or insect cells. For example, AAV2 particles are known to be made from VP3 and VP2 capsid proteins in baculovirus. The same basic protocol can produce an empty AAVX particle comprising AAVX capsid proteins and also full particles. The empty AAVX particles can be used to deliver, for example, antigens, drugs, proteins, or metals to cells or cells in a subject. Antigens can be directly incorporated into the capsid of an empty AAVX particle. An antigen can further be coupled via an antibody-antigen complex to the empty particle. Also disclosed is the coupling of drugs, proteins, or metals on the inside of the empty particles.

The herein described recombinant AAVX nucleic acid derived vector can be encapsidated in a viral particle. The viral particle can be a parvovirus particle. The parvovirus particle can be a dependovirus particle. The viral particle can be an AAV particle. In particular, the recombinant AAVX nucleic acid derived vector can be encapsidated in an

AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAAV, BAAV, AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 particle, a particle comprising a portion of any of these capsids, or a chimeric capsid particle as described above, by standard methods using the appropriate capsid proteins in the encapsidation process, as long as the nucleic acid vector fits within the size limitation of the particle utilized. The encapsidation process itself is standard in the art. The AAVX replication machinery, i.e. the rep initiator proteins and other functions required for replication, can be utilized to produce the AAVX genome that can be packaged in an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAAV, BAAV, AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 capsid.

The recombinant AAVX virion containing a vector can also be produced by recombinant methods utilizing multiple plasmids. In one example, the AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAAV, BAAV, AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 rep nucleic acid would be cloned into one plasmid, the AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAAV, BAAV, AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 ITR nucleic acid would be cloned into another plasmid and the AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAAV, BAAV, AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 capsid nucleic acid would be cloned on another plasmid. These plasmids would then be introduced into cells. The cells that were efficiently transduced by all three plasmids, would exhibit specific integration as well as the ability to produce AAVX recombinant virus. Additionally, two plasmids could be used where the AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAAV, BAAV, AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 rep nucleic acid would be cloned into one plasmid and the AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAAV, BAAV, AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 ITR and AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAAV, BAAV, AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 capsid would be

cloned into another plasmid. These plasmids would then be introduced into cells. The cells that were efficiently transduced by both plasmids, would exhibit specific integration as well as the ability to produce AAVX recombinant virus.

An AAV-X1, AAV-X1b, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, or AAV-X25 capsid can have about 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% homology to the polypeptide having the amino acid sequence encoded by nucleotides in SEQ ID NOS:11, 12, 14, 15, 16, 17, 18, or 19, respectively. An AAV-X5 capsid can have about 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, or 99% homology to the polypeptide having the amino acid sequence encoded by nucleotides in SEQ ID NO:13. An AAV-X26 capsid can have about 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, or 99% homology to the polypeptide having the amino acid sequence encoded by nucleotides in SEQ ID NO:20.

An AAV-X1, AAV-X1b, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, or AAV-X25 capsid protein can have about 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% homology to the protein having the amino acid sequence encoded by the nucleotides set forth in SEQ ID NOS:21, 22, 24, 25, 26, 27, 28, or 29, respectively. An AAV-X5 capsid protein can have about 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, or 99% homology to the protein having the amino acid sequence encoded by the nucleotides set forth in SEQ ID NO:23. An AAV-X26 capsid protein can have about 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, or 99% homology to the protein having the amino acid sequence encoded by the nucleotides set forth in SEQ ID NO:30.

The percent homology used to identify proteins herein, can be based on a nucleotide-by-nucleotide comparison or more preferable is based on a computerized algorithm as described herein. Variations in the amino acid sequence of the AAVX capsid protein are contemplated herein, as long as the resulting particle comprising an AAVX capsid protein remains antigenically or immunologically distinct from AAV1-11, AAV, or BAAV capsid, as can be routinely determined by standard methods. Specifically, for example, ELISA and Western blots can be used to determine whether a viral particle is antigenically or immunologically distinct from AAV2 or the other serotypes. Furthermore, the AAVX particle preferably retains tissue tropism distinction from other AAVs, such as that exemplified in the examples herein. An AAVX chimeric particle comprising at least one AAVX coat protein

may have a different tissue tropism from that of an AAVX particle consisting only of AAVX coat proteins, but is still distinct from the tropism of an AAV2 particle.

Provided herein is a recombinant AAVX virion, comprising an AAVX particle containing, *i.e.*, encapsidating, a vector comprising a pair of AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, BAAV, AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 inverted terminal repeats. The recombinant vector can further comprise an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, BAAV, AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 Rep-encoding nucleic acid. The vector encapsidated in the particle can further comprise an exogenous nucleic acid inserted between the inverted terminal repeats.

Further contemplated are chimeric recombinant ITRs that contain a rep binding site and a TRS site recognized by that Rep protein. By "Rep protein" is meant one or more of the Rep proteins, Rep 40, Rep 78, Rep 52, Rep 68. Alternatively, "Rep protein" could be all four of the Rep proteins described herein.

Examples of the combinations of ITR, Rep protein and Capsids that will produce recombinant virus include but are not limited to:

AAVX ITR + AAVX Rep + AAVX Cap=virus

AAV5 ITR + AAVX Rep + AAVX Cap=virus

AAV5 ITR + AAVX Rep + AAV1 Cap=virus

AAV5 ITR + AAVX Rep + AAV2 Cap=virus

AAV5 ITR + AAVX Rep + AAV3 Cap=virus

AAV5 ITR + AAVX Rep + AAV4 Cap=virus

AAV5 ITR + AAVX Rep + AAV5 Cap=virus

AAV5 ITR + AAVX Rep + AAV6 Cap=virus

AAV5 ITR + AAVX Rep + AAV7 Cap=virus

AAV5 ITR + AAVX Rep + AAV8 Cap=virus

AAV5 ITR + AAVX Rep + AAV9 Cap=virus

AAV5 ITR + AAVX Rep + AAV10 Cap=virus

AAV5 ITR + AAVX Rep + AAV11 Cap=virus

AAV5 ITR + AAVX Rep + AAV Cap=virus

AAV5 ITR + AAVX Rep + BAAV Cap=virus

AAVX ITR + AAV5 Rep + AAVX Cap=virus

AAVX ITR + AAV5 Rep + AAV1 Cap=virus
 AAVX ITR + AAV5 Rep + AAV2 Cap=virus
 AAVX ITR + AAV5 Rep + AAV3 Cap=virus
 AAVX ITR + AAV5 Rep + AAV4 Cap=virus
 AAVX ITR + AAV5 Rep + AAV5 Cap=virus
 AAVX ITR + AAV5 Rep + AAV6 Cap=virus
 AAVX ITR + AAV5 Rep + AAV7 Cap=virus
 AAVX ITR + AAV5 Rep + AAV8 Cap=virus
 AAVX ITR + AAV5 Rep + AAV9 Cap=virus
 AAVX ITR + AAV5 Rep + AAV10 Cap=virus
 AAVX ITR + AAV5 Rep + AAV11 Cap=virus
 AAVX ITR + AAV5 Rep + AAV Cap=virus
 AAVX ITR + AAV5 Rep + BAAV Cap=virus
 AAV1 ITR + AAV1 Rep + AAVX Cap=virus
 AAV2 ITR + AAV2 Rep + AAVX Cap=virus
 AAV3 ITR + AAV3 Rep + AAVX Cap=virus
 AAV4 ITR + AAV4 Rep + AAVX Cap=virus
 AAV5 ITR + AAV5 Rep + AAVX Cap=virus
 AAV6 ITR + AAV6 Rep + AAVX Cap=virus
 AAV7 ITR + AAV7 Rep + AAVX Cap=virus
 AAV8 ITR + AAV8 Rep + AAVX Cap=virus
 AAV9 ITR + AAV9 Rep + AAVX Cap=virus
 AAV10 ITR + AAV10 Rep + AAVX Cap=virus
 AAV11 ITR + AAV11 Rep + AAVX Cap=virus
 AAV ITR + AAV Rep + AAVX Cap=virus
 BAAV ITR + BAAV Rep + AAVX Cap=virus
 [Note that AAVX can be AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26]

One of skill in the art would know how to employ standard techniques to obtain the sequences from any of AAV1-11, AAV, BAAV or AAVX in order to combine them with AAVX sequences. Examples of AAVX sequences that can be utilized in these constructs can be found herein. Examples of AAV1 sequences that can be utilized in these constructs can be found in GenBank under Accession No. AF063497 and these sequences are hereby

incorporated in their entirety by this reference. Examples of AAV2 sequences that can be utilized in these constructs can be found in GenBank under Accession No. AF043303 and these sequences are hereby incorporated in their entirety by this reference. Examples of AAV3 sequences that can be utilized in these constructs can be found in GenBank under Accession No. NC_001729 and these sequences are hereby incorporated in their entirety by this reference. Examples of AAV4 sequences that can be utilized in these constructs can be found in GenBank under Accession No. U89790 and these sequences are hereby incorporated in their entirety by this reference. Examples of AAV5 sequences that can be utilized in these constructs can be found in GenBank under Accession No. AF085716 and these sequences are hereby incorporated in their entirety by this reference. Examples of AAV6 sequences that can be utilized in these constructs can be found in GenBank under Accession No. NC_001862 and AF028704 and these sequences are hereby incorporated in their entirety by this reference. Examples of AAV7 sequences that can be utilized in these constructs can be found in GenBank under Accession No. AF513851 and these sequences are hereby incorporated in their entirety by this reference. Examples of AAV8 sequences that can be utilized in these constructs can be found in GenBank under Accession No. AF513852 and these sequences are hereby incorporated in their entirety by this reference. Examples of AAV9 sequences that can be utilized in these constructs can be found in GenBank under Accession No. AY530579 and these sequences are hereby incorporated in their entirety by this reference. Examples of AAV10 sequences that can be utilized in these constructs can be found in GenBank under Accession No. AY631965 and these sequences are hereby incorporated in their entirety by this reference. Examples of AAV11 sequences that can be utilized in these constructs can be found in GenBank under Accession No. AY631966 and these sequences are hereby incorporated in their entirety by this reference. Examples of AAV sequences that can be utilized in these constructs can be found in GenBank under Accession No. AY186198 and these sequences are hereby incorporated in their entirety by this reference. Examples of BAAV sequences that can be utilized in these constructs can be found in GenBank Accession No. AY388617 and these sequences are hereby incorporated in their entirety by this reference.

In any of the constructs described herein, inclusion of a promoter is preferred. As used in the constructs herein, unless otherwise specified, Cap (capsid) refers to any of VP1, VP2, VP3, combinations thereof, functional fragments of any of VP1, VP2 or VP3, or chimeric

capsids as described herein. The ITRs of the constructs described herein, can be chimeric recombinant ITRs as described elsewhere in the application.

Conjugates of recombinant or wild-type AAVX virions and nucleic acids or proteins can be used to deliver those molecules to a cell. For example, the purified AAVX can be used as a vehicle for delivering DNA bound to the exterior of the virus. Examples of this are to conjugate the DNA to the virion by a bridge using poly-L-lysine or other charged molecule. Also contemplated are virosomes that contain AAVX structural proteins (AAVX capsid proteins), lipids such as DOTAP, and nucleic acids that are complexed via charge interaction to introduce DNA into cells.

Also provided herein are AAVX capsid proteins (e.g. VP1, VP2 or VP3 or combinations thereof), or AAVX particles consisting of AAVX capsid proteins, wherein the capsid proteins or particles do not contain AAV nucleic acid, vector or plasmid, and are therefore not infectious. These capsid proteins and "empty particles" can comprise other substances such as biologically active molecules (e.g., small molecules, polypeptides, or non-AAV nucleic acids). The substances can be conjugated to the capsid proteins or comprise a fusion protein with an AAVX capsid polypeptide. Alternatively, the substance can be incorporated within an AAVX empty particle. AAVX capsid proteins and empty particles can be used to deliver the substance to a target cell using the targeting ability of the capsid protein to achieve the desired tissue tropism. In addition, the empty particles can function to protect the substance from degradation or immune response.

Also provided herein are conjugates that utilize the AAVX capsid or a unique region of the AAVX capsid protein (e.g. VP1, VP2 or VP3 or combinations thereof) to introduce DNA into cells. For example, the AAVX VP1 protein or fragment thereof, can be conjugated to a DNA on a plasmid that is conjugated to a lipid. Cells can be infected using the targeting ability of the VP1 capsid protein to achieve the desired tissue tropism, specific to the AAVX. AAVX VP2 and VP3 proteins can also be utilized to introduce DNA or other molecules into cells. By further incorporating the Rep protein and the AAV TRS into the DNA-containing conjugate, cells can be transduced and targeted integration can be achieved. For example, if AAVX specific targeted integration is desired, a conjugate composed of the AAVX VP1 capsid, AAVX Rep or a fragment of AAVX Rep, AAVX TRS, the Rep binding site, the exogenous DNA of interest, and a lipid, can be utilized to achieve AAVX specific tropism and AAVX specific targeted integration in the genome.

Further provided herein are chimeric viruses where AAVX vectors can be encapsidated by herpes simplex virus (HSV) (Heister, T., et al. J Virol. 2002 Jul;76(14):7163-73), incorporated herein for its teaching of HSV/AAV hybrid vectors), baculovirus or other viruses to achieve a desired tropism associated with another virus. For example, the AAVX ITRs could be encapsidated by HSV and cells could be infected. Post-infection, the ITRs of AAVX could be acted on by AAVX Rep provided in the system or in a separate vehicle to rescue AAVX from the genome. Therefore, the cellular tropism of HSV can be combined with AAVX Rep mediated targeted integration. Other viruses that could be utilized to construct chimeric viruses include lentivirus, retrovirus, pseudotyped retroviral vectors and adenoviral vectors.

Provided herein are isolated nucleic acids of AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, and AAV-X26. For example, provided is an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:1 (AAV-X1 partial genome). Also provided is an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:2 (AAV-X1b partial genome). Also provided is an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:3 (AAV-X5 partial genome). Also provided is an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:4 (AAV-X19 partial genome). Also provided is an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:5 (AAV-X21 partial genome). Also provided is an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:6 (AAV-X22 partial genome). Also provided is an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:7 (AAV-X23 partial genome). Also provided is an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:8 (AAV-X24 partial genome). Also provided is an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:9 (AAV-X25 partial genome). Also provided is an isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:10 (AAV-X26 partial genome).

This nucleic acid, or unique portions thereof, can be inserted into vectors, such as plasmids, yeast artificial chromosomes, or other viral vector (particle), if desired, by standard cloning methods. Also provided is an isolated nucleic acid consisting essentially of the nucleotide sequence set forth in SEQ ID NOs:1-10.

The phrase "consisting essentially of" is used herein to refer to a composition that comprises the essential characteristics of the identified composition. By "essential" is meant

the characteristics that contribute to the structure or function of the disclosed molecule. Thus, any substitution, deletion or addition to the provided composition that does not significantly alter the defining characteristics of the composition are considered therein.

For example, if an amino acid sequence X is disclosed, then a provided polypeptide consisting essentially of the amino acid sequence X includes, for example, conservative amino acid substitutions (as described below) that do not significantly alter the essential characteristics of the polypeptide, e.g., secondary/ tertiary structure or function of the protein. The provided polypeptide can further constitute a fusion protein or otherwise have additional N-terminal, C-terminal, or intermediate amino acid sequences, e.g., linkers or tags. "Linker", as used herein, is an amino acid sequences or insertion that can be used to connect or separate two distinct polypeptides or polypeptide fragments, wherein the linker does not otherwise contribute to the essential function of the composition. A polypeptide provided herein, can have an amino acid linker comprising, for example, the amino acids GLS, ALS, or LLA. A "tag", as used herein, refers to a distinct amino acid sequence that can be used to detect or purify the provided polypeptide, wherein the tag does not otherwise contribute to the essential function of the composition. The provided polypeptide can further have deleted N-terminal, C-terminal or intermediate amino acids that do not contribute to the essential activity of the polypeptide.

As another example, if a nucleic acid X is disclosed, then a provided nucleic acid consisting essentially of nucleic acid sequence X, includes, for example, nucleotide substitutions that do not alter the amino acid sequence of the encoded polypeptide, i.e., due to degeneracy. If sequence X comprises introns and exons, then the provided nucleic acid can further be the cDNA sequence that lacks the introns but comprises the exons of sequence X. To the extent that specific genes within a genome are identified herein, it is further understood that the disclosure of a nucleic acid consisting essentially of the genome sequence would include fragments of the genome such as isolated sequences comprising a gene or genes within the genome.

Other characteristics of nucleic acid or amino acid sequences that are not herein considered essential include, for example, junk DNA between genes or any identifiable sequence unit, e.g., promoters, enhancers, transmembrane domains, poly-adenylation sequences, signal sequences, etc., that when substituted or removed would be presumed by one skilled in the art to not significantly alter the essential characteristics of the disclosed sequence.

Thus, the nucleotides of SEQ ID NOS:1-10 can have minor modifications and still be contemplated herein. For example, modifications that do not alter the amino acid encoded by any given codon (such as by modification of the third, "wobble," position in a codon) can readily be made, and such alterations are known in the art. Furthermore, modifications that cause a resulting neutral (conserved) amino acid substitution of a similar amino acid can be made in a coding region of the genome. Additionally, modifications as described herein for the AAVX components, such as the ITRs, the p5 promoter, etc. are contemplated herein. Furthermore, modifications to regions of SEQ ID NOS:1-10, other than in the ITR, TRS, Rep binding site and hairpin, are likely to be tolerated without serious impact on the function of the nucleic acid as a recombinant vector.

As used herein, the term "isolated" refers to a nucleic acid separated or significantly free from at least some of the other components of the naturally occurring organism, for example, the cell structural components or viral components commonly found associated with nucleic acids in the environment of the virus and/or other nucleic acids. The isolation of the native nucleic acids can be accomplished, for example, by techniques such as cell lysis followed by phenol plus chloroform extraction, followed by ethanol precipitation of the nucleic acids. The nucleic acids provided herein can be isolated from cells according to any of many methods well known in the art.

As used herein, the term "nucleic acid" refers to single- or multiple-stranded molecules which may be DNA or RNA, or any combination thereof, including modifications to those nucleic acids. The nucleic acid may represent a coding strand or its complement, or any combination thereof. Nucleic acids may be identical in sequence to the sequences which are naturally occurring for any of the genes discussed herein or may include alternative codons which encode the same amino acid as those provided herein, including that which is found in the naturally occurring sequence. These nucleic acids can also be modified from their typical structure. Such modifications include, but are not limited to, methylated nucleic acids, the substitution of a non-bridging oxygen on the phosphate residue with either a sulfur (yielding phosphorothioate deoxynucleotides), selenium (yielding phosphorselenoate deoxynucleotides), or methyl groups (yielding methylphosphonate deoxynucleotides).

Additionally provided is an isolated nucleic acid that selectively hybridizes with any nucleic acid disclosed herein, including the AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 genome (SEQ ID NOS:1-10) and any unique fragment thereof, including the Rep and capsid encoding sequences,

promoters and ITRs. Specifically, the nucleic acid can selectively or specifically hybridize to an isolated nucleic acid consisting of the nucleotide sequence set forth in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. By "selectively hybridizes" as used herein is meant a nucleic acid that hybridizes to one of the disclosed nucleic acids under sufficient stringency conditions without significant hybridization to a nucleic acid encoding an unrelated protein, and particularly, without detectably hybridizing to nucleic acids of other AAVs. Thus, a nucleic acid that selectively hybridizes with a nucleic acid provided herein will not selectively hybridize under stringent conditions with a nucleic acid encoding a different protein or the corresponding protein from a different serotype of the virus, and vice versa. A "specifically hybridizing" nucleic acid is one that hybridizes under stringent conditions to only a nucleic acid found in AAVX. Therefore, nucleic acids for use, for example, as primers and probes to detect or amplify the target nucleic acids are contemplated herein. Nucleic acid fragments that selectively hybridize to any given nucleic acid can be used, *e.g.*, as primers and or probes for further hybridization or for amplification methods (*e.g.*, polymerase chain reaction (PCR), ligase chain reaction (LCR)). Additionally, for example, a primer or probe can be designed that selectively hybridizes with both AAVX and a gene of interest carried within the AAVX vector (*i.e.*, a chimeric nucleic acid).

Stringency of hybridization is controlled by both temperature and salt concentration of either or both of the hybridization and washing steps. Typically, the stringency of hybridization to achieve selective hybridization involves hybridization in high ionic strength solution (6X SSC or 6X SSPE) at a temperature that is about 12-25°C below the T_m (the melting temperature at which half of the molecules dissociate from their hybridization partners) followed by washing at a combination of temperature and salt concentration chosen so that the washing temperature is about 5°C to 20°C below the T_m . The temperature and salt conditions are readily determined empirically in preliminary experiments in which samples of reference DNA immobilized on filters are hybridized to a labeled nucleic acid of interest and then washed under conditions of different stringencies. Hybridization temperatures are typically higher for DNA-RNA and RNA-RNA hybridizations. The washing temperatures can be used as described above to achieve selective stringency, as is known in the art. (Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989; Kunkel et al. *Methods Enzymol.* 1987:154:367, 1987). A preferable stringent hybridization condition for a DNA:DNA hybridization can be at about 68°C (in aqueous solution) in 6X SSC or 6X SSPE followed by washing at 68°C. Stringency

of hybridization and washing, if desired, can be reduced accordingly as the degree of complementarity desired is decreased, and further, depending upon the G-C or A-T richness of any area wherein variability is searched for. Likewise, stringency of hybridization and washing, if desired, can be increased accordingly as homology desired is increased, and further, depending upon the G-C or A-T richness of any area wherein high homology is desired, all as known in the art.

A nucleic acid that selectively hybridizes to any portion of the AAVX genome is contemplated herein. Therefore, a nucleic acid that selectively hybridizes to AAVX can be of longer length than the AAVX genome, it can be about the same length as the AAVX genome or it can be shorter than the AAVX genome. The length of the nucleic acid is limited on the shorter end of the size range only by its specificity for hybridization to AAVX, *i.e.*, once it is too short, typically less than about 5 to 7 nucleotides in length, it will no longer bind specifically to AAVX, but rather will hybridize to numerous background nucleic acids. Additionally contemplated herein is a nucleic acid that has a portion that specifically hybridizes to AAVX and a portion that specifically hybridizes to a gene of interest inserted within AAVX.

Provided is an isolated nucleic acid comprising an AAVX p5 promoter. Provided is an isolated nucleic acid comprising an AAVX p19 promoter. Provided is an isolated nucleic acid comprising an AAVX p40 promoter. Provided is an isolated nucleic acid comprising an AAVX ITR. Further provided is an isolated nucleic acid encoding an AAVX Rep protein. The AAVX Rep proteins are encoded by open reading frame (ORF) 1 of the AAVX genome. Examples of the AAV Rep proteins include Rep78, Rep68, Rep52 and Rep40. However, it is contemplated that the Rep nucleic acid can encode any one, two, three, or four of the four Rep proteins, in any order.

Furthermore, minor modifications are contemplated in the nucleic acid, such as silent mutations in the coding sequences, mutations that make neutral or conservative changes in the encoded amino acid sequence, and mutations in regulatory regions that do not disrupt the expression of the gene. Examples of other minor modifications are known in the art. Further modifications can be made in the nucleic acid, such as to disrupt or alter expression of one or more of the Rep proteins in order to, for example, determine the effect of such a disruption; such as to mutate one or more of the Rep proteins to determine the resulting effect, etc.

Further provided is an isolated nucleic acid encoding an AAVX Capsid protein. Furthermore, provided is a nucleic acid encoding each of the three AAVX capsid proteins,

VP1, VP2, and VP3. Thus, provided is an isolated nucleic acid encoding AAVX VP1, a nucleic acid encoding AAVX VP2, and an isolated nucleic acid encoding AAVX VP3. Thus, provided is an isolated nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:21 (AAV-X1 VP1). Thus, provided is an isolated nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:22 (AAV-X1b VP1). Thus, provided is an isolated nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:23 (AAV-X5 VP1). Thus, provided is an isolated nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:24 (AAV-X19 VP1). Thus, provided is an isolated nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:25 (AAV-X21 VP1). Thus, provided is an isolated nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:26 (AAV-X22 VP1). Thus, provided is an isolated nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:27 (AAV-X23 VP1). Thus, provided is an isolated nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:28 (AAV-X24 VP1). Thus, provided is an isolated nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:29 (AAV-X25 VP1). Thus, provided is an isolated nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:30 (AAV-X26 VP1).

Also specifically provided is an isolated nucleic acid comprising SEQ ID NO:11 (AAV-X1 VP1). Also specifically provided is an isolated nucleic acid comprising SEQ ID NO:12 (AAV-X1b VP1). Also specifically provided is an isolated nucleic acid comprising SEQ ID NO:13 (AAV-X5 VP1). Also specifically provided is an isolated nucleic acid comprising SEQ ID NO:14 (AAV-X19 VP1). Also specifically provided is an isolated nucleic acid comprising SEQ ID NO:15 (AAV-X21 VP1). Also specifically provided is an isolated nucleic acid comprising SEQ ID NO:16 (AAV-X22 VP1). Also specifically provided is an isolated nucleic acid comprising SEQ ID NO:17 (AAV-X23 VP1). Also specifically provided is an isolated nucleic acid comprising SEQ ID NO:18 (AAV-X24 VP1). Also specifically provided is an isolated nucleic acid comprising SEQ ID NO:19 (AAV-X25 VP1). Also specifically provided is an isolated nucleic acid comprising SEQ ID NO:20 (AAV-X26 VP1).

Minor modifications in the nucleotide sequences encoding the capsid, or coat, proteins are contemplated, as described above for other AAVX nucleic acids. However, in general, a modified nucleic acid encoding a capsid protein will have at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99%, 99.5% or 99.9% or 100% homology to the capsid nucleic sequences described herein e.g., SEQ ID NOS:11-20, and the capsid polypeptide encoded therein will have overall about 80%,

81%, 82%, 83%, 84%, 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99%, 99.5% or 99.9% or 100% homology with the amino acid sequence described herein, e.g., SEQ ID NOS:21-30. Isolated nucleic acids that selectively hybridize with the nucleic acids of SEQ ID NOS:11-20 under the conditions described above are also provided.

Also provided is a cell containing one or more of the herein described nucleic acids, such as the AAVX genome, AAVX ORF1 and ORF2, each AAVX Rep protein gene, or each AAVX capsid protein gene. Such a cell can be any desired cell and can be selected based upon the use intended. For example, cells can include bacterial cells, yeast cells, insect cells, human HeLa cells and simian Cos cells as well as other human and mammalian cells and cell lines. Primary cultures as well as established cultures and cell lines can be used. Nucleic acids provided herein can be delivered into cells by any selected means, in particular depending upon the target cells. Many delivery means are well-known in the art. For example, electroporation, calcium phosphate precipitation, microinjection, cationic or anionic liposomes, and liposomes in combination with a nuclear localization signal peptide for delivery to the nucleus can be utilized, as is known in the art. Additionally, if the nucleic acids are in a viral particle, the cells can simply be transduced with the virion by standard means known in the art for AAV transduction. Small amounts of the recombinant AAVX virus can be made to infect cells and produce more of itself.

Provided herein are purified AAVX polypeptides. The term "polypeptide" as used herein refers to a polymer of amino acids and includes full-length proteins and fragments thereof. Thus, "protein," polypeptide," and "peptide" are often used interchangeably herein. Substitutions can be selected by known parameters to be neutral (*see, e.g.*, Robinson WE Jr, and Mitchell WM., AIDS 4:S151-S162 (1990)). As will be appreciated by those skilled in the art, also provided herein are those polypeptides having slight variations in amino acid sequences or other properties. Such variations may arise naturally as allelic variations (*e.g.*, due to genetic polymorphism) or may be produced by human intervention (*e.g.*, by mutagenesis of cloned DNA sequences), such as induced point, deletion, insertion and substitution mutants. Minor changes in amino acid sequence are generally preferred, such as conservative amino acid replacements, small internal deletions or insertions, and additions or deletions at the ends of the molecules. Substitutions may be designed based on, for example, the model of Dayhoff, *et al.* (in *Atlas of Protein Sequence and Structure* 1978, Nat'l Biomed. Res. Found., Washington, D.C.). These modifications can result in changes in the amino acid

sequence, provide silent mutations, modify a restriction site, or provide other specific mutations. The location of any modifications to the polypeptide will often determine its impact on function. Particularly, alterations in regions non-essential to protein function will be tolerated with fewer effects on function. Elsewhere in the application regions of the AAVX proteins are described to provide guidance as to where substitutions, additions or deletions can be made to minimize the likelihood of disturbing the function of the variant.

Protein variants and derivatives are well understood to those of skill in the art and in can involve amino acid sequence modifications. For example, amino acid sequence modifications typically fall into one or more of three classes: substitutional, insertional or deletional variants. Insertions include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to four residues. Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. Typically, no more than about from 2 to 6 residues are deleted at any one site within the protein molecule. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example M13 primer mutagenesis and PCR mutagenesis. Amino acid substitutions are typically of single residues, but can occur at a number of different locations at once; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. Deletions or insertions preferably are made in adjacent pairs, i.e. a deletion of 2 residues or insertion of 2 residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final construct. The mutations must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. Substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Tables 1 and 2 and are referred to as conservative substitutions.

TABLE 1: Amino Acid Abbreviations		
Amino Acid	Abbreviations	
alanine	Ala	A
allosoleucine	Alle	
arginine	Arg	R
asparagine	Asn	N

TABLE 1: Amino Acid Abbreviations		
Amino Acid	Abbreviations	
aspartic acid	Asp	D
cysteine	Cys	C
glutamic acid	Glu	E
glutamine	Gln	Q
glycine	Gly	G
histidine	His	H
isoleucine	Ile	I
leucine	Leu	L
lysine	Lys	K
phenylalanine	Phe	F
proline	Pro	P
pyroglutamic acid	pGlu	
serine	Ser	S
threonine	Thr	T
tyrosine	Tyr	Y
tryptophan	Trp	W
valine	Val	V

TABLE 2: Amino Acid Substitutions	
Original Residue Exemplary Conservative Substitutions, others are known in the art.	
Ala	Ser
Arg	Lys; Gln
Asn	Gln; His
Asp	Glu
Cys	Ser
Gln	Asn, Lys
Glu	Asp
Gly	Pro
His	Asn; Gln
Ile	Leu; Val
Leu	Ile; Val
Lys	Arg; Gln
Met	Leu; Ile
Phe	Met; Leu; Tyr
Ser	Thr
Thr	Ser
Trp	Tyr
Tyr	Trp; Phe
Val	Ile; Leu

Substantial changes in function or immunological identity can result from selecting substitutions that are less conservative than those in Table 2, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. The

substitutions which in general are expected to produce the greatest changes in the protein properties will be those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine, in this case, (e) by increasing the number of sites for sulfation and/or glycosylation.

For example, the replacement of one amino acid residue with another that is biologically and/or chemically similar is known to those skilled in the art as a conservative substitution. For example, a conservative substitution would be replacing one hydrophobic residue for another, or one polar residue for another. The substitutions include combinations such as, for example, Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. Such conservatively substituted variations of each explicitly disclosed sequence are included within the mosaic polypeptides provided herein.

Generally, a conservative substitution is a substitution of an amino acid residue for another amino acid residue having similar biochemical properties. Typically, conservative substitutions have little to no impact on the biological activity of a resulting polypeptide. In a particular example, a conservative substitution is an amino acid substitution in a peptide that does not substantially affect the biological function of the peptide. A peptide can include one or more amino acid substitutions, for example 2-10 conservative substitutions, 2-5 conservative substitutions, 4-9 conservative substitutions, such as 2, 5 or 10 conservative substitutions.

For example, a conservative substitution in an AAVX VP1 peptide (such as a peptides encoded by SEQ ID NOS:21-30) does not substantially affect the ability of VP1 peptide to confer the unique tropism of the AAVX particle. A polypeptide can be produced to contain one or more conservative substitutions by manipulating the nucleotide sequence that encodes that polypeptide using, for example, standard procedures such as site-directed mutagenesis or PCR. Alternatively, a polypeptide can be produced to contain one or more conservative substitutions by using standard peptide synthesis methods. An alanine scan can be used to identify which amino acid residues in a protein can tolerate an amino acid substitution. In one example, the biological activity of the protein is not decreased by more than 25%, for example not more

than 20%, for example not more than 10%, when an alanine, or other conservative amino acid (such as those listed below), is substituted for one or more native amino acids.

Examples of amino acids which can be substituted for an original amino acid in a protein and which are regarded as conservative substitutions include, but are not limited to: Ser for Ala; Lys for Arg; Gln or His for Asn; Glu for Asp; Ser for Cys; Asn for Gln; Asp for Glu; Pro for Gly; Asn or Gln for His; Leu or Val for Ile; Ile or Val for Leu; Arg or Gln for Lys; Leu or Ile for Met; Met, Leu or Tyr for Phe; Thr for Ser; Ser for Thr; Tyr for Trp; Trp or Phe for Tyr; and Ile or Leu for Val.

Further information about conservative substitutions can be found in, among other locations in, Ben-Bassat et al., (J. Bacteriol. 169:751-7, 1987), O'Regan et al., (Gene 77:237-51, 1989), Sahin-Toth et al., (Protein Sci. 3:240-7, 1994), Hochuli et al., (Bio/Technology 6:1321-5, 1988) and in standard textbooks of genetics and molecular biology.

Substitutional or deletional mutagenesis can be employed to insert sites for N-glycosylation (Asn-X-Thr/Ser) or O-glycosylation (Ser or Thr). Deletions of cysteine or other labile residues also may be desirable. Deletions or substitutions of potential proteolysis sites, e.g. Arg, is accomplished for example by deleting one of the basic residues or substituting one by glutaminyl or histidyl residues.

Certain post-translational derivatizations are the result of the action of recombinant host cells on the expressed polypeptide. Glutaminyl and asparaginyl residues are frequently post-translationally deamidated to the corresponding glutamyl and asparyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the o-amino groups of lysine, arginine, and histidine side chains (T.E. Creighton, *Proteins: Structure and Molecular Properties*, W. H. Freeman & Co., San Francisco pp 79-86 [1983]), acetylation of the N-terminal amine and, in some instances, amidation of the C-terminal carboxyl.

It is understood that there are numerous amino acid and peptide analogs which can be incorporated into the disclosed compositions. For example, there are numerous D amino acids or amino acids which have a different functional substituent than the amino acids shown in Table 1 and Table 2. The opposite stereo isomers of naturally occurring peptides are disclosed, as well as the stereo isomers of peptide analogs. These amino acids can readily be incorporated into polypeptide chains by charging tRNA molecules with the amino acid of choice and engineering genetic constructs that utilize, for example, amber codons, to insert the

analog amino acid into a peptide chain in a site specific way (Thorson et al., *Methods in Molec. Biol.* 77:43-73 (1991), Zoller, *Current Opinion in Biotechnology*, 3:348-354 (1992); Ibba, *Biotechnology & Genetic Engineering Reviews* 13:197-216 (1995), Cahill et al., *TIBS*, 14(10):400-403 (1989); Benner, *TIB Tech*, 12:158-163 (1994); Ibba and Hennecke, *Bio/technology*, 12:678-682 (1994) all of which are herein incorporated by reference at least for material related to amino acid analogs).

Molecules can be produced that resemble peptides, but which are not connected via a natural peptide linkage. For example, linkages for amino acids or amino acid analogs can include $\text{CH}_2\text{NH--}$, $\text{--CH}_2\text{S--}$, $\text{--CH}_2\text{--CH}_2\text{--}$, --CH=CH-- (cis and trans), $\text{--COCH}_2\text{--}$, $\text{--CH(OH)CH}_2\text{--}$, and $\text{--CHH}_2\text{SO--}$ (These and others can be found in Spatola, A. F. in *Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins*, B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983); Spatola, A. F., *Vega Data* (March 1983), Vol. 1, Issue 3, *Peptide Backbone Modifications* (general review); Morley, *Trends Pharm Sci* (1980) pp. 463-468; Hudson, D. et al., *Int J Pept Prot Res* 14:177-185 (1979) ($\text{--CH}_2\text{NH--}$, $\text{CH}_2\text{CH}_2\text{--}$); Spatola et al. *Life Sci* 38:1243-1249 (1986) ($\text{--CH H}_2\text{--S}$); Hann J. *Chem. Soc Perkin Trans. I* 307-314 (1982) (--CH--CH-- , cis and trans); Almquist et al. *J. Med. Chem.* 23:1392-1398 (1980) ($\text{--COCH}_2\text{--}$); Jennings-White et al. *Tetrahedron Lett* 23:2533 (1982) ($\text{--COCH}_2\text{--}$); Szelke et al. *European Appln*, EP 45665 CA (1982): 97:39405 (1982) ($\text{--CH(OH)CH}_2\text{--}$); Holladay et al. *Tetrahedron. Lett* 24:4401-4404 (1983) ($\text{--C(OH)CH}_2\text{--}$); and Hruby *Life Sci* 31:189-199 (1982) ($\text{--CH}_2\text{--S--}$); each of which is incorporated herein by reference. A particularly preferred non-peptide linkage is $\text{--CH}_2\text{NH--}$. It is understood that peptide analogs can have more than one atom between the bond atoms, such as β -alanine, γ -aminobutyric acid, and the like.

Amino acid analogs and analogs and peptide analogs often have enhanced or desirable properties, such as, more economical production, greater chemical stability, enhanced pharmacological properties (half-life, absorption, potency, efficacy, etc.), altered specificity (e.g., a broad-spectrum of biological activities), reduced antigenicity, and others.

D-amino acids can be used to generate more stable peptides, because D amino acids are not recognized by peptidases and such. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place of L-lysine) can be used to generate more stable peptides. Cysteine residues can be used to cyclize or attach two or more peptides together. This can be beneficial to constrain peptides into

particular conformations. (Rizo and Gierasch Ann. Rev. Biochem. 61:387 (1992), incorporated herein by reference).

A polypeptide provided herein can be readily obtained by any of several means. For example, the polypeptide of interest can be synthesized chemically by standard methods. Additionally, the coding regions of the genes can be recombinantly expressed and the resulting polypeptide isolated by standard methods. Furthermore, an antibody specific for the resulting polypeptide can be raised by standard methods (see, *e.g.*, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1988), and the protein can be isolated from a cell expressing the nucleic acid encoding the polypeptide by selective hybridization with the antibody. This protein can be purified to the extent desired by standard methods of protein purification (see, *e.g.*, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989).

An antigenic or immunoreactive fragment of the provided compositions and methods is typically an amino acid sequence of at least about 5 consecutive amino acids, and it can be derived from the AAVX polypeptide amino acid sequence. An antigenic AAVX fragment is any fragment unique to the AAVX protein, as described herein, against which an AAVX-specific antibody can be raised, by standard methods. Thus, the resulting antibody-antigen reaction should be specific for AAVX.

By "unique fragment thereof" is meant any smaller polypeptide fragment encoded by an AAVX rep gene that is of sufficient length to be found only in the Rep polypeptide. Substitutions and modifications of the amino acid sequence can be made as described herein and, further, can include protein processing modifications, such as glycosylation, to the polypeptide. Typically, to be unique, a polypeptide fragment provided herein will be at least about 5 amino acids in length; however, unique fragments can be 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more amino acids in length. A unique polypeptide will typically comprise such a unique fragment; however, a unique polypeptide can also be determined by its overall homology. A unique polypeptide can be 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more amino acids in length. Uniqueness of a polypeptide fragment can readily be determined by standard methods such as searches of computer databases of known peptide or nucleic acid sequences or by hybridization studies to the nucleic acid encoding the protein or to the protein itself, as known in the art. The uniqueness of a polypeptide fragment can also be

determined immunologically as well as functionally. Uniqueness can be simply determined in an amino acid-by-amino acid comparison of the polypeptides.

Provided is an isolated AAVX Rep protein. An AAVX Rep polypeptide is encoded by ORF1 of AAVX. Also provided is each individual AAVX Rep protein. Provided is an isolated polypeptide, comprising AAVX Rep 52, or a unique fragment thereof. Provided is an isolated polypeptide, comprising AAV Rep 78, or a unique fragment thereof.

Further provided is an isolated AAVX Capsid protein or a unique fragment thereof. AAVX capsid protein is encoded by ORF 2 of AAVX. Further provided are the individual AAVX capsid proteins, VP1, VP2 and VP3 or unique fragments thereof. Thus, provided is an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:21 (AAV-X1 VP1). Also provided is an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:22 (AAV-X1b VP1). Also provided is an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:23 (AAV-X5 VP1). Also provided is an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:24 (AAV-X19 VP1). Also provided is an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:25 (AAV-X21 VP1). Also provided is an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:26 (AAV-X22 VP1). Also provided is an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:27 (AAV-X23 VP1). Also provided is an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:28 (AAV-X24 VP1). Also provided is an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:29 (AAV-X25 VP1). Also provided is an isolated polypeptide having the amino acid sequence set forth in SEQ ID NO:30 (AAV-X26 VP1). Further provided is an isolated polypeptide consisting essentially of the amino acid sequence set forth in SEQ ID NO:21, 22, 23, 24, 25, 26, 27, 28, 29, or 30.

By "unique fragment thereof" is meant any smaller polypeptide fragment encoded by any AAVX capsid gene that is of sufficient length to be found only in the AAVX capsid protein. Substitutions and modifications of the amino acid sequence can be made as described above and, further, can include protein processing modifications, such as glycosylation, to the polypeptide. However, an AAVX Capsid polypeptide including all three coat proteins will have greater than about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99%, 99.5% or 99.9% overall homology to the polypeptide encoded by the nucleotides set forth in SEQ ID NOS:21-30.

Also provided herein are isolated AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, and AAV-X26 viruses. In one aspect, the isolated viruses can be used to produce antibodies specific for each AAVX. Thus, provided is an isolated antibody that specifically binds an AAVX-specific protein. The isolated viruses can be used to detect antibodies specific for each AAVX.

Thus, provided is an isolated antibody that specifically binds an AAVX Rep protein, or a unique epitope thereof. Thus, also provided is an isolated antibody that specifically bind AAVX Rep 52 or AAVX Rep 78, or a unique fragment thereof. Additionally provided is an isolated antibody that specifically binds any of the AAVX capsid proteins (VP1, VP2 or VP3), a unique epitope thereof, or the polypeptide comprising all three AAVX coat proteins. Also provided is an isolated antibody that specifically binds the AAVX capsid protein having the amino acid sequence set forth in SEQ ID NO:21 (AAV-X1 VP1), or that specifically binds a unique fragment thereof. Also provided is an isolated antibody that specifically binds the AAVX capsid protein having the amino acid sequence set forth in SEQ ID NO:22 (AAV-X1b VP1), or that specifically binds a unique fragment thereof. Also provided is an isolated antibody that specifically binds the AAVX capsid protein having the amino acid sequence set forth in SEQ ID NO:23 (AAV-X5 VP1), or that specifically binds a unique fragment thereof. Also provided is an isolated antibody that specifically binds the AAVX capsid protein having the amino acid sequence set forth in SEQ ID NO:24 (AAV-X19 VP1), or that specifically binds a unique fragment thereof. Also provided is an isolated antibody that specifically binds the AAVX capsid protein having the amino acid sequence set forth in SEQ ID NO:25 (AAV-X21 VP1), or that specifically binds a unique fragment thereof. Also provided is an isolated antibody that specifically binds the AAVX capsid protein having the amino acid sequence set forth in SEQ ID NO:26 (AAV-X22 VP1), or that specifically binds a unique fragment thereof. Also provided is an isolated antibody that specifically binds the AAVX capsid protein having the amino acid sequence set forth in SEQ ID NO:27 (AAV-X23 VP1), or that specifically binds a unique fragment thereof. Also provided is an isolated antibody that specifically binds the AAVX capsid protein having the amino acid sequence set forth in SEQ ID NO:28 (AAV-X24 VP1), or that specifically binds a unique fragment thereof. Also provided is an isolated antibody that specifically binds the AAVX capsid protein having the amino acid sequence set forth in SEQ ID NO:29 (AAV-X25 VP1), or that specifically binds a unique fragment thereof. Also provided is an isolated antibody that specifically binds the AAVX capsid protein having the amino acid sequence set forth in SEQ ID NO:30 (AAV-X26 VP1), or that specifically

binds a unique fragment thereof. Again, any given antibody can recognize and bind one of a number of possible epitopes present in the polypeptide; thus only a unique portion of a polypeptide (having the epitope) needs to be present in an assay to determine if the antibody specifically binds the polypeptide.

The antibody can be a component of a composition that comprises an antibody that specifically binds the AAVX protein. The composition can further comprise, *e.g.*, serum, serum-free medium, or a pharmaceutically acceptable carrier such as physiological saline, etc.

By "an antibody that specifically binds" an AAVX polypeptide or protein is meant an antibody that selectively binds to an epitope on any portion of the AAVX peptide such that the antibody binds specifically to the corresponding AAVX polypeptide without significant background. Specific binding by an antibody further means that the antibody can be used to selectively remove the target polypeptide from a sample comprising the polypeptide or and can readily be determined by radioimmunoassay (RIA), bioassay, or enzyme-linked immunosorbant (ELISA) technology. An ELISA method effective for the detection of the specific antibody-antigen binding can, for example, be as follows: (1) bind the antibody to a substrate; (2) contact the bound antibody with a sample containing the antigen; (3) contact the above with a secondary antibody bound to a detectable moiety (*e.g.*, horseradish peroxidase enzyme or alkaline phosphatase enzyme); (4) contact the above with the substrate for the enzyme; (5) contact the above with a color reagent; (6) observe the color change.

An antibody can include antibody fragments such as Fab fragments which retain the binding activity. Antibodies can be made as described in, *e.g.*, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1988). Briefly, purified antigen can be injected into an animal in an amount and in intervals sufficient to elicit an immune response. Antibodies can either be purified directly, or spleen cells can be obtained from the animal. The cells are then fused with an immortal cell line and screened for antibody secretion. Individual hybridomas are then propagated as individual clones serving as a source for a particular monoclonal antibody.

Additionally provided is a method of screening a cell for infectivity by AAVX, comprising contacting the cell with AAVX and detecting the presence of AAVX in the cells. AAVX particles can be detected using any standard physical or biochemical methods. For example, physical methods that can be used for this detection include DNA based methods such as 1) polymerase chain reaction (PCR) for viral DNA or RNA or 2) direct hybridization with labeled probes, and immunological methods such as by 3) antibody directed against the

viral structural or non- structural proteins. Catalytic methods of viral detection include, but are not limited to, detection of site and strand specific DNA nicking activity of Rep proteins or replication of an AAV origin- containing substrate. Reporter genes can also be utilized to detect cells that transduce AAVX. For example, β -gal, green fluorescent protein or luciferase can be inserted into a recombinant AAVX. The cell can then be contacted with the recombinant AAVX, either *in vitro* or *in vivo* and a colorimetric assay could detect a color change in the cells that would indicate transduction of AAVX in the cell. Additional detection methods are outlined in Fields, *Virology*, Raven Press, New York, New York. 1996.

Provided is a method of screening a cell for infectivity by AAVX, wherein the presence of AAVX in the cells is determined by nucleic acid hybridization methods, a nucleic acid probe for such detection can comprise, for example, a unique fragment of any of the AAVX nucleic acids provided herein. The uniqueness of any nucleic acid probe can readily be determined as described herein. Additionally, the presence of AAVX in cells can be determined by fluorescence, antibodies to gene products, focus forming assays, plaque lifts, Western blots and chromogenic assays. The nucleic acid can be, for example, the nucleic acid whose nucleotide sequence is set forth in SEQ ID NOS:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or a unique fragment thereof.

Provided is a method of determining the suitability of an AAVX vector for administration to a subject comprising contacting an antibody-containing sample from the subject with an antigenic fragment of an isolated AAVX Rep or Capsid protein, and detecting an antibody-antigen reaction in the sample, the presence of a neutralizing reaction indicating the AAVX vector to be unsuitable for use in the subject. Further provided is a method of determining the presence in a subject of an AAVX-specific antibody comprising contacting an antibody-containing sample from the subject with an antigenic fragment of an isolated AAVX Rep or Capsid protein and detecting an antibody-antigen reaction in the sample, the presence of a reaction indicating the presence of an AAVX-specific antibody in the subject. The present methods of determining the suitability of an AAVX vector for administration to a subject or the presence of an AAVX-specific antibody in a subject can comprise contacting an antibody-containing sample from the subject with a unique antigenic or immunogenic fragment of an AAVX Rep protein (e.g. Rep 52, Rep 78) and detecting an antibody-antigen reaction in the sample, the presence of a reaction indicating the presence of an AAVX-specific antibody and therefore the AAVX vector to be unsuitable for use in the subject. The AAVX Rep proteins are provided herein, and their antigenic fragments are routinely determined. The AAVX

capsid protein can be used to select an antigenic or immunogenic fragment, for example from the amino acid sequence set forth in SEQ ID NO:21 (AAV-X1 VP1), the amino acid sequence set forth in SEQ ID NO:22 (AAV-X1b VP1), the amino acid sequence set forth in SEQ ID NO:23 (AAV-X5 VP1), the amino acid sequence set forth in SEQ ID NO:24 (AAV-X19 VP1), the amino acid sequence set forth in SEQ ID NO:25 (AAV-X21 VP1), the amino acid sequence set forth in SEQ ID NO:26 (AAV-X22 VP1), the amino acid sequence set forth in SEQ ID NO:27 (AAV-X23 VP1), the amino acid sequence set forth in SEQ ID NO:28 (AAV-X24 VP1), the amino acid sequence set forth in SEQ ID NO:29 (AAV-X25 VP1), or the amino acid sequence set forth in SEQ ID NO:30 (AAV-X26 VP1)

Alternatively, or additionally, an antigenic or immunogenic fragment of an isolated AAVX Rep protein can be utilized in this determination method. Any given antibody can recognize and bind one of a number of possible epitopes present in the polypeptide; thus only a unique portion of a polypeptide (having the epitope) may need to be present in an assay to determine if the antibody specifically binds the polypeptide.

The AAVX polypeptide fragments can be analyzed to determine their antigenicity, immunogenicity and/or specificity. Briefly, various concentrations of a putative immunogenically specific fragment are prepared and administered to a subject and the immunological response (e.g., the production of antibodies or cell mediated immunity) of an animal to each concentration is determined. The amounts of antigen administered depend on the subject, e.g. a human, rabbit or a guinea pig, the condition of the subject, the size of the subject, etc. Thereafter an animal so inoculated with the antigen can be exposed to the AAVX viral particle or AAVX protein to test the immunoreactivity or the antigenicity of the specific immunogenic fragment. The specificity of a putative antigenic or immunogenic fragment can be ascertained by testing sera, other fluids or lymphocytes from the inoculated animal for cross reactivity with other closely related viruses, such as AAV1-11, AAV, or BAAV.

By the "suitability of an AAVX vector for administration to a subject" is meant a determination of whether the AAVX vector will elicit a neutralizing immune response upon administration to a particular subject. A vector that does not elicit a significant immune response is a potentially suitable vector, whereas a vector that elicits a significant, neutralizing immune response (e.g. at least 90%) is thus likely to be unsuitable for use in that subject. Significance of any detectable immune response is a standard parameter understood by the skilled artisan in the field. For example, one can incubate the subject's serum with the virus,

then determine whether that virus retains its ability to transduce cells in culture. If such virus cannot transduce cells in culture, the vector likely has elicited a significant immune response.

Alternatively, or additionally, one skilled in the art could determine whether or not AAVX administration would be suitable for a particular cell type of a subject. For example, the artisan could culture muscle cells *in vitro* and transduce the cells with AAVX in the presence or absence of the subject's serum. If there is a reduction in transduction efficiency, this could indicate the presence of a neutralizing antibody or other factors that may inhibit transduction. Normally, greater than 90% inhibition would have to be observed in order to rule out the use of AAVX as a vector. However, this limitation could be overcome by treating the subject with an immunosuppressant that could block the factors inhibiting transduction.

As will be recognized by those skilled in the art, numerous types of immunoassays are available for use in the present methods to detect binding between an antibody and an AAVX polypeptide as provided herein. For instance, direct and indirect binding assays, competitive assays, sandwich assays, and the like, as are generally described in, *e.g.*, U.S. Pat. Nos. 4,642,285; 4,376,110; 4,016,043; 3,879,262; 3,852,157; 3,850,752; 3,839,153; 3,791,932; and Harlow and Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, N.Y. (1988). For example, enzyme immunoassays such as immunofluorescence assays (IFA), enzyme linked immunosorbent assays (ELISA) and immunoblotting can be readily adapted to accomplish the detection of the antibody. An ELISA method effective for the detection of the antibody bound to the antigen can, for example, be as follows: (1) bind the antigen to a substrate; (2) contact the bound antigen with a fluid or tissue sample containing the antibody; (3) contact the above with a secondary antibody specific for the antigen and bound to a detectable moiety (*e.g.*, horseradish peroxidase enzyme or alkaline phosphatase enzyme); (4) contact the above with the substrate for the enzyme; (5) contact the above with a color reagent; (6) observe color change.

The antibody-containing sample of this method can comprise any biological sample which would contain the antibody or a cell containing the antibody, such as blood, plasma, serum, bone marrow, saliva and urine.

Also provided is a method of producing the AAVX virus by transducing a cell with the nucleic acid encoding the virus.

The present method further provides a method of delivering an exogenous nucleic acid to a cell comprising administering to the cell an AAVX particle containing a vector comprising

the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

The AAV ITRs in the vector for the herein described delivery methods can be AAVX ITRs. Furthermore, the AAV ITRs in the vector for the herein described nucleic acid delivery methods can also comprise AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, or BAAV inverted terminal repeats.

Also provided is a method of delivering an exogenous nucleic acid to a subject comprising administering to a cell of or from the subject an AAVX particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, and returning the cell to the subject, thereby delivering the nucleic acid to the subject. The AAV ITRs can be any AAV ITRs, including AAVX ITRs, AAV5 ITRs and AAV2 ITRs. For example, in an *ex vivo* administration, cells are isolated from a subject by standard means according to the cell type and placed in appropriate culture medium, again according to cell type (*see, e.g.,* ATCC catalog). Viral particles are then contacted with the cells as described above, and the virus is allowed to transduce the cells. Cells can then be transplanted back into the subject's body, again by means standard for the cell type and tissue (*e. g.,* in general, U.S. Patent No. 5,399,346; for neural cells, Dunnett, S.B. and Björklund, A., eds., *Transplantation: Neural Transplantation-A Practical Approach*, Oxford University Press, Oxford (1992)). If desired, prior to transplantation, the cells can be studied for degree of transduction by the virus, by known detection means and as described herein. Cells for *ex vivo* transduction followed by transplantation into a subject can be selected from those listed above, or can be any other selected cell. Preferably, a selected cell type is examined for its capability to be transfected by AAVX. Preferably, the selected cell will be a cell readily transduced with AAVX particles; however, depending upon the application, even cells with relatively low transduction efficiencies can be useful, particularly if the cell is from a tissue or organ in which even production of a small amount of the protein or antisense RNA encoded by the vector will be beneficial to the subject.

Further provided is a method of delivering an exogenous nucleic acid to a cell in a subject comprising administering to the subject an AAVX particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to a cell in the subject. Administration can be an *ex vivo* administration directly to a cell removed from a subject, such as any of the cells listed above, followed by replacement of the cell back into the subject, or administration can be *in*

vivo administration to a cell in the subject. For *ex vivo* administration, cells are isolated from a subject by standard means according to the cell type and placed in appropriate culture medium, again according to cell type (see, e.g., ATCC catalog). Viral particles are then contacted with the cells as described above, and the virus is allowed to transfect the cells. Cells can then be transplanted back into the subject's body, again by means standard for the cell type and tissue (e.g., for neural cells, Dunnett, S.B. and Björklund, A., eds., *Transplantation: Neural Transplantation-A Practical Approach*, Oxford University Press, Oxford (1992)). If desired, prior to transplantation, the cells can be studied for degree of transfection by the virus, by known detection means and as described herein.

Further provided is a method of delivering a nucleic acid to a cell in a subject having neutralizing antibodies to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, or BAAV comprising administering to the subject an AAVX particle containing a vector comprising the nucleic acid, thereby delivering the nucleic acid to a cell in the subject. A subject that has neutralizing antibodies to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, or BAAV can readily be determined by any of several known means, such as contacting AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, or BAAV protein(s) with an antibody-containing sample, such as blood, from a subject and detecting an antigen-antibody reaction in the sample. Delivery of the AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, or BAAV particle can be by either *ex vivo* or *in vivo* administration as herein described. Thus, a subject who might have an adverse immunogenic reaction to a vector administered in an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, or BAAV viral particle can have a desired nucleic acid delivered using an AAVX particle. This delivery system can be particularly useful for subjects who have received therapy utilizing AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, or BAAV particles in the past and have developed antibodies to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, or BAAV. An AAVX regimen can now be substituted to deliver the desired nucleic acid.

In any of the methods of delivering exogenous nucleic acids to a cell or subject described herein, the AAVX-conjugated nucleic acid or AAVX particle-conjugated nucleic acids described herein can be used.

In vivo administration to a human subject or an animal model can be by any of many standard means for administering viruses, depending upon the target organ, tissue or cell. Virus particles can be administered orally, parenterally (*e.g.*, intravenously), by intramuscular injection, intrarectally, by direct tissue or organ injection, by intraperitoneal injection, topically, transdermally, via aerosol delivery, via the mucosa or the like. Viral nucleic acids (non-encapsidated) can also be administered, *e.g.*, as a complex with cationic liposomes, or encapsulated in anionic liposomes. The present compositions can include various amounts of the selected viral particle or non-encapsidated viral nucleic acid in combination with a pharmaceutically acceptable carrier and, in addition, if desired, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc. Parental administration, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Dosages will depend upon the mode of administration, the disease or condition to be treated, and the individual subject's condition, but will be that dosage typical for and used in administration of other AAV vectors, such as AAV2 vectors. Often a single dose can be sufficient; however, the dose can be repeated if desirable. Administration methods for gene delivery to the cochlea are routine and are described in Jero, J. et al. (Gene Ther. 2001 Mar 20;12(5):539-48) and Staecker H, et al. (Acta Otolaryngol. 2001 Jan;121(2):157-63), both references herein incorporated by reference for these methods.

Administration methods can be used to treat brain disorders such as Parkinson's disease, Alzheimer's disease, and demyelination disease. Other diseases that can be treated by these methods include metabolic disorders such as musculoskeletal diseases, cardiovascular disease, cancer, and autoimmune disorders.

Administration of this recombinant AAVX virion to the cell can be accomplished by any means, including simply contacting the particle, optionally contained in a desired liquid such as tissue culture medium, or a buffered saline solution, with the cells. The virion can be allowed to remain in contact with the cells for any desired length of time, and typically the virion is administered and allowed to remain indefinitely. For such *in vitro* methods, the virion can be administered to the cell by standard viral transduction methods, as known in the art and as exemplified herein. Titers of virus to administer can vary, particularly depending upon the cell type, but will be typical of that used for AAV transduction in general which is well known in the art. Additionally the titers used to transduce the particular cells in the present examples can be utilized.

The cells that can be transduced by the present recombinant AAVX virion can include any desired cell, such as the following cells and cells derived from the following tissues, human as well as other mammalian tissues, such as primate, horse, sheep, goat, pig, dog, rat, and mouse and avian species: Adipocytes, Adenocyte, Adrenal cortex, Amnion, Aorta, Ascites, Astrocyte, Bladder, Bone, Bone marrow, Brain, Breast, Bronchus, Cardiac muscle, Cecum, Cervix, Chorion, Cochlear, Colon, Conjunctiva, Connective tissue, Cornea, Dermis, Duodenum, Embryonic stem cells, Endometrium, Endothelium, Endothelial cells, Epithelial tissue, Epithelial cells, Epidermis, Esophagus, Eye, Fascia, Fibroblasts, Foreskin, Gastric, Glial cells, Glioblast, Gonad, Hepatic cells, Histocyte, Hair cells in the inner ear, auditory (organ of Corti) sensory epithelia, vestibular sensory epithelia, Ileum, Intestine, small Intestine, Jejunum, Keratinocytes, Kidney, Larynx, Leukocytes, Lipocyte, Liver, Lung, Lymph node, Lymphoblast, Lymphocytes, Macrophages, Mammary alveolar nodule, Mammary gland, Mastocyte, Maxilla, Melanocytes, Mesenchymal, Monocytes, Mouth, Myelin, Myoblasts Nervous tissue, Neuroblast, Neurons, Neuroglia, Osteoblasts, Osteogenic cells, Ovary, Palate, Pancreas, Papilloma, Peritoneum, Pituicytes, Pharynx, Placenta, Plasma cells, Pleura, Prostate, Rectum, Salivary gland, Skeletal muscle, Skin, Smooth muscle, Somatic, Spleen, Squamous, Stem cells, Stomach, Submandibular gland, Submaxillary gland, Synoviocytes, Testis, Thymus, Thyroid, Trabeculae, Trachea, Turbinate, Umbilical cord, Ureter, Uterus, and vestibular hair cells.

For example, provided herein is a method of transducing a cancer cell (e.g., lung cancer cell, non-small cell lung cancer cell), colon cell, CNS derived cell, ovarian cell, prostate cell, breast derived cell, cervical cord cell, kidney cell, salivary gland cell, or muscle cell using an AAV particle disclosed herein.

Also provided herein is a method of delivering a nucleic acid to a cancer cell (e.g., lung cancer cell, non-small cell lung cancer cell), colon cell, CNS derived cell, ovarian cell, prostate cell, breast derived cell, cervical cord cell, kidney cell, salivary gland cell, or muscle cell comprising administering to the cell an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

The cell of the provided methods can be an inner ear epithelial cell. Thus, the cell of the provided method can be an inner ear hair cell. The cell of the provided methods can be an inner or outer hair cell of the organ of Corti or a vestibular hair cell. The cell of the provided

methods can be an inner ear supporting cell such as Hensen's, phalangal, interdental, or vestibular supporting cells.

The cell of the provided method can be an airway epithelial cell. The cell of the provided method can be a columnar, goblet or basal cell.

The cell of the provided method can be a cell of the submandibular gland. The cell of the provided method can be a ductal or acinar cell.

Provided are recombinant vectors based on AAVX. Such vectors may be useful for transducing erythroid progenitor cells or cells resistant to transduction by other serotypes of AAV. These vectors may also be useful for transducing cells with a nucleic acid of interest in order to produce cell lines that could be used to screen for agents that interact with the gene product of the nucleic acid of interest. In addition to transduction of other cell types, transduction of erythroid cells would be useful for the treatment of cancer and genetic diseases which can be corrected by bone marrow transplants using matched donors. Some examples of this type of treatment include, but are not limited to, the introduction of a therapeutic gene such as genes encoding interferons, interleukins, tumor necrosis factors, adenosine deaminase, cellular growth factors such as lymphokines, blood coagulation factors such as factor VIII and IX, cholesterol metabolism uptake and transport protein such as EpoE and LDL receptor, and antisense sequences to inhibit viral replication of, for example, hepatitis or HIV.

Provided is a vector, comprising the AAVX virus as well as AAVX viral particles. While AAVX is similar to AAV1-11, the viruses are found herein to be physically and genetically distinct. These differences endow AAVX with some unique advantages, which better suit it as a vector for gene therapy.

Furthermore, as shown herein, AAVX capsid protein is distinct from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, or BAAV capsid proteins and exhibits different tissue tropism. AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, BAAV, and AAVX likely utilize distinct cellular receptors. AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, BAAV, and AAVX are serologically distinct and humans are not reported to have neutralizing antibodies to AAVX, thus in a gene therapy or gene transfer application, AAVX would allow for transduction of a patient who already possess neutralizing antibodies to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV, or BAAV either as a result of natural immunological

defense or from prior exposure to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, or BAAV vectors.

Each of the herein disclosed AAVX vectors, or vectors comprising AAVX capsid proteins, can have unique or distinct tissue tropism. As shown in Figure 11, transduction profiles of AAV-X1, AAV-X5, AAV-X25 and AAV-X26 were different from that of known AAVs. AAVX1 and AAVX25 utilize α 2-3 link sialic acid as a cell attachment factor, whereas AAVX26 does not utilize sialic acid in the transduction process. Further, AAV12 (AAVX26) can be used to transduce cells lacking cell surface heparan sulfate or glycosphingolipids. Instead, mannosamine can be part of the AAV12 receptor or attachment.

As disclosed herein, cells that can be transduced by AAV12 include, but are not limited to, non-small cell lung cancer cells (e.g., NSCLC), (e.g., A549, EKVX, NCI-H226), colon cells (e.g., HCT-15), CNS derived cells (e.g., SF-268 and SF295), ovarian cells (e.g., IGROV1), prostate cells (e.g., PC-3), breast derived cells (e.g., T-47D), kidney cells (e.g., 293T), salivary glands (e.g., ductal cells), muscle cells.

Further, many of the AAV contaminated simian adenoviruses were originally isolated from pooled primary kidney cell cultures (Hull et al. 1957, 1956, 1958) originally established as part of a vaccine development program (VR-195, VR-197, VR-198, VR-200, VR-202, VR-209 and VR-353), but also from rectal swabs (VR-204), cervical cord (VR-355) and CNS cultures (VR-207) demonstrating that the tropism of the AAVs isolated from these adenovirus stocks include cells of kidney, cervical cord and CNS origin.

Thus, provided herein is a method of transducing a cancer cell (e.g., lung cancer cell, non-small cell lung cancer cell), colon cell, CNS derived cell, ovarian cell, prostate cell, breast derived cell, cervical cord cell, kidney cell, salivary gland cell, or muscle cell using an AAV particle disclosed herein.

Thus, provided herein is a method of delivering a nucleic acid to a cancer cell (e.g., lung cancer cell, non-small cell lung cancer cell) comprising administering to the cell an AAV12 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

Thus, provided herein is a method of delivering a nucleic acid to a colon cell comprising administering to the cell an AAV12 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

Thus, provided herein is a method of delivering a nucleic acid to a CNS derived cell comprising administering to the cell an AAV12 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

Thus, provided herein is a method of delivering a nucleic acid to an ovarian cell comprising administering to the cell an AAV12 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

Thus, provided herein is a method of delivering a nucleic acid to a prostate cell comprising administering to the cell an AAV12 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

Thus, provided herein is a method of delivering a nucleic acid to a breast derived cell comprising administering to the cell an AAV12 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

Thus, provided herein is a method of delivering a nucleic acid to a cervical cord cell comprising administering to the cell an AAV12 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

Thus, provided herein is a method of delivering a nucleic acid to a kidney cell comprising administering to the cell an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

Thus, provided herein is a method of delivering a nucleic acid to a salivary gland cell comprising administering to the cell an AAV12 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

Thus, provided herein is a method of delivering a nucleic acid to a muscle cell comprising administering to the cell an AAV12 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.

VECTOR SYSTEM

Provided herein is a vector system for producing infectious virus particles having a characteristic of AAVX. As used herein, a "vector system" is a combination of one or more vectors that, when added to an appropriate cell system, can produce a recombinant AAVX virion, as provided herein. Thus, the provided vector system comprises at least one vector comprising a nucleic acid selected from the group consisting of a pair of AAV ITRs, a nucleic acid encoding an AAV capsid protein, and a nucleic acid encoding an AAV Rep protein. In addition, it is understood that an AAV vector system comprises at least one adenovirus helper plasmid.

The vector system can comprise one or more unique AAV vectors. Thus, the vector system can comprise, for example, 1, 2, 3, 4, 5, or 6 unique AAV vectors. In a three-vector system, the first AAV vector can comprise a nucleic acid encoding an AAV capsid protein, the second AAV vector can comprise a nucleic acid encoding an AAV Rep protein, and the third AAV vector can comprise a pair of AAV ITRs (Table 3). It is understood that Rep and Cap sequences can be efficiently combined in the same vector. Thus, in an example of a two-vector system, the first AAV vector can comprise a nucleic acid encoding an AAV capsid protein and a nucleic acid encoding an AAV Rep protein and the second AAV vector can comprise a pair of AAV ITRs (Table 3). It is understood that at least one AAV vector in the provided AAVX vector system comprises an AAVX capsid, Rep or ITR (Table 3).

Thus, provided is an AAV vector system, wherein the first vector can comprise a nucleic acid encoding an AAVX capsid protein and the second vector can comprise a pair of AAV ITRs. The AAV ITRs of the second vector can be a pair of AAV1 ITRs. The AAV inverted terminal repeats can be a pair of AAV2 ITRs. The AAV ITRs can be a pair of AAV3 ITRs. The AAV ITRs can be a pair of AAV4 ITRs. The AAV ITRs can be a pair of AAV5 ITRs. The AAV ITRs can be a pair of AAV6 ITRs. The AAV ITRs can be a pair of AAV7 ITRs. The AAV ITRs can be a pair of AAV8 ITRs. The AAV ITRs can be a pair of AAV9 ITRs. The AAV ITRs can be a pair of AAV10 ITRs. The AAV ITRs can be a pair of AAV11 ITRs. The AAV ITRs can be a pair of AAV ITRs. The AAV ITRs can be a pair of BAAV ITRs. The AAV ITRs can be a pair of AAVX ITRs.

Also provided is an AAV vector system, wherein the first vector can comprise a nucleic acid encoding an AAV capsid protein and the second vector can comprise a pair of AAVX ITRs. The capsid protein can be an AAV1 capsid protein. The capsid protein can be an AAV2 capsid protein. The capsid protein can be an AAV3 capsid protein. The capsid protein can be

an AAV4 capsid protein. The capsid protein can be an AAV5 capsid protein. The capsid protein can be an AAV6 capsid protein. The capsid protein can be an AAV Rep protein. The capsid protein can be a BAAV Rep protein. The capsid protein can be an AAVX Rep protein.

In either of the above vector systems, the first vector or a third vector can further comprise a nucleic acid encoding an AAV Rep protein. The AAV Rep protein can be AAV1 Rep protein. The AAV Rep protein can be AAV2 Rep protein. The AAV Rep protein can be AAV3 Rep protein. The AAV Rep protein can be AAV4 Rep protein. The AAV Rep protein can be AAV5 Rep protein. The AAV Rep protein can be AAV6 Rep protein. The AAV Rep protein can be AAV7 Rep protein. The AAV Rep protein can be AAV8 Rep protein. The AAV Rep protein can be AAV9 Rep protein. The AAV Rep protein can be AAV10 Rep protein. The AAV Rep protein can be AAV11 Rep protein. The AAV Rep protein can be AAV Rep protein. The AAV Rep protein can be BAAV Rep protein. The AAV Rep protein can be AAVX Rep protein.

Also provided is an AAV vector system, wherein the first vector can comprise a nucleic acid encoding an AAVX Rep protein and the second vector can comprise a pair of AAV ITRs. The AAV ITRs of the second vector can be a pair of AAV1 ITRs. The AAV inverted terminal repeats can be a pair of AAV2 ITRs. The AAV ITRs can be a pair of AAV3 ITRs. The AAV ITRs can be a pair of AAV4 ITRs. The AAV ITRs can be a pair of AAV5 ITRs. The AAV ITRs can be a pair of AAV6 ITRs. The AAV ITRs can be a pair of AAV7 ITRs. The AAV ITRs can be a pair of AAV8 ITRs. The AAV ITRs can be a pair of AAV9 ITRs. The AAV ITRs can be a pair of AAV10 ITRs. The AAV ITRs can be a pair of AAV11 ITRs. The AAV ITRs can be a pair of AAV ITRs. The AAV ITRs can be a pair of BAAV ITRs. The AAV ITRs can be a pair of AAVX ITRs.

The first vector or a third vector can further comprise a nucleic acid encoding an AAV Capsid protein. The capsid protein can be an AAV1 capsid protein. The capsid protein can be an AAV2 capsid protein. The capsid protein can be an AAV3 capsid protein. The capsid protein can be an AAV4 capsid protein. The capsid protein can be an AAV5 capsid protein. The capsid protein can be an AAV6 capsid protein. The capsid protein can be an AAV Rep protein. The capsid protein can be a BAAV Rep protein. The capsid protein can be an AAVX Rep protein.

Table 3: AAVX Vector Systems

First Vector	Second Vector	Third Vector
AAVX capsid + AAV Rep	AAV ITR	-
AAV capsid + AAV Rep	AAVX ITR	-
AAV capsid + AAVX Rep	AAV ITR	

AAVX capsid	AAV ITR	AAV Rep
AAV capsid	AAVX ITR	AAV Rep
AAV capsid	AAV ITR	AAVX Rep
<p>"AAV" includes: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAAV, BAAV, AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26.</p> <p>"AAVX" includes: AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26.</p>		

In either of the above vector systems, the second vector comprising a pair of AAV ITRs can further comprise a promoter between the ITRs. The promoter can be AAV2 p5 promoter. The promoter can be AAV5 p5 promoter. The promoter can be AAVX p5 promoter. Furthermore, smaller fragments of p5 promoter that retain promoter activity can readily be determined by standard procedures including, for example, constructing a series of deletions in the p5 promoter, linking the deletion to a reporter gene, and determining whether the reporter gene is expressed, *i.e.*, transcribed and/or translated. The promoter can be the AAVX p19 promoter. The promoter can be the AAVX p40 promoter. The promoter can be a promoter of any of the AAV serotypes. The promoter can be a constitutive promoter. Thus, the promoter can be CMV. The promoter can be RSV. The promoter can be LTR. The promoter can be eF1. The promoter can be beta actin promoter. The promoter can be a tissue specific promoter. The promoter can be an inducible promoter. The promoter can further be functionally linked to an exogenous nucleic acid.

Further provided is any of the disclosed vectors of the vector systems encapsidated into an AAV particle. The AAV particle can be an AAV1 virus particle comprising at least one AAV1 capsid protein. The AAV particle can be an AAV2 virus particle comprising at least one AAV2 capsid protein. The AAV particle can be an AAV3 virus particle comprising at least one AAV3 capsid protein. The AAV particle can be an AAV4 virus particle comprising at least one AAV4 capsid protein. The AAV particle can be an AAV5 virus particle comprising at least one AAV5 capsid protein. The AAV particle can be an AAV6 virus particle comprising at least one AAV6 capsid protein. The AAV particle can be an AAV7 virus particle comprising at least one AAV7 capsid protein. The AAV particle can be an AAV8 virus particle comprising at least one AAV8 capsid protein. The AAV particle can be an AAV9 virus particle comprising at least one AAV9 capsid protein. The AAV particle can be an AAV10 virus particle comprising at least one AAV10 capsid protein. The AAV particle can be an AAV11 virus particle comprising at least one AAV11 capsid protein. The AAV particle can be an AAAV virus particle comprising at least one AAAV capsid protein. The AAV particle can be a BAAV virus particle comprising

at least one BAAV capsid protein. . The AAV particle can be an AAVX virus particle comprising at least one AAVX capsid protein. The AAV particle can be a chimeric capsid virus particle (described above) comprising a capsid protein from more than one serotype of AAV.

Examples

It is understood that the disclosed method and compositions are not limited to the particular methodology, protocols, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

Example 1: Identification and Characterization of Novel AAV Isolates in ATCC Virus Stocks

Materials and Methods

Cell culture and virus propagation: 293T and COS cells were maintained in DMEM, supplemented with 10% FBS, 2mM L-glutamine, 100U/ml penicillin, and 0.1mg/ml streptomycin or RPMI with 5% FBS. SF295, MCF7, EKVX, Igrov1, CAKI, Ovar 5 cells were cultured in RPMI supplemented with 5% FBS, 2mM L-glutamine, 100U/ml penicillin, and 0.1mg/ml streptomycin. Cells were maintained at 37°C in a 5% CO₂ humidified atmosphere.

Screening for novel AAVs: 109 virus samples, obtained from the ATCC (American Type Culture Collection) as lysate of infected cells, were analyzed for the presence of AAV DNA by PCR as described earlier (Katano, H., et al. 2004. Biotechniques 36:676-80). Briefly, low molecular weight DNA was purified with High Pure Viral Nucleic Acid Kit (Roche). These DNA samples were assayed for AAV contamination by PCR using the GC Rich PCR Kit (Roche). This method detects the presence of AAV DNA by PCR using degenerative PCR primers, which were shown to amplify a fragment containing sequences of the rep and vp ORF of all known AAV serotypes. PCR using DNA isolated from ATCC VR-195, VR-197, VR-198, VR-200, VR-202, VR-204, VR-207, VR-209, VR-353, VR-355, VR-942, VR-943 as template resulted in the generation of a 1.4kb amplification product, which was subsequently cloned using the TOPO TA Cloning KIT (Invitrogen) and sequenced with an ABI Prism 3100 Genetic Analyzer (ABI) and FS dye-terminator chemistry (ABI). The obtained sequences showed homology to AAV6 rep ORF and cap ORF but were not identical to any known AAV.

Viral DNA isolation, cloning and sequencing: The rep and cap ORF of the new AAVs was PCR amplified and subcloned. Viral DNA that was isolated from VR-195, VR-197, VR-198, VR-200, VR-202, VR-204, VR-207, VR-209, VR-353, VR-355, VR-942, VR-943 was PCR amplified with primers:

AAV1-4 225(+): GCGACAKTTTGGCAGACCAAYGTGG (SEQ ID NO:31) and

UNI-NC: CCANNNGGAATCGCAATGCCAAT (SEQ ID NO:32), or

UNIC: ATGNTNATNTGGTGGGAGGAGGG (SEQ ID NO:33) and

AAV1-4 polyA4400(-): CGAATNAAMCGGTTTATTGATTAAC (SEQ ID NO:34), or

AAV 4500 (+): CAATAAACCGkTnATTCGtTCAGT (SEQ ID NO:38) and

AAV 450 (-): ACANNWGAGTCAGAAATKCCNGGCAG (SEQ ID NO:39)

(N can be A, C, G, or T; K can be G or T; Y can be C or T; M can be A or C)

to amplify the Rep ORF, capsid ORF, and ITR(3'-AAVX terminus, ITR and 3'-terminus of circular or concatemeric AAVs), respectively. The PCR products were subcloned using the TOPO TA Cloning KIT (Invitrogen) and at least three clones of each isolate were sequenced with an ABI Prism 3100 Genetic Analyzer (ABI) and FS dye-terminator chemistry (ABI). The obtained sequences showed homology to AAV1 and AAV6 but were not identical to any known AAV. As shown in Table 5, there are three naming conventions used herein. For example, the newly identified AAVs were named according to the ATCC adenovirus strains from which they were discovered (e.g., AAV(VR-943)). Also, each unique AAV isolate was assigned a temporary identifier (e.g., AAV-X26). Finally, ... (e.g., AAV-12).

Identical AAV sequences were detected in VR-195, VR-197, VR-198 and VR-202 and named AAV-X1. VR-195 also contained a homolog of AAV-X1 termed AAV-X1b.

AAV detected in VR-200 was named AAV-X19. AAV detected in VR-204 was named AAV-X21. AAV detected in VR-207 was named AAV-X22. AAV detected in VR-209 was named AAV-X23. AAV detected in VR-353 was named AAV-X24. AAV detected in VR-355 was named AAV-X25. AAV detected in VR-942 was named AAV-X5. AAV detected in VR-943 was named AAV-X26. (Table 5).

Sequence analysis: DNA and protein sequence alignments were performed using the Clustal W multiple sequence alignment tool of the Biology Workbench web based software (SDSC), MacVector 7 (Oxford Molecular). The sequences amplified from ATCC virus stocks were compared to sequences in GenBank using BLAST (Basic Local Alignment Search Tool at <http://www.ncbi.nlm.nih.gov/BLAST/>). DNA alignments were performed using the

ClustalW multiple sequence alignment tool of the Biology Workbench web based software at <http://seqtool.sdsc.edu> (SDSC) and MacVector 7 (Accelrys, Burlington, MA). Divergent amino acids in VP1 were mapped on the capsid by superimposing the VP1 sequence onto a pseudoatomic structure for AAV-6. The AAV6 crystal structure was predicted by remodeling the AAV2 capsid structure, obtained from the Virus Particle Explorer, at the Swiss-Model server with the AAV6 capsid sequence.

AAV-X17 partial ITR sequence was 98% identical to corresponding AAV2 ITR sequence. AAV-X22 partial ITR sequence was 99% identical to corresponding AAV2 ITR sequence. AAV-X25 partial ITR sequence was 96% identical to corresponding AAV1 ITR sequence. AAV-X26 was only about 80% identical to corresponding AAV2 ITR sequence. However, the TRS signal (e.g., aa 176-181 of SEQ ID NO:40) and Rep Binding site (e.g., aa 195-210 of SEQ ID NO:40) were conserved in AAV-X26 ITR as compared to the AAV2 ITR.

Generation of recombinant virus: Recombinant AAV-X1, AAV-X1b, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, AAV-X5, and AAV-X26 were generated by transfecting 293 T cells with AAV2 vector plasmid (AAV2-NLS-GFP) consisting of an GFP expression cassette flanked by AAV-2 ITRs and AAV-X1, AAV-X1b, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, AAV-X5, or AAV-X26 packaging (subcloned UNI-C/ AAV1-4 polyA4400(-) PCR fragment), an AAV-2 like Rep expression plasmid, AAV-X26_Rep, (subcloned AAV-X26 Rep ORF, AAV1-4 225(+)) and UNI-NC PCR fragment), and Ad helper plasmids, 449B, which provided the essential adenovirus functions that are required for AAV replication (Smith, R. H., et al. (2002). *Biotechniques* 33(1): 204-6, 208, 210-1). Two confluent T175 flasks of 293T cells were harvested, resuspended in 100ml DMEM 10%FCS, seeded in five 150mm plates and incubated at 37 °C, 5% CO₂ until cells are 80% confluent (typically 48h). Cells were transfected with 15µg pAAV2-NLS-GFP, 10µg AAV-X1, AAV-X1b, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, AAV-X5, or AAV-X26 packaging plasmid, 5µg AAV-X26_Rep and 30µg p449B. 48h after transfection, cells were harvested, washed with PBS and resuspended in 11ml TD buffer (0.14 M NaCl, 5.0 mM KCl, 0.7 mM K₂HPO₄, 25.0 mM Tris, pH7.4. Cells were lysed by 3 freeze thaw cycles and incubated for 30 minutes at 37°C after adding benzonase to a final concentration of 20 U/ml sodium deoxycholate (final concentration of 0.5%). After adding 0.55g/ml CsCl, the lysate was fractionated using density gradient centrifugation in a SW41 rotor for 48h at 38,000 rpm. The gradients were harvested in 0.5 ml aliquots. Aliquots were assayed for infectivity and DNase-resistant genome copy titers of the

vector preparations were determined by quantitative real-time PCR using the TAQMAN system (Applied Biosystems, Inc. (ABI), Foster City, CA) with probes specific to the CMV promoter.

Recombinant virus was successfully generated using each of the AAVX packaging plasmids with AAV2 ITR vector plasmids and AAV-X26 rep plasmids. Recombinant virus was also successfully generated using Rep plasmids derived from each of the AAVX viruses in combination with AAV2 ITR vector plasmids. There is therefore sufficient homology between AAVX and AAV2 Rep and ITR sequences that they can be used interchangeably in the herein provided vectors and vector systems:

Neutralization assay: Exponentially growing COS cells were plated at a density of 5×10^3 /well in a flat-bottom 96-well plate. Twenty-four hours after seeding, cells were incubated for 60 min with 2×10^6 rAAV particles that were pre-incubated with serial dilutions of pooled human IgGs (Immune Globuline Intravenous, 10%, Gamunex, BAYER, Leverkusen, Germany). Twenty-four hours after infection, cells were analyzed for GFP expression with the Guava PCA-96 (Guava Technologies, Hayward, CA) fluorescent cell counter. GFP expression was used as a surrogate marker for transduction efficiency.

Determination of tissue tropism: Transduction efficiency of recombinant AAV-X1, AAV-X1b, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, AAV-X5, or AAV-X26 vector containing an expression cassette for GFP was analyzed in cancer cell lines. Cells were infected with dilutions ranging from 10^6 to 10^9 particles/well. 24-48h after infection, cells were analyzed for GFP expression by flow cytometry.

Neuraminidase treatment: To analyze if sialic acid is required for transduction of AAV-X1 and AAV-X25, neuraminidases were used to digest cell surface sialic acid before infection. Cos cells were seeded at 5,000 cells/well in a 96 well plate. 24h after seeding, cells were incubated for 60 min with a broad spectrum neuraminidase from *Arthrobacter ureafaciens* (0.05-1U/ml) or a 2-3 linkage specific neuraminidase from *S. pneumoniae* (0.04-0.2U/ml) (Calbiochem, La Jolla, CA). Cells were washed and transduced with a multiplicity of infection (MOI) of 500 with recombinant AAV6, AAV-X1 or AAV-X25 particles expressing GFP. Cells were analyzed for GFP expression by flow cytometry with the Guava PCA-96 (Guava Technologies) 24 h after transduction.

Binding assay: COS cells were seeded at 5000 cells/well in a 96-well plate. Forty-eight hours after seeding, cells were incubated for 60 min at 37°C with neuraminidases from *A. ureafaciens* (0.1 U/ml), *S. pneumoniae* (0.08 U/ml) (Calbiochem) or mock. Cells were then

chilled for 30 min at 4°C and then incubated for 60 min at 4°C with 5×10^7 recombinant AAV6, AAV(VR-195), or AAV(VR-355) particles expressing GFP. Cells were then washed twice with cold medium and phosphate buffered saline (PBS) and lysed in 50 µl PCRNGo buffer (Pierce). Copy numbers of cell-associated vector genomes in the cell lysates were determined by quantitative real-time PCR using the TAQMAN system (Applied Biosystems) with probes specific to the CMV promoter.

Lectin competition: COS cells were seeded at 5,000-10,000 cells/well in a 96 well plate. 16-24h after seeding, cells were precubated for 30 min at 4°C with 100 µg/ml of either ConA, MalII, LCA, ECL, WGA, UEA I, DBA, PNA, SBA, GSL I, PSA, LCA, PHA-E, PHA-L, SJA, succinylated WGA. Subsequently, cells were washed and transduced for 60 min at 4°C with 3000 transducing units or 10^8 recombinant AAV-2, AAV-4, AAV-5, AAV-6, BAAV, AAV-X1, AAV-X5, AAV-X25 or AAV-X26 particles expressing GFP in 50 µl medium supplemented with lectins (100 µg/ml). 24h after transduction, cells were analyzed for GFP expression by flow cytometry.

Sugar competition: COS cells were seeded at 5,000 cells/well in a 96 well plate. 24h after seeding, cells were precubated for 30 min at 4°C before being transduced for 60 min at 4°C with 10^8 recombinant AAV-2, AAV-4, AAV-5, AAV-6, BAAV, AAV-X1, AAV-X5, AAV-X25 or AAV-X26 particles expressing GFP in 50 µl medium supplemented with various sugars (see Fig. 9). 24h after transduction, cells were analyzed for GFP expression by flow cytometry.

Heparin competition assay: COS cells were plated at a density of 5×10^3 /well in a flat-bottom 96-well plate. After 24 h, 10^7 particles rAAV6-NLS-GFP, rAAV(VR-195)-NLS-GFP and rAAV(VR-355)-NLSGFP were preincubated for 1 h at room temperature in medium containing 0 to 2000 µg/ml heparin (Sigma, St. Louis, MO). Cells were then transduced for 1 h at 37°C with this preincubation mixture, washed with medium and incubated for 24 h. GFP expression was detected with a fluorescent cell counter (Guava Technologies).

NaCl competition assay: COS cells were seeded at 5,000 cells/well in a 96 well plate. 24h after seeding, were transduced for 60 min at 37°C with MOI of 500 or 10^8 recombinant AAV-2, AAV-4, AAV-5, AAV-6, BAAV, AAV-X1, AAV-X5, AAV-X25 or AAV-X26 particles expressing GFP in 50 µl medium supplemented with NaCl to 150mM, 300mM, and 450mM final NaCl concentration. 24h after transduction, cells were analyzed for GFP expression by flow cytometry/ fluorescent cell counter (Guava Technologies).

Viral cross-competition: COS cells were plated at a density of 5×10^3 /well in a flat-bottom 96-well plate. After 24 h, cells were preincubated for 1h at 37°C with increasing titers of rAAV6-lacZ, an AAV6 derived vector expressing a nuclear localized β -galactosidase, ranging from 0 to 2.6×10^9 particles/well. The cells were then washed with medium and transduced for 45 min with 2×10^6 particles of rAAV2-NLS-GFP, rAAV6-NLS-GFP, rAAV(VR-195)-NLS-GFP, or rAAV(VR-355)-NLS-GFP. GFP expression was analyzed 48 h after transduction by flow cytometry.

Results

Identification of AAV contaminations in ATCC virus isolates: Viral stocks, supplied by the ATCC were analyzed for the presence of AAV DNA by a PCR based assay as described earlier (Katano, H., et al. 2004). PCR primers in this study were designed to bind to highly conserved regions in the rep and cap ORFs resulting in amplification of a 1.5kb fragment spanning from nucleotide 1437 to 2904 relative to the AAV-2 genome. This method is highly sensitive and can detect as few as 10 copies of viral DNA/ μ L of sample (Katano, H., et al. 2004). AAV DNA was detected in 13/137 samples analyzed (Table 4). AAV contaminations were detected in 26 % of adenovirus isolates. Interestingly, no AAV was detected in herpesvirus, retrovirus, coronavirus, orthomyxovirus, poxvirus, or reovirus stocks. Many of the AAV contaminated simian adenoviruses were originally isolated from pooled primary kidney cell cultures (Hull, R. N., et al. 1957; Hull, R. N., et al. 1958; Hull, R. N., et al. 1956) originally established as part of a vaccine development program (VR-195, VR-197, VR-198, VR-200, VR-202, VR-209, and VR-353), but also from rectal swabs (VR-204), cervical cord (VR-355), and CNS cultures (VR-207). AAV was also detected in stocks of human adenovirus type 9 (VR-10) as well as in bovine adenovirus type 1 (VR-313) and type 2 (VR-314). Ten of these isolates have high similarity to AAV1 and AAV6 (>98%), while AAV-X5 isolated from VR-942 and AAV-X26 isolated from VR-943 showed highest homology in the capsid protein VP-1 to AAV-3B (93%) and AAV-11 (83%) respectively.

Construction of packaging plasmids and generation of recombinant virus: The entire coding region for Rep and Cap of the AAV contaminations detected in VR-195 and VR-355 termed AAV(VR-195) and AAV(VR-355), respectively, as well as the capsid ORF under control of the viral P40 promoter from the adenovirus isolates VR-10, VR-195, VR-197, VR-198, VR-200, VR-202, VR-209, VR-353, VR-204, VR-355, and VR-207 were PCR amplified and subcloned to generate packaging plasmids.

Table 4. Screening of viral samples for the presence of AAV

Family	# tested	# AAV positive	frequency (%)
<i>Adenovirida</i>	53	13	26%
primate <i>Adenovirida</i>	16	13	81%
<i>Herpesviridae</i>	43	0	0
<i>Coronaviridae</i>	9	0	0
<i>Retrovirida</i>	15	0	0
<i>Reoviridae</i>	4	0	0
<i>Orthomyxovirida</i>	4	0	0

Recombinant AAV was produced by cotransfecting plasmids encoding the capsid of the novel AAVs, an AAV type 2 Rep expression plasmid, an AAV-2 vector plasmid, encoding a nuclear localized GFP together with an adenovirus helper plasmid. Recombinant viruses were then assayed for transduction activity. Capsid plasmids encoding functional VP proteins were sequenced on both strands. Several clones of each isolate were analyzed. GenBank accession numbers are as follows: AAV(VR-195): DQ180604(SEQ ID NO:1) and AAV(VR-355): DQ180605 (SEQ ID NO:9).

The evolutionary relationship among mammalian AAVs and the AAV contaminants detected in human and non-human primate adenovirus stocks was analyzed by ClustalW alignments of VP1 amino acid sequences and plotted as a rooted phylogenetic tree (Fig. 1). All AAVs detected in simian adenovirus stocks displayed at least 96% homology on the DNA level and 98% identity in the capsid amino acid sequence to either AAV1, AAV6, or to each other. The amino acid sequence of VP1 encoded by AAV contaminants in VR-197, VR-198, and VR-202 were identical to each other but distinct from AAV1 and AAV6. The VP1 sequence of the only positive human adenovirus stock, VR-10 (adenovirus type 9), was greater than 99.9% identical to AAV2.

AAV-X1(97%, 99%), AAV-X1B (96%, 98%), AAV-X19 (97%, 99%), AAV-X21(97%, 99%), AAV-X22 (97%, 99%), AAV-X23(97%, 98%), AAV-X24(97%, 97%), and AAV-X25 (97%, 98%) share 96 - 99% sequence identity to AAV6 or AAV1 at the DNA level (based on a 3kb partial genome fragment) (see Figure 1). Numbers in brackets indicate identities to AAV6 and AAV1. The amino acid sequence of AAV-X5 capsid protein shows highest homology to AAV-3B (93%), and AAV-X26 capsid protein shows highest homology to AAV-11 (83%). AAV-X5 and AAV-X26 DNA sequences show highest homology to AAV-3 (88%) and AAV-11 (79%) respectively (based on a 3kb partial genome fragment) (see Figure 1).

Mapping of sequence variation: AAV contaminations, which were greater than 98% identical to AAV6 in the amino acid sequence of the capsid protein VP1, were detected in 10 adenovirus isolates. AAV-X5 isolated from VR-942 and AAV-X26 isolated from VR-943 showed homology (sequence similarity) in the capsid protein VP1 to AAV-3B (93%) and AAV-11 (83%), respectively, and only low homology to AAV6 (87% and 61%, respectively). AAV-X5 and AAV-X26 are therefore very different from the other new AAVs disclosed herein. The capsid protein VP1 of AAV(VR-195) and AAV(VR-355) differs in 7 or 6 amino acids, respectively, from that of AAV6 (Table 5). To identify the location of the amino acids that are unique for AAV(VR-195) and AAV(VR-355) within the capsid, we superimposed the AAV(VR-195) and AAV(VR-355) VP1 sequence onto a pseudoatomic structure for AAV-6. Divergent regions in the capsid proteins are located on exposed surface loops at the threefold axis of symmetry, an area of the capsid that has been associated with receptor binding (Kern, A., et al. 2003; Opie, S. R., et al. 2003). AAV(VR-195) specific amino acids of three different VP3 subunits were clustered in close proximity. AAV(VR-355) specific changes relative to AAV6 were similarly organized. Since the amino acid changes among AAV(VR-195), AAV(VR-355), and AAV6 are surface exposed, we hypothesized they may effect antigenicity or cell tropism.

Table 5. Novel AAVs were isolated from ATCC adenovirus samples

Name	A.K.A.	Isolated from	Classification	Family
AAV-X1, AAV-X1b	AAV(VR-195)	VR-195	Simian virus 1	<i>Adenovirida</i>
AAV-X1	AAV(VR-197)	VR-197	Simian virus 15	<i>Adenovirida</i>
AAV-X1	AAV(VR-198)	VR-198	Simian virus 17	<i>Adenovirida</i>
AAV-X19	AAV(VR-200)	VR-200	Simian virus 23	<i>Adenovirida</i>
AAV-X1	AAV(VR-202)	VR-202	Simian virus 27	<i>Adenovirida</i>
AAV-X21	AAV(VR-204)	VR-204	Simian virus 31	<i>Adenovirida</i>
AAV-X22	AAV(VR-207)	VR-207	Simian virus 34	<i>Adenovirida</i>
AAV-X23	AAV(VR-209)	VR-209	Simian virus 37	<i>Adenovirida</i>
AAV-X24	AAV(VR-353)	VR-353	Simian virus 39	<i>Adenovirida</i>
AAV-X25	AAV(VR-355)	VR-355	Simian virus 38	<i>Adenovirida</i>
AAV-X5	AAV(VR-942)	VR-942	Simian adenovirus 17	<i>Adenovirida</i>
AAV-X26	AAV(VR-943) AAV-12	VR-943	Simian adenovirus 18	<i>Adenovirida</i>

Table 6. Comparison of the amino acid sequence of VP1

	162	198	327	386	418	495	514	531	584	590
AAV6	T	V	<i>N</i>	<i>Q</i>	<u>D</u>	<u>D</u>	R	K	L	<u>D</u>
AAV(VR-195)	T	V	S	<i>Q</i>	<u>E</u>	G	H	<u>E</u>	<u>F</u>	H
AAV(VR-355)	S	L	<i>N</i>	K	<u>E</u>	<u>D</u>	R	<u>E</u>	<u>F</u>	<u>D</u>

Numbers on top indicate the amino acid in AAV6 VP1, where either AAV (VR-195) or AAV(VR-355) diverges from AAV6. Bold are basic amino acids; Outlined are acidic; Italic are polar or slightly acidic; Underlined are aromatic.

Immunological characterization: To test for a difference in the immunological response to the isolates, IgGs purified from pooled human serum were assayed to determine if they contained neutralizing antibodies against the recombinant AAVs and whether a difference in the neutralization activity against either AAV6, AAV(VR-195) or AAV(VR-355) existed (Fig. 2). In this assay, all three viruses displayed similar sensitivity to neutralization with the purified pooled IgGs. Thus, the changes in the capsid of AAV(VR-195) or AAV(VR-355) compared to AAV6 and do not appear to alter their sensitivity to neutralization by human serum.

Heparin competition: Heparan sulfate, a ubiquitous cell surface glycosaminoglycan, is an attachment receptor for AAV2 (Summerford, C., et al. 1998). AAV2 transduction can be inhibited by heparin, a heparan sulfate analog. Like AAV2, AAV6 can be purified using a heparin affinity column; however, transduction is not inhibited by a low heparin concentration, indicating that heparan sulfate does not act as an AAV6 receptor (Halbert, C. L., et al. 2001). To investigate the role of heparan sulfate in AAV(VR-195) or AAV(VR-355) transduction, competition transduction experiments were performed with increasing amounts of heparin. At low concentrations of heparin (25 µg/ml), AAV2 was the only rAAV that was inhibited (Fig. 3). However, at 2000 µg/ml, approximately 50% inhibition of AAV6 and AAV(VR-195) was observed. No inhibition was observed with either AAV(VR-355) or AAV5. Therefore, heparan sulfate does not appear to be a co-receptor for either AAV(VR-195) or AAV(VR-355).

AAV6 and AAV(VR-195) transduction is charge sensitive: Heparin is a highly charged molecule. The observed inhibition of AAV6 and AAV(VR-195) at high concentrations of heparin could be caused by a charge driven interaction between the viruses and heparin rather than a specific interaction. Increasing the ionic strength in the medium during transduction can minimize charge dependent interactions (Arnberg, N., et al. 2002). Salt ions can bind to charged groups on the cell surface and virus capsid, thereby reducing these electrostatic interactions. To analyze if AAV6, AAV(VR-195), and AAV(VR-355) transduction is charge dependent, the ionic strength was increased during transduction by adjusting the NaCl concentration in the tissue culture medium from 150mM up to 450mM. Transduction of

rAAV-6, rAAV(VR-195), and rAAV(VR-355) was inhibited to different amounts by increasing concentrations of NaCl (Fig.4). While 250mM NaCl was sufficient to inhibit rAAV6 by 50%, higher NaCl concentrations were required to inhibit AAV(VR-195) and AAV(VR-355) with IC50 of 350mM and 450mM respectively. The relative dependence on charge follows the inhibition of these viruses by heparin and indicates that the inhibition of AAV6 and AAV(VR-195) by heparin is charge dependent.

Effect of neuraminidase treatment on rAAV transduction and virus binding: Dependent parvoviruses are also reported to use sialic acid as a co-receptor for binding and transduction (Kaludov, N., et al. 2001; Seiler, M. P., et al. 2002; Walters, R. W., et al. 2001). To analyze if sialic acid is required for transduction with AAV(VR-195) and AAV(VR-355) vectors, the effect of the removal of cell surface sialic acids was studied by neuraminidase treatment on transduction (Fig. 5A) and virus binding (Fig. 5B). Treating COS cells with a broad-spectrum neuraminidase from *A. ureafaciens* inhibited rAAV6, rAAV(VR-195), and rAAV(VR-355) transduction 3-5 fold. Neuraminidase isolated from *S. pneumoniae* will only remove α 2-3 linked sialic acid. Treatment of the cells with this enzyme again inhibited transduction with all three rAAVs. Removal of cell surface sialic acids with neuraminidases from *A. ureafaciens* or *S. pneumoniae* also resulted in a greater than 90% reduction in cell binding of rAAV6, rAAV(VR-195) and rAAV(VR-355), indicating that these viruses utilize α 2-3 link sialic acid as an cell attachment factor.

AAV6, AAV(VR-195), and AAV(VR-355) can be distinguished based upon lectin competition: Lectins are proteins that recognize and bind oligosaccharides conjugated to proteins and lipids and can be used to block virus binding (Summerford, C., et al. 1998). MalII, a lectin that recognizes α 2-3 linked sialic acid, inhibited transduction of rAAV-6, rAAV(VR-195), and rAAV(VR-355) (Fig. 6).

Many glycoproteins contain a core oligosaccharide structure which includes α -linked mannose. To study, if these "high-mannose" proteins play a role in AAV-X1 or AAV-X25 transduction, these proteins were blocked with ConA, a lectin that recognizes α -linked mannose. AAV-6, AAV-X1 or AAV-X25 were blocked equally by ConA, indicating that proteins with a mannose core are involved in binding and/ or uptake. Lens Culinaris Agglutinin (LCA) recognizes α -linked mannose together with neighboring oligosachharides. It is less broad specific than ConA. LCA inhibited all recombinant viruses tested and had an approximately twofold higher inhibitory potential on rAAV6 than on rAAV(VR-195) or rAAV(VR355). ECL is a lectin specific toward galactose residues and had the highest binding

activity toward galactosyl (β -1,4) N-acetylglucosamine. ECL blocked AAV-X1 mediated transduction less specific than AAV-6 or AAV-X25. While ECL, which recognizes α -mannose in conjugation with galactosyl (β -1,4) N-acetylglucosamine, did not inhibit rAAV(VR-195), it reduced rAAV6 and rAAV(VR-355) transduction 7 and 5-fold, respectively. STL, which recognizes Nacetylglucosamine, did not inhibit rAAV(VR-195), but reduced rAAV6 and rAAV(VR-355) transduction 30 and 12-fold, respectively. These results indicate that while all three viruses bind terminal α 2-3 linked sialic acid, the amino acid changes on the capsid surface affected the cell binding activity of each isolate.

These differences observed between AAV-6, AAV-X1 and AAV-X25 in lectin competition experiments and NaCl competition indicates utilization of different receptors or differences in receptor interaction that can result in a different cell tropism of vectors based on these isolates. The transduction efficiency of AAV-6, AAV-X1 and AAV-X25 based vectors were therefore analyzed in human cancer cell lines (Fig.9). Each recombinant virus has a unique transduction profile indicating that they bind to different receptors or interact differently with a common receptor.

AAV-X5 isolated from VR-942 and AAV-X26 isolated from VR-943 showed homology (sequence similarity) in the capsid protein VP1 to AAV-3B (93%) and AAV-11 (83%), respectively, and only low homology to AAV6 (87% and 61%, respectively). AAV-X5 and AAV-X26 are therefore very different from the other new AAVs disclosed herein. To study the attachment factors that are involved in AAV-X5 and AAV-X26 mediated transduction, competition with various carbohydrates was analyzed (Fig. 10). Heparin is a known attachment factor/ receptor for AAV2 and addition of Heparin and homolog sugars to the medium during transduction resulted in an inhibition of AAV-2 mediated gene transfer. Heparin had no effect on AAV-X5 and AAV-X26 mediated gene transfer demonstrating that extracellular heparin can not block AAV-X5 and AAV-X26 mediated gene transfer. Heparin and related carbohydrates do not appear to have receptor function for these viruses.

AAV-X5 and AAV-X26 therefore utilize unique uptake pathways/ receptors that are different from all other AAVs analyzed thus far. Transduction efficiencies in four cancer cell lines were therefore examined (Fig. 11). AAV-X5 and AAV-X26 have unique transduction properties and tropism. Thus, the application range and potential use of recombinant vectors based on AAV-X5 and AAV-X26 are unique and different from other AAVs described thus far.

rAAV6, rAAV(VR-195), and rAAV(VR-355) differ in their cell tropism: As a result of the few sequence changes on the surface of the rAAV(VR-195) and rAAV(VR-355) capsid, each virus appears to exhibit different biological characteristics from each other and from rAAV6. To analyze if this difference also results in a change in tropism or transduction activity, six human cancer cell lines and African green monkey kidney cells, COS, were transduced with recombinant vectors based on rAAV6, rAAV(VR-195), and rAAV(VR-355) (Fig. 7). AAV6 and AAV(VR-195) transduced COS cells, the non-small cell lung cancer cell line EKVX, ovarian IGROV1, and renal CAKI cells with similar efficiency. However, the transduction rates of AAV(VR-195) on ovarian Ovar5 cells and the CNS derived SF295 cell line were approximately 4 times lower compared to AAV6. AAV(VR-355) demonstrated efficient gene transfer in COS and EKVX cells, but transduction of Igrov1, CAKI, Ovar5 and SF295 was 10 to 17-fold lower than for AAV6. The different transduction efficiencies of rAAV6, rAAV(VR-195), and rAAV(VR-355) indicate that each isolate may have a distinct cell tropism which could be the result of utilization distinct receptors for attachment or internalization or have different affinities for a common receptor.

rAAV6 competition: rAAV6, rAAV(VR-195), and rAAV(VR-355) require β 2-3 linked sialic acid for cell attachment and transduction but differ in their charge dependency, sensitivity to lectin competition, and transduction activity on a panel of cells. To investigate if these viruses use distinct receptors, competition experiments were used to assay for change in transduction between AAV6 and the other isolates. COS cells were pre-incubated with increasing doses of rAAV6-lacZ followed by transduction with identical particle titers of either rAAV2, rAAV6, rAAV(VR-195), or rAAV(VR-355) expressing GFP. Changes in GFP expression were detected by flow cytometry (Fig. 8). rAAV6-LacZ competition had the greatest effect on rAAV6-NLS-GFP transduction. Fifty percent inhibition of rAAV6-NLS-GFP transduction was observed at approximately 60-fold excess of the competitor, whereas a 220-fold excess was required for the same level of inhibition of rAAV(VR-195) or rAAV(VR-355). Fifty percent inhibition of rAAV2-NLS-GFP transduction required greater than 250-fold particle excess. The stronger inhibition of rAAV6-NLS-GFP by rAAV6-lacZ compared with rAAV(VR-195) or rAAV(VR-355) suggests, that while rAAV6, rAAV(VR-195) and rAAV(VR-355) share a common attachment factor and potentially a common receptors, differences in the attachment factor and receptor interaction exist.

Example 2: Identification and Characterization of AAV12

Materials And Methods

Cells culture and virus: African green monkey kidney COS cells, obtained from the American Type Culture Collection (ATCC) (Manassas, VA), were cultured in RPMI-1640 medium (Biosource, Camarillo, CA), supplemented with 5% fetal bovine serum (Hyclone, Logan, UT), 2 mM L-glutamine, 100 U of penicillin/ml, and 0.1 mg of streptomycin/ml (Invitrogen, Carlsbad, CA). Cells were maintained at 37°C under a 5% CO₂ humidified atmosphere. Simian Virus 18 isolate, VR-943, was obtained from the ATCC as crude lysate of virus-infected cells.

Subcloning of the AAV12 rep and cap gene: The complete coding region of AAV12 rep and cap were PCR amplified and subcloned. DNA was isolated from lysate of Simian Virus 18 infected cells with the QIAprep Spin Miniprep kit (Qiagen, Valencia, CA). The rep open reading frame (ORF) was PCR amplified from this DNA with the primers AAV225(+):GCGACAKTTTGGCAGACCAAYGTGG (SEQ ID NO:44) and UNI-NC: CCANNNGGAATCGCAATGCCAAT (SEQ ID NO:45). AAV12 cap was amplified with the primers UNI-C: 5'-ATGNTNATNTGGTGGGAGGAGGG-3' (SEQ ID NO:46) and AAV1-4 polyA4400(-):5'-CGAATNAAMCGGTTTATTGATTAAC-3' (SEQ ID NO:47). The PCR fragments were subcloned using the TOPO TA Cloning KIT (Invitrogen) resulting in the plasmids pAAV12-Rep and pAAV12-Cap. Three clones, that were capable of generating recombinant virus, were sequenced with an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA) and FS dye-terminator chemistry (Applied Biosystems).

Sequence analysis: The sequences of AAV12 rep and cap were compared to sequences in GenBank using BLAST. DNA alignments were performed using the ClustalW multiple sequence alignment tool of the Biology Workbench web based software at <http://seqtool.sdsc.edu> (SDSC) and MacVector 7 (Accelrys, Burlington, MA).

Generation of recombinant virus: AAV12 (AAVX26) vectors, expressing a nuclear localized green fluorescent protein (GFP), rAAV12GFP, were produced as described above. Briefly, 293T cells were cotransfected with pAAV2-NLS-GFP, pAAV12Rep and pAAV12Cap and the Ad helper plasmids 449B. Recombinant particles were purified by CsCl gradient centrifugation. DNase-resistant genome copy numbers of the vector stocks were determined by quantitative real-time PCR using the TAQMAN system (Applied Biosystems) with probes specific to the CMV promoter. AAV12-Epo expressing human erythropoietin was generated accordingly by packaging pAAVhEPO with pAAV12Rep and pAAV12Cap.

Digestion of cell surface sialic acid: Exponentially growing COS cells were plated at a density of 5×10^3 /well in a flat-bottom 96-well plate. Twenty-four hours after seeding, cells

were incubated for 30 min with 0.1 and 1 mU of the broad-spectrum neuraminidase from *Vibrio cholerae* (Calbiochem, La Jolla, CA). Cells were then washed with medium and transduced with 1×10^7 particles of rAAV2-GFP, rAAV4-GFP, rAAV5-GFP or rAAV12-GFP. GFP expression, which serves as a surrogate marker for transduction, was detected twenty-four hours later with a fluorescent cell counter (Guava PCA-96, Guava Technologies, Hayward, CA).

Heparin competition assay: COS cells were plated at a density of 5×10^3 /well in a flat-bottom 96-well plate one day prior to transduction. 2×10^7 particles rAAV2-GFP, rAAV12-GFP were preincubated for 1 h at room temperature in medium supplemented with either heparin, mannose or mannosamine (Sigma, St. Louis, MO). This pre-incubation mixture was then added and left on the cells for 1 h at 37°C. Cells were then washed with medium and incubated for one day before GFP expression was detected with a fluorescent cell counter (Guava Technologies).

Protease treatment: COS cells were cultured in a 15-cm diameter culture dish until cells were 80% confluent. Cells were then washed twice with PBS, scraped, resuspended in 10 ml PBS and incubated with 0.05% trypsin (Biosource), or mock (untreated control) for 15 min at 37°C. Cells were then washed twice with medium and seeded at a density of 10,000 cells/well in a 96-well dish. After 1 h culture at 37°C, cells were transduced with 2×10^7 particles rAAV2-GFP, rAAV12-GFP. Transduction efficiency was determined 24 h later by GFP expression detection with a fluorescent cell counter (Guava Technologies).

Inhibition of glycolipid synthesis: COS cells were plated at a density of 5×10^3 /well in a flat-bottom 96-well plate. Eight hours after seeding, cells were incubated for 40 h with the glucosylceramide synthase inhibitors DL-threo-1-Phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) (Sigma, St. Louis, MO). Cells were then washed with medium and transduced with 2×10^8 particles of rAAV2-GFP, rAAV12-GFP and rBAAV-GFP for 1 h. GFP expression was analyzed 48 h after transduction by detection with a fluorescent cell counter (Guava Technologies).

Neutralization assay: COS cells were seeded at a density of 5×10^3 /well in a 96-well plate 1 day before inoculation. 2×10^7 rAAV2-GFP, rAAV6-GFP and rAAV12-GFP particles that were pre-incubated with serial dilutions of pooled human IgGs (Immune Globuline Intravenous, 10%, Gamunex, BAYER, Leverkusen, Germany) in medium for 1 h at room temperature. Cells were then inoculated with this mixture for 1 h at 37°C and then washed

with medium. Twenty-four hours after transduction, cells were analyzed for GFP expression by flow cytometry (Guava Technologies).

Animal experiments: Male Balb/c mice were obtained from the Division of Cancer Treatment, NCI, Bethesda, MD. Mice were administered 10^9 particles (suspended in 100 μ l of 0.9% NaCl) of either AAV2-hEPO (n=3) or AAV12-hEPO (n=2) by retrograde ductal delivery to both submandibular glands (SG). Two additional groups (n=3 and n=2, respectively) received an equal dose of 10^9 particles (suspended in 100 μ l of 0.9% NaCl) in both their tibialis anterior (two injection sites per muscle). A further group (n=3) of naïve mice (administered with 50 μ l of 0.9% NaCl to each SG) was included. Mild anesthesia was induced to all participating animals with 1 μ l/g body weight of a 60 mg/ml ketamine (Phoenix Scientific, St. Joseph, MO) and 8 mg/ml xylazine (Phoenix Scientific) solution given intramuscularly. Blood samples were obtained by orbital bleeding at distinct time points. Hematocrits (Hcts) were determined using micro-hematocrit capillary tubes (Fisher Scientific, Pittsburgh, PA). Secretion of hEPO in mouse serum was determined by an ELISA using commercial assay kits (R&D systems, MN, USA). The lower limit of detection was 0.6 mU/ml. Assays were performed according to the manufacturer's instructions.

Results

Identification of AAV contaminations in ATCC virus isolates: AAV sequences were detected in a Simian Adenovirus 18 strain C676 stock, VR-943, which was isolated from a Vervet monkey (*Cercopithecus aethiops*). The entire rep and cap coding region of the AAV contamination in VR-943, termed AAV12, has been PCR amplified and subcloned (Fig.1). Since the rep and cap encoding PCR fragments also contain viral promoter elements, these plasmids could be used as packaging constructs for the generation of recombinant virus. Vectors based on AAV12 were produced by cotransfecting an AAV-2 vector plasmid, encoding a nuclear localized GFP flanked by AAV2 inverted terminal repeats (ITRs), and plasmids encoding AAV12 rep and cap together with an adenovirus helper plasmid. Recombinant viruses were then assayed for transduction activity by inoculating COS cells and assaying for GFP expression by flow cytometry. Three clones, which were capable of generating recombinant virus were sequenced.

Phylogenetic analysis: The evolutionary relationship among mammalian AAVs and AAV12 was analyzed by ClustalW alignments of genomic, Rep78 and VP1 sequences and plotted as a rooted phylogenetic tree (Fig. 1). The DNA sequence of AAV12 showed highest homology with AAV11 and AAV4, 83% and 81% respectively, whereas lowest similarity was

observed with AAV5 (63%). The Rep78 amino acid sequence of AAV12 demonstrated high homology to AAV13, AAV4, AAV10 and AAV11 with 89% or 88% identity. For the capsid protein VP1, highest homology was observed with AAV11 and AAV4, 84% and 78% respectively, whereas AAV5 VP1 displayed lowest similarity with 53%.

Heparin competition: Heparan sulfate, a cell surface glycosaminoglycan, which is expressed by virtually all cells, is an attachment receptor for AAV2 (Summerford, C., et al. 1998). AAV2 transduction can be inhibited by heparin, a heparan sulfate analog. Thus, analysis was conducted to determine whether AAV12 uses heparan sulfate as a receptor by heparin competition experiments. COS cells were transduced with rAAV12 in the presence of increasing amounts of heparin. rAAV2 served as a control. rAAV2 transduction was inhibited to 75% at a concentration of 12.5µg/ml heparin, whereas no inhibition of rAAV12 was observed at a 80 fold higher heparin concentration of 1000µg/ml (Fig.12). Since heparin has no inhibitory potential towards AAV12 transduction, heparan sulfate appears not to be involved in AAV12 transduction.

Effect of neuraminidase treatment on rAAV12 transduction: Sialic acids, a family of monosaccharides based on N-acetylneuramic acid, are commonly found on the outermost end of glykans and glycolipids. Sialic acids have been identified to serve as receptors for several viruses, including influenza virus, AAV4, AAV5 AAV6 and AAV(VR-355). To analyze, if AAV12 transduction is sialic acid dependent, the effect of the removal of cell surface sialic acids was studied by neuraminidase treatment on gene transfer (Fig.134). Enzymatic digestion of COS cells with a broad spectrum neuraminidase from *Vibrio cholera* inhibited rAAV4 and rAAV5 transduction dose-dependently and blocked gene transfer up to 99% and 97% respectively. AAV12 transduction was unaffected by the enzymatic removal of cell surface sialic acids, indicating that AAV12 does not utilize sialic acid in the transduction process.

rAAV12 transduction is protease sensitive and does not require glycosphingolipids (GSLs): rBAAV cell entry and transduction depend on gangliosides, glycosphingolipids with sialic acid groups, and are resistant to protease treatment of the cell. To analyze if the rAAV12 receptor is a protein and if glycolipids are involved in the transduction process, the effect of proteolytically digesting cell surface proteins prior to transduction was studied (Fig.14A). The dependency of rAAV12 transduction on GSLs was studied by incubating cells with DL-threo-1-Phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP), a glucosylceramide synthase inhibitors, which act to deplete GSLs from the cell membrane prior to transduction (Fig.14B).

As shown in Figure 14, AAV12 transduction is protease sensitive, but AAV12 can transduce cells lacking glycosphingolipids.

rAAV12 is inhibited by extracellular mannosamine: Since rAAV12 transduction does not depend on either heparin or sialic acid, a broad panel of carbohydrates was screened for the ability to interfere with rAAV12 transduction to identify components that might be involved in the rAAV12 cell interaction. In this assay, mannosamine was identified as compound with inhibitory function against rAAV12. Pre-incubation of rAAV12 with mannosamine prior to transduction resulted in a dose-dependent inhibition of rAAV12 transduction (Fig. 15), while no specific inhibition of rAAV2 was observed. This result indicates that mannosamine could be part of the rAAV12 receptor or attachment factor.

rAAV12 has a broad tropism in human cancer cell lines: All studied AAVs utilize either sialic acid or heparin as cellular receptor or attachment factor. In contrast, rAAV12 transduced cells independently of heparin and sialic acid but was inhibited by mannosamine, indicating that rAAV12 interacts in a unique way with the cell. To analyze if unique cell interaction results in a unique tropism, the transduction efficiency of rAAV12 was studied in 13 human cancer cell lines and compared it to rAAV4, a virus that shows 78% homology to rAAV12 in the capsid protein VP1 (Fig. 16). rAAV12 and rAAV4 demonstrated both a broad tropism with overall similar transduction efficiencies, but both viruses had a unique transduction profile. While only rAAV4 transduced HCT10 cells, rAAV12 gene transfer was specific for A549 and HCT15 cells.

Immunological characterization of rAAV12: Infections with AAV2 are very common and approximately 80% of the human population are seropositive. Neutralization of human AAV serotypes, such as AAV2, AAV3 and AAV5, as well as the simian AAV6 by human serum have been reported. This pre-existing immunity against these AAVs might limit their usability as vectors for gene therapy. To test if rAAV12 is antigenically distinct from rAAV2 and rAAV6, assays were conducted to determine if IgGs, purified from pooled human serum, contain neutralizing antibodies against the recombinant AAVs and whether there was a difference in the neutralization activity against either rAAV2, AAV6, or rAAV12 (Fig. 17). In this assay the human rAAV2 and simian rAAV6 displayed similar sensitivity to neutralization with the purified pooled IgGs and transduction was inhibited to 50% at a concentration of 0.01mg/ml IgGs. In contrast, rAAV12 was highly resistant to neutralization by pooled human IgGs, and even at the highest concentration of 0.67mg/ml, a concentration

where 100% inhibition of rAAV2 and rAAV6 was observed, rAAV12 transduction was only reduced by 30%.

rAAV12 transduces salivary glands and skeletal muscles in vivo: rAAV12 transduced salivary glands and skeletal muscles with similar efficiency as rAAV2 (Fig.18).

References

- Allen, J.M., Halbert, C.L. and Miller, A.D.: Improved adeno-associated virus vector production with transfection of a single helper adenovirus gene, E4orf6. *Mol Ther* 1 (2000) 88-95.
- Arnberg, N., A. H. Kidd, K. Edlund, J. Nilsson, P. Pring-Akerblom, and G. Wadell. 2002. Adenovirus type 37 binds to cell surface sialic acid through a charge-dependent interaction. *Virology* 302:33-43.
- Atchison, R. W., B. C. Casto, and W. M. Hammon. 1965. Adenovirus-Associated Defective Virus Particles. *Science* 149:754-6.
- Bartlett, J.S., Wilcher, R. and Samulski, R.J.: Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. *J Virol* 74 (2000) 2777-85.
- Ben-Israel, H. and Kleinberger, T.: Adenovirus and cell cycle control. *Front Biosci* 7 (2002) D1369-95.
- Berns, K. I. 1996. Parvoviridae: the viruses and their replication, p. 2173-2197. In F. B. N., K. D. M., and H. P. M. (ed.), *Fields virology*, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
- Blacklow, N.R., Hoggan, M.D. and Rowe, W.P.: Isolation of adenovirus-associated viruses from man. *Proc Natl Acad Sci U S A* 58 (1967) 1410-5.
- Blacklow, N.R., Hoggan, M.D. and Rowe, W.P.: Serologic evidence for human infection with adenovirus-associated viruses. *J Natl Cancer Inst* 40 (1968) 319-27.
- Bossis, I. and Chiorini, J.A.: Cloning of an Avian Adeno-Associated Virus (AAAV) and Generation of Recombinant AAAV Particles. *J Virol* 77 (2003) 6799-810.
- Carter, B. J., B. A. Antoni, and D. F. Klessig. 1992. Adenovirus containing a deletion of the early region 2A gene allows growth of adeno-associated virus with decreased efficiency. *Virology* 191:473-6.
- Carter, B. J., C. A. Laughlin, L. M. de la Maza, and M. Myers. 1979. Adenoassociated virus autointerference. *Virology* 92:449-62.
- Casto, B. C., J. A. Armstrong, R. W. Atchison, and W. M. Hammon. 1967. Studies on the relationship between adeno-associated virus type 1 (AAV-1) and adenoviruses. II. Inhibition of adenovirus plaques by AAV; its nature and specificity. *Virology* 33:452-8.
- Casto, B. C., R. W. Atchison, and W. M. Hammon. 1967. Studies on the relationship between adeno-associated virus type I (AAV-1) and adenoviruses. I. Replication of AAV-1 in certain cell cultures and its effect on helper adenovirus. *Virology* 32:52-9.
- Chang, L.S. and Shenk, T.: The adenovirus DNA-binding protein stimulates the rate of transcription directed by adenovirus and adeno-associated virus promoters. *J Virol* 64 (1990) 2103-9.

- Chiorini, J. A., F. Kim, et al. (1999). "Cloning and characterization of adeno-associated virus type 5." *J Virol* 73(2): 1309-19.
- Chiorini, J. A., L. Yang, Y. Liu, B. Safer, and R. M. Kotin. 1997. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. *J Virol* 71:6823-33.
- Chiorini, J.A., Wiener, S.M., Owens, R.A., Kyostio, S.R., Kotin, R.M. and Safer, B.: Sequence requirements for stable binding and function of Rep68 on the adeno-associated virus type 2 inverted terminal repeats. *J Virol* 68 (1994) 7448-57.
- Davidson, B. L., C. S. Stein, et al. (2000). "Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system." *Proc Natl Acad Sci U S A* 97(7): 3428-32.
- Derby, M. L., M. Sena-Esteves, et al. (1999). "Gene transfer into the mammalian inner ear using HSV-1 and vaccinia virus vectors." *Hear Res* 134(1-2): 1-8.
- Di Pasquale, G., and J. A. Chiorini. 2003. PKA/PrKX activity is a modulator of AAV/adenovirus interaction. *EMBO J* 22:1716-24.
- Di Pasquale, G., B. L. Davidson, et al. (2003). "Identification of PDGFR as a receptor for AAV5 transduction." *Nat Med* 9(10): 1306-12.
- Di Pasquale, G., Rzadzinska, A., Schneider, M.E., Bossis, I., Chiorini, J.A., Kachar, B., A novel bovine virus efficiently transduces inner ear neuroepithelial cells, Manuscript submitted.
- Erles, K., Sebokova, P. and Schlehofer, J.R.: Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). *J Med Virol* 59 (1999) 406-11.
- Gao, G., L. H. Vandenberghe, M. R. Alvira, Y. Lu, R. Calcedo, X. Zhou, and J. M. Wilson. 2004. Clades of Adeno-associated viruses are widely disseminated in human tissues. *J Virol* 78:6381-8.
- Gao, G.P., Alvira, M.R., Wang, L., Calcedo, R., Johnston, J. and Wilson, J.M.: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. *Proc Natl Acad Sci U S A* 99 (2002) 11854-9.
- Georg-Fries, B., S. Biederlack, J. Wolf, and H. zur Hausen. 1984. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. *Virology* 134:64-71.
- Grimm, D. and M. A. Kay (2003). "From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy." *Curr Gene Ther* 3(4): 281-304.
- Halbert, C. L., J. M. Allen, and A. D. Miller. 2001. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. *J Virol* 75:6615-24.
- He, D. Z., J. Zheng, et al. (2001). "Development of acetylcholine receptors in cultured outer hair cells." *Hear Res* 162(1-2): 113-25.
- Heister, T., Heid, I. Ackermann, M., Fraefel, C. Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19. *J Virol*. 2002 Jul;76(14):7163-73.
- Hoggan, M. D. 1970. Adenovirus associated viruses. *Prog Med Virol* 12:211-39.

- Hoggan, M. D., N. R. Blacklow, and W. P. Rowe. 1966. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. *Proc Natl Acad Sci U S A* 55:1467-74.
- Holt, J. R. (2002). "Viral-mediated gene transfer to study the molecular physiology of the Mammalian inner ear." *Audiol Neurotol* 7(3): 157-60.
- Holt, J. R., D. C. Johns, et al. (1999). "Functional expression of exogenous proteins in mammalian sensory hair cells infected with adenoviral vectors." *J Neurophysiol* 81(4): 1881-8.
- Hull, R. N., and J. R. Minner. 1957. New viral agents recovered from tissue cultures of monkey kidney cells. II. Problems of isolation and identification. *Ann N Y Acad Sci* 67:413-23.
- Hull, R. N., J. R. Minner, and C. C. Mascoli. 1958. New viral agents recovered from tissue cultures of monkey kidney cells. III. Recovery of additional agents both from cultures of monkey tissues and directly from tissues and excreta. *Am J Hyg* 68:31-44.
- Hull, R. N., J. R. Minner, and J. W. Smith. 1956. New viral agents recovered from tissue cultures of monkey kidney cells. I. Origin and properties of cytopathogenic agents S.V.1, S.V.2, S.V.4, S.V.5, S.V.6, S.V.11, S.V.12 and S.V.15. *Am J Hyg* 63:204-15.
- Janik, J.E., Huston, M.M., Cho, K. and Rose, J.A.: Efficient synthesis of adeno-associated virus structural proteins requires both adenovirus DNA binding protein and VA I RNA. *Virology* 168 (1989) 320-9.
- Jero J, Mhatre AN, Tseng CJ, Stern RE, Coling DE, Goldstein JA, Hong K, Zheng WW, Hoque AT, Lalwani AK. Cochlear gene delivery through an intact round window membrane in mouse. *Hum Gene Ther*. 2001 Mar 20;12(5):539-48.
- Kaludov, N., K. E. Brown, et al. (2001). "Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity." *J Virol* 75(15): 6884-93.
- Kanzaki, S., K. Ogawa, et al. (2002). "Transgene expression in neonatal mouse inner ear explants mediated by first and advanced generation adenovirus vectors." *Hear Res* 169(1-2): 112-20.
- Katano H, Afione S, Schmidt M, Chiorini JA. Identification of adeno-associated virus contamination in cell and virus stocks by PCR. *Biotechniques*. 2004 Apr;36(4):676-80.
- Kelsell, D.P., Dunlop, J., Stevens, H.P., Lench, N.J., Liang, J.N., Parry, G., Mueller, R.F., Leigh, I.M. Connexin 26 mutations in hereditary non-syndromic sensorineural deafness. *Nature*. 1997 May 1;387(6628):80-3
- Kern, A., K. Schmidt, C. Leder, O. J. Muller, C. E. Wobus, K. Bettinger, C. W. Von der Lieth, J. A. King, and J. A. Kleinschmidt. 2003. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. *J Virol* 77:11072-81.
- Li Duan, M., T. Bordet, et al. (2002). "Adenoviral and adeno-associated viral vector mediated gene transfer in the guinea pig cochlea." *Neuroreport* 13(10): 1295-9.
- Luchsinger, E., Strobbe, R., Dekegel, D. and Wellemans, G.: Use of B-IV zonal rotor centrifugation as a simple tool for the separation of adeno-associated X 7 virus (AAVX 7) from helper adenoviruses. *Arch Gesamte Virusforsch* 33 (1971) 251-8.

- Luchsinger, E., Strobbe, R., Wellemans, G., Dekegel, D. and Sprecher-Goldberger, S.: Haemagglutinating adeno-associated virus (AAV) in association with bovine adenovirus type 1. Brief report. *Arch Gesamte Virusforsch* 31 (1970) 390-2.
- Luebke, A. E., J. D. Steiger, et al. (2001). "A modified adenovirus can transfect cochlear hair cells in vivo without compromising cochlear function." *Gene Ther* 8(10): 789-94.
- Luebke, A. E., P. K. Foster, et al. (2001). "Cochlear function and transgene expression in the guinea pig cochlea, using adenovirus- and adeno-associated virus-directed gene transfer." *Hum Gene Ther* 12(7): 773-81.
- McPherson, R. A., L. J. Rosenthal, and J. A. Rose. 1985. Human cytomegalovirus completely helps adeno-associated virus replication. *Virology* 147:217-22.
- Meyers, C., M. Mane, N. Kokorina, S. Alam, and P. L. Hermonat. 2000. Ubiquitous human adeno-associated virus type 2 autonomously replicates in differentiating keratinocytes of a normal skin model. *Virology* 272:338-46.
- Mori, S., L. Wang, T. Takeuchi, and T. Kanda. 2004. Two novel adenoassociated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. *Virology* 330:375-83.
- Mouw, M.B. and Pintel, D.J.: Adeno-associated virus RNAs appear in a temporal order and their splicing is stimulated during coinfection with adenovirus. *J Virol* 74 (2000) 9878-88.
- Muramatsu, S., H. Mizukami, et al. (1996). "Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3." *Virology* 221(1): 208-17.
- Myrup, A.C., Mohanty, S.B. and Hetrick, F.M.: Isolation and characterization of adeno-associated viruses from bovine adenovirus types 1 and 2. *Am J Vet Res* 37 (1976) 907-10.
- Naz, S., Griffith, A.J., Riazuddin, S., Hampton, L.L., Battey, J.F. Jr, Khan, S.N., Riazuddin, S., Wilcox, E.R., Friedman, T.B. Mutations of ESPN cause autosomal recessive deafness and vestibular dysfunction. *J Med Genet*. 2004 Aug;41(8):591-5.
- No D, Yao TP, Evans RM. (1996). Ecdysone-inducible gene expression in mammalian cells and transgenic mice. *Proc Natl Acad Sci U S A*. 93(8):3346-51.
- Ogston, P., K. Raj, and P. Beard. 2000. Productive replication of adenoassociated virus can occur in human papillomavirus type 16 (HPV-16) episomecontaining keratinocytes and is augmented by the HPV-16 E2 protein. *J Virol* 74:3494-504.
- Opie, S. R., K. H. Warrington, Jr., et al. (2003). "Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding." *J Virol* 77(12): 6995-7006.
- Parks, W. P., J. L. Melnick, R. Rongey, and H. D. Mayor. 1967. Physical assay and growth cycle studies of a defective adeno-satellite virus. *J Virol* 1:171-80.
- Rabinowitz JE, Bowles DE, Faust SM, Ledford JG, Cunningham SE, Samulski RJ. Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. *J Virol*. 2004 May;78(9):4421-32.
- Reddy, V. S., P. Natarajan, B. Okerberg, K. Li, K. V. Damodaran, R. T. Morton, C. L. Brooks, 3rd, and J. E. Johnson. 2001. Virus Particle Explorer (VIPER), a website for virus capsid structures and their computational analyses. *J Virol* 75:11943-7.

- Richardson, W. D., and H. Westphal. 1984. Requirement for either early region 1a or early region 1b adenovirus gene products in the helper effect for adenoassociated virus. *J Virol* 51:404-10.
- Rutledge, E. A., C. L. Halbert, and D. W. Russell. 1998. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. *J Virol* 72:309-19.
- Rzadzinska, A. K., M. E. Schneider, et al. (2004). "An actin molecular treadmill and myosins maintain stereocilia functional architecture and self-renewal." *J Cell Biol* 164(6): 887-97.
- Saffer, L. D., R. Gu, et al. (1996). "An RT-PCR analysis of mRNA for growth factor receptors in damaged and control sensory epithelia of rat utricles." *Hear Res* 94(1-2): 14-23.
- Samulski, R. J., and T. Shenk. 1988. Adenovirus E1B 55-Mr polypeptide facilitates timely cytoplasmic accumulation of adeno-associated virus mRNAs. *J Virol* 62:206-10.
- Samulski, R. J., K. I. Berns, M. Tan, and N. Muzyczka. 1982. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. *Proc Natl Acad Sci U S A* 79:2077-81.
- Sanlioglu, S., Benson, P.K., Yang, J., Atkinson, E.M., Reynolds, T. and Engelhardt, J.F.: Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. *J Virol* 74 (2000) 9184-96.
- Schlehofer, J. R., M. Ehrbar, and H. zur Hausen. 1986. Vaccinia virus, herpes simplex virus, and carcinogens induce DNA amplification in a human cell line and support replication of a helpervirus dependent parvovirus. *Virology* 152:110-7.
- Schmidt, M., H. Katano, et al. (2004). "Cloning and characterization of a bovine adeno-associated virus." *J Virol* 78(12): 6509-16.
- Schmidt, M., H. Katano, I. Bossis, and J. A. Chiorini. 2004. Cloning and characterization of a bovine adeno-associated virus. *J Virol* 78:6509-16.
- Schneider, M. E., I. A. Belyantseva, et al. (2002). "Rapid renewal of auditory hair bundles." *Nature* 418(6900): 837-8.
- Schwede, T., J. Kopp, N. Guex, and M. C. Peitsch. 2003. SWISS-MODEL: An automated protein homology-modeling server. *Nucleic Acids Res* 31:3381-5.
- Seiler, M. P., C. L. Halbert, J. A. Chiorini, A. D. Miller, and J. Zabner. 2002. AAV5 and AAV6 Mediate Gene Transfer to Human Airway Epithelia Via Different Receptors. *Mol Ther.* 5:S40.
- Shou, J., J. L. Zheng, et al. (2003). "Robust generation of new hair cells in the mature mammalian inner ear by adenoviral expression of Hath1." *Mol Cell Neurosci* 23(2): 169-79.
- Smith, R. H., and R. M. Kotin. 2002. Adeno-associated virus as a transposable element. *In* R. C. Nancy L. Craig, Martin Gellert, and Alan M. Lambowitz (ed.), *Mobile DNA II*. ASM Press.
- Smith, R. H., S. A. Afione, and R. M. Kotin. 2002. Transposase-mediated construction of an integrated adeno-associated virus type 5 helper plasmid. *Biotechniques* 33:204-6, 208, 210-1.
- Sobkowicz, H. M., J. M. Loftus, et al. (1993). "Tissue culture of the organ of Corti." *Acta Otolaryngol Suppl* 502: 3-36.

- Srivastava, A., E. W. Lusby, and K. I. Berns. 1983. Nucleotide sequence and organization of the adeno-associated virus 2 genome. *J Virol* 45:555-64.
- Staecker H, Li D, O'Malley BW Jr, Van De Water TR. Gene expression in the mammalian cochlea: a study of multiple vector systems. *Acta Otolaryngol.* 2001 Jan;121(2):157-63.
- Stracker, T. H., G. D. Cassell, P. Ward, Y. M. Loo, B. van Breukelen, S. D. Carrington-Lawrence, R. K. Hamatake, P. C. van der Vliet, S. K. Weller, T. Melendy, and M. D. Weitzman. 2004. The Rep protein of adeno-associated virus type 2 interacts with single-stranded DNA-binding proteins that enhance viral replication. *J Virol* 78:441-53.
- Summerford, C. and R. J. Samulski (1998). "Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions." *J Virol* 72(2): 1438-45.
- Superti, F., M. L. Marziano, A. Tinari, and G. Donelli. 1993. Effect of polyions on the infectivity of SA-11 rotavirus in LCC-MK2 cells. *Comp Immunol Microbiol Infect Dis* 16:55-62.
- Suzuki, H., Y. Katori, et al. (1995). "Carbohydrate distribution in the living utricular macula of the guinea pig detected by lectins." *Hear Res* 87(1-2): 32-40.
- Tratschin, J. D., M. H. West, T. Sandbank, and B. J. Carter. 1984. A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. *Mol Cell Biol* 4:2072-81.
- Walters, R. W., S. M. Yi, S. Keshavjee, K. E. Brown, M. J. Welsh, J. A. Chiorini, and J. Zabner. 2001. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. *J Biol Chem* 276:20610-6.
- Walz, C., A. Deprez, T. Dupressoir, M. Durst, M. Rabreau, and J. R. Schlehofer. 1997. Interaction of human papillomavirus type 16 and adenoassociated virus type 2 co-infecting human cervical epithelium. *J Gen Virol* 78 (Pt 6):1441-52.
- Wang, X. S., and A. Srivastava. 1998. Rescue and autonomous replication of adeno-associated virus type 2 genomes containing Rep-binding site mutations in the viral p5 promoter. *J Virol* 72:4811-8.
- Ward, P., F. B. Dean, M. E. O'Donnell, and K. I. Berns. 1998. Role of the adenovirus DNA-binding protein in in vitro adeno-associated virus DNA replication. *J Virol* 72:420-7.
- Weindler, F. W., and R. Heilbronn. 1991. A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. *J Virol* 65:2476-83.
- Xiao, W., N. Chirmule, S. C. Berta, B. McCullough, G. Gao, and J. M. Wilson. 1999. Gene therapy vectors based on adeno-associated virus type 1. *J Virol* 73:3994-4003.
- Yakinoglu, A. O., R. Heilbronn, A. Burkle, J. R. Schlehofer, and H. zur Hausen. 1988. DNA amplification of adeno-associated virus as a response to cellular genotoxic stress. *Cancer Res* 48:3123-9.
- Yakobson, B., T. A. Hrynko, M. J. Peak, and E. Winocour. 1989. Replication of adeno-associated virus in cells irradiated with UV light at 254 nm. *J Virol* 63:1023-30.
- Yamano, S., Huang, L.Y., Ding, C., Chiorini, J.A., Goldsmith, C.M., Wellner, R.B., Golding, B., Kotin, R.M., Scott, D.E. and Baum, B.J.: Recombinant adeno-associated virus serotype

2 vectors mediate stable interleukin 10 secretion from salivary glands into the bloodstream.
Hum Gene Ther 13 (2002) 287-98.

Zabner, J., Seiler, M., Walters, R., Kotin, R.M., Fulgeras, W., Davidson, B.L., Chiorini, J.A.
Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of
airway epithelia and facilitates gene transfer. J Virol. 2000 Apr;74(8):3852-8.

CLAIMS

What is claimed is:

1. A nucleic acid vector comprising an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26-specific nucleic acid or a nucleic acid encoding an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26-specific protein.
2. The nucleic acid vector of claim 1, wherein the nucleic acid encoding an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26-specific protein encodes an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 capsid protein or an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 Rep protein.
3. The nucleic acid vector of claim 2, wherein the AAV-X1 capsid protein is selected from the group consisting of AAV-X1 VP1, AAV-X1 VP2, and AAV-X1 VP3.
4. The nucleic acid vector of claim 3, wherein the AAV-X1 VP1 capsid protein has the amino acid sequence set forth in SEQ ID NO:21.
5. The nucleic acid vector of claim 2, wherein the AAV-X1b capsid protein is selected from the group consisting of AAV-X1b VP1, AAV-X1b VP2, and AAV-X1b VP3.
6. The nucleic acid vector of claim 5, wherein the AAV-X1b VP1 capsid protein has the amino acid sequence set forth in SEQ ID NO:22.
7. The nucleic acid vector of claim 2, wherein the AAV-X5 capsid protein is selected from the group consisting of AAV-X5 VP1, AAV-X5 VP2, and AAV-X5 VP3.
8. The nucleic acid vector of claim 7, wherein the AAV-X5 VP1 capsid protein has the amino acid sequence set forth in SEQ ID NO:23.
9. The nucleic acid vector of claim 2, wherein the AAV-X19 capsid protein is selected from the group consisting of AAV-X19 VP1, AAV-X19 VP2, and AAV-X19 VP3.
10. The nucleic acid vector of claim 9, wherein the AAV-X19 VP1 capsid protein has the amino acid sequence set forth in SEQ ID NO:24.
11. The nucleic acid vector of claim 2, wherein the AAV-X21 capsid protein is selected from the group consisting of AAV-X21 VP1, AAV-X21 VP2, and AAV-X21 VP3.
12. The nucleic acid vector of claim 11, wherein the AAV-X21 VP1 capsid protein has the amino acid sequence set forth in SEQ ID NO:25.

13. The nucleic acid vector of claim 2, wherein the AAV-X22 capsid protein is selected from the group consisting of AAV-X21 VP1, AAV-X21 VP2, and AAV-X21 VP3.
14. The nucleic acid vector of claim 11, wherein the AAV-X22 VP1 capsid protein has the amino acid sequence set forth in SEQ ID NO:26.
15. The nucleic acid vector of claim 2, wherein the AAV-X23 capsid protein is selected from the group consisting of AAV-X23 VP1, AAV-X23 VP2, and AAV-X23 VP3.
16. The nucleic acid vector of claim 15, wherein the AAV-X23 VP1 capsid protein has the amino acid sequence set forth in SEQ ID NO:27.
17. The nucleic acid vector of claim 2, wherein the AAV-X24 capsid protein is selected from the group consisting of AAV-X24 VP1, AAV-X24 VP2, and AAV-X24 VP3.
18. The nucleic acid vector of claim 17, wherein the AAV-X24 VP1 capsid protein has the amino acid sequence set forth in SEQ ID NO:28.
19. The nucleic acid vector of claim 2, wherein the AAV-X25 capsid protein is selected from the group consisting of AAV-X25 VP1, AAV-X25 VP2, and AAV-X25 VP3.
20. The nucleic acid vector of claim 19, wherein the AAV-X25 VP1 capsid protein has the amino acid sequence set forth in SEQ ID NO:29.
21. The nucleic acid vector of claim 2, wherein the AAV-X26 capsid protein is selected from the group consisting of AAV-X26 VP1, AAV-X26 VP2, and AAV-X26 VP3.
22. The nucleic acid vector of claim 21, wherein the AAV-X26 VP1 capsid protein has the amino acid sequence set forth in SEQ ID NO:30.
23. The nucleic acid vector of claim 2, wherein the AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 Rep protein is selected from the group consisting of Rep40, Rep52, Rep68 and Rep78.
24. The nucleic acid vector of claim 23, wherein the AAV-X1 VP1 capsid protein has the amino acid sequence set forth in SEQ ID NO:49.
25. The nucleic acid vector of claim 23, wherein the AAV-X25 VP1 capsid protein has the amino acid sequence set forth in SEQ ID NO:51.
26. The nucleic acid vector of claim 23, wherein the AAV-X26 VP1 capsid protein has the amino acid sequence set forth in SEQ ID NO:53.
27. The nucleic acid vector of claim 2, comprising a pair of AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 inverted terminal repeats and a promoter between the inverted terminal repeats.
28. The nucleic acid vector of claim 27, wherein the promoter is an AAV promoter p5.

29. The nucleic acid vector of claim 28, wherein the p5 promoter is AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 p5 promoter.
30. The particle of claim 28, wherein the p5 promoter is an AAV1 p5 promoter, an AAV2 p5 promoter, an AAV3 p5 promoter, an AAV4 p5 promoter, AAV5 p5 promoter, an AAV6 p5 promoter, an AAAV p5 promoter, or a BAAV p5 promoter.
31. The nucleic acid vector of claim 27, further comprising an exogenous nucleic acid functionally linked to the promoter.
32. The nucleic acid vector of claim 27, encapsidated in an adeno-associated virus particle.
33. The nucleic acid vector of claim 32, wherein the particle is an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 particle.
34. The nucleic acid vector of claim 32, wherein the particle is an AAV1 particle, an AAV2 particle, an AAV3 particle, an AAV4 particle, AAV5 particle, AAV6 particle, AAAV particle, or an BAAV particle.
35. A recombinant AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 virion containing a vector comprising a pair of AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 inverted terminal repeats.
36. The virion of claim 35, wherein the vector further comprises an exogenous nucleic acid inserted between the inverted terminal repeats.
37. The nucleic acid vector of claim 1, wherein the AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26-specific nucleic acid is a pair of AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 inverted terminal repeats or an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 p5 promoter.
38. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.
39. An isolated nucleic acid consisting essentially of the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.

40. An isolated nucleic acid that selectively hybridizes with the nucleic acid of claim 39.
41. An isolated nucleic acid encoding an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 capsid protein.
42. The isolated nucleic acid of claim 41, comprising the nucleotide sequence set forth in SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, or SEQ ID NO:20.
43. The isolated nucleic acid of claim 41, wherein the AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 capsid protein has the amino acid sequence set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, or SEQ ID NO:30.
44. An isolated AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 capsid protein.
45. The isolated AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 capsid protein of claim 44, having the amino acid sequence set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, or SEQ ID NO:30, or a unique fragment thereof.
46. The isolated AAV-X1, AAV-X1b, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, or AAV-X25 capsid protein of claim 44, having at least a 98% sequence identity to the amino acid sequence set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:29.
47. The isolated AAV-X5 capsid protein of claim 44, having at least an 93% sequence identity to the amino acid sequence set forth in SEQ ID NO:23 or SEQ ID NO:30.
48. The isolated AAV-X26 capsid protein of claim 44, having at least an 83% sequence identity to the amino acid sequence set forth in SEQ ID NO:23 or SEQ ID NO:30.
49. An isolated antibody that specifically binds the protein of claim 44.
50. An AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 particle comprising a capsid protein consisting essentially of the amino acid sequence set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, or SEQ ID NO:30.

51. A method of screening a cell for infectivity by AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26, comprising contacting the cell with AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 and detecting the presence of AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 in the cells.
52. A method of determining the suitability of an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 vector for administration to a subject, comprising contacting an antibody-containing sample from the subject with an antigenic fragment of a protein of claim 44 and detecting an antibody-antigen reaction in the sample, the presence of a neutralizing reaction indicating the AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 vector to be unsuitable for use in the subject.
53. A method of determining the presence in a subject of an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 -specific antibody comprising, contacting an antibody-containing sample from the subject with an antigenic fragment of the protein of claim 44 and detecting an antibody-antigen reaction in the sample, the presence of a reaction indicating the presence of an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 -specific antibody in the subject.
54. A method of delivering a nucleic acid to a cell, comprising administering to the cell an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 particle containing a vector comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to the cell.
55. The method of claim 54, wherein the AAV inverted terminal repeats are AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 inverted terminal repeats.
56. A method of delivering a nucleic acid to a subject comprising administering to a cell from the subject an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 particle comprising the nucleic acid

- inserted between a pair of AAV inverted terminal repeats, and returning the cell to the subject, thereby delivering the nucleic acid to the subject.
57. A method of delivering a nucleic acid to a cell in a subject comprising administering to the subject an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 particle comprising the nucleic acid inserted between a pair of AAV inverted terminal repeats, thereby delivering the nucleic acid to a cell in the subject.
58. A method of delivering a nucleic acid to a cell in a subject having antibodies to AAV2 comprising administering to the subject an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 particle comprising the nucleic acid, thereby delivering the nucleic acid to a cell in the subject.
59. A vector system for producing infectious virus particles having a characteristic of AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 comprising: at least one vector comprising a nucleic acid selected from the group consisting of a pair of AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 inverted terminal repeats, a nucleic acid encoding an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 capsid protein, and a nucleic acid encoding an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 Rep protein.
60. The vector system of claim 59, comprising two vectors.
61. The vector system of claim 60, wherein the first vector comprises a nucleic acid encoding an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 Rep protein and the second vector comprises a pair of AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 inverted terminal repeats.
62. The vector system of claim 60, wherein the first vector comprises a nucleic acid encoding an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 capsid protein and a nucleic acid encoding an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 Rep protein and the second vector comprises a

- pair of AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 inverted terminal repeats.
63. The vector system of claim 60, wherein the first vector comprises a nucleic acid encoding an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 capsid protein and the second vector comprises a pair of AAV inverted terminal repeats.
64. The vector system of claim 63, wherein the second vector comprises a pair of AAV1 inverted terminal repeats.
65. The vector system of claim 63, wherein the second vector comprises a pair of AAV2 inverted terminal repeats.
66. The vector system of claim 63, wherein the second vector comprises a pair of AAV3 inverted terminal repeats.
67. The vector system of claim 63, wherein the second vector comprises a pair of AAV4 inverted terminal repeats.
68. The vector system of claim 63, wherein the second vector comprises a pair of AAV5 inverted terminal repeats.
69. The vector system of claim 63, wherein the second vector comprises a pair of AAV6 inverted terminal repeats.
70. The vector system of claim 63, wherein the second vector comprises a pair of AAV7 inverted terminal repeats.
71. The vector system of claim 63, wherein the second vector comprises a pair of AAV8 inverted terminal repeats.
72. The vector system of claim 63, wherein the second vector comprises a pair of AAV9 inverted terminal repeats.
73. The vector system of claim 63, wherein the second vector comprises a pair of AAV10 inverted terminal repeats.
74. The vector system of claim 63, wherein the second vector comprises a pair of AAV11 inverted terminal repeats.
75. The vector system of claim 63, wherein the second vector comprises a pair of AAV inverted terminal repeats.
76. The vector system of claim 63, wherein the second vector comprises a pair of BAAV inverted terminal repeats.

77. The vector system of claim 63, wherein the second vector comprises a pair of AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 inverted terminal repeats.
78. The vector system of claim 63, wherein the first vector further comprises a nucleic acid encoding an AAV1 Rep protein.
79. The vector system of claim 63, wherein the first vector further comprises a nucleic acid encoding an AAV2 Rep protein.
80. The vector system of claim 63, wherein the first vector further comprises a nucleic acid encoding an AAV3 Rep protein.
81. The vector system of claim 63, wherein the first vector further comprises a nucleic acid encoding an AAV4 Rep protein.
82. The vector system of claim 63, wherein the first vector further comprises a nucleic acid encoding an AAV5 Rep protein.
83. The vector system of claim 63, wherein the first vector further comprises a nucleic acid encoding an AAV6 Rep protein.
84. The vector system of claim 63, wherein the first vector further comprises a nucleic acid encoding an AAV7 Rep protein.
85. The vector system of claim 63, wherein the first vector further comprises a nucleic acid encoding an AAV8 Rep protein.
86. The vector system of claim 63, wherein the first vector further comprises a nucleic acid encoding an AAV9 Rep protein.
87. The vector system of claim 63, wherein the first vector further comprises a nucleic acid encoding an AAV10 Rep protein.
88. The vector system of claim 63, wherein the first vector further comprises a nucleic acid encoding an AAV11 Rep protein.
89. The vector system of claim 63, wherein the first vector further comprises a nucleic acid encoding an AAV Rep protein.
90. The vector system of claim 63, wherein the first vector further comprises a nucleic acid encoding a BAAV Rep protein.
91. The vector system of claim 63, wherein the first vector further comprises a nucleic acid encoding an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 Rep protein.

92. The vector system of claim 60, wherein the first vector comprises a nucleic acid encoding an AAV capsid protein and the second vector comprises a pair of AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 inverted terminal repeats.
93. The vector system of claim 92, wherein the first vector comprises a nucleic acid encoding an AAV1 capsid protein.
94. The vector system of claim 92, wherein the first vector comprises a nucleic acid encoding an AAV2 capsid protein.
95. The vector system of claim 92, wherein the first vector comprises a nucleic acid encoding an AAV3 capsid protein.
96. The vector system of claim 92, wherein the first vector comprises a nucleic acid encoding an AAV4 capsid protein.
97. The vector system of claim 92, wherein the first vector comprises a nucleic acid encoding an AAV5 capsid protein.
98. The vector system of claim 92, wherein the first vector comprises a nucleic acid encoding an AAV6 capsid protein.
99. The vector system of claim 92, wherein the first vector comprises a nucleic acid encoding an AAV7 capsid protein.
100. The vector system of claim 92, wherein the first vector comprises a nucleic acid encoding an AAV8 capsid protein.
101. The vector system of claim 92, wherein the first vector comprises a nucleic acid encoding an AAV9 capsid protein.
102. The vector system of claim 92, wherein the first vector comprises a nucleic acid encoding an AAV10 capsid protein.
103. The vector system of claim 92, wherein the first vector comprises a nucleic acid encoding an AAV11 capsid protein.
104. The vector system of claim 92, wherein the first vector comprises a nucleic acid encoding an AAV capsid protein.
105. The vector system of claim 92, wherein the first vector comprises a nucleic acid encoding a BAAV capsid protein.
106. The vector system of claim 92, wherein the first vector comprises a nucleic acid encoding an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 capsid protein.

107. The vector system of any of claims 92 to 105, wherein the first vector further comprises a nucleic acid encoding an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 Rep protein.
108. The vector system of any of claims 92 to 105, wherein the second vector further comprises a promoter between the inverted terminal repeats.
109. The vector system of claim 108, wherein the promoter is functionally linked to an exogenous nucleic acid.
110. The vector system of any of claims 92 to 105, wherein a vector of the vector system is encapsidated in an AAV particle.
111. The vector system of claim 110, wherein the vector is encapsidated in a dependent parvovirus particle.
112. The vector system of claim 111, wherein the parvovirus particle which encapsidates the vector is an AAV1 particle, an AAV2 particle, an AAV3 particle, an AAV4 particle, an AAV5 particle, an AAV6 particle, an AAV7 particle, an AAV8 particle, an AAV9 particle, an AAV10 particle, an AAV11 particle, an AAV particle, a BAAV particle, an AAV-X1 particle, an AAV-X1b particle, an AAV-X5 particle, an AAV-X19 particle, an AAV-X21 particle, an AAV-X23 particle, an AAV-X24 particle, an AAV-X25 particle, or an AAV-X26 particle.
113. A vector comprising a pair of AAV inverted terminal repeats, a nucleic acid encoding an AAV-X1, AAV-X1b, AAV-X5, AAV-X19, AAV-X21, AAV-X22, AAV-X23, AAV-X24, AAV-X25, or AAV-X26 capsid protein and a nucleic acid encoding an AAV Rep protein.

1/16




FIG. 1

2/16




FIG. 2

3/16




FIG.3




FIG.4

4/16




FIG.5A




FIG.5B

5/16




FIG. 6




FIG. 7

6/16




FIG. 8

7/16




FIG.9A




FIG.9B

8/16




FIG.9C




FIG.9D

9/16




FIG.10A




FIG.10B

10/16




FIG. 10C




FIG. 10D

11/16




FIG.11A




FIG.11B

12/16




FIG.12




FIG.13

13/16




FIG. 14A




FIG. 14B

14/16




FIG. 15




FIG. 16

15/16




FIG.17

16/16




FIG.18A




FIG.18B

140140433P1.TXT

SEQUENCE LISTING

<110> Government of the United States of America, as represented by the
Secretary, Department of Health and Human Services

<120> Isolation, Cloning and Characterization
of New Adeno-Associated Virus (AAV) Serotypes

<130> 14014.0433P1

<150> 60/676,604

<151> 2005-04-29

<160> 54

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 4259

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<221> misc_feature

<222> 6

<223> N can be A, C, G, or T

<400> 1

tttgcgacat	tttgcgacac	cacgtggcca	ttcagggtat	atatggccga	gtgagcgagc	60
aggatcccca	ttttgaccgc	gaaatttgaa	cgagcagcag	ccatgccggg	cttctacgag	120
atcgtgatca	aggtgccgag	cgacctggac	gagcacctgc	cgggcatttc	tgactcgttt	180
gtgaactggg	tggccgagaa	ggaatgggag	ctgcccccg	attctgacat	ggatctgaat	240
ctgattgagc	aggcaccctt	gaccgtggcc	gagaagctgc	agcgcgactt	cctgggtccaa	300
tggcgccgcg	tgagtaagyc	cccggaggcc	ctcttctttg	ttcagttcga	gaagggcgag	360
tcctacttcc	acctccatat	tctgggtggag	accacggggg	tcaaattccat	ggtgctgggc	420
cgcttcttga	gtcagattag	ggacaagctg	gtgcagacca	tctaccgcgg	gatcgagccg	480
accctgcccc	actggttcgc	ggtgaccaag	acgcgtaatg	gcgccggagg	ggggaacaag	540
gtggtggagc	agtgtacat	ccccaaactac	ctcttgccca	agactcagcc	cgagctgcag	600
tgggcgtgga	ctaactgga	ggagtatata	agcgcgtgtt	tgaacctggc	cgagcgcaaa	660
cggctcgtgg	cgcagcacct	gaccacgctc	agccagaccc	aggagcagaa	caaggagaaat	720
ctgaacccca	attctgacgc	gcctgtcatc	cgggtcaaaaa	cctccgcgcg	ctacatggag	780
ctggtcgggt	ggctgggtgga	ccggggcatc	acctccgaga	agcagtggat	ccaggaggac	840
caggcctcgt	acatctcctt	caacgcccgc	tccaactcgc	ggtcccagat	caaggccgct	900
ctggacaatg	ccggcaagat	catggcgctg	accaaattcg	cgccccgacta	cctggtaggc	960
cccgtccttc	ccgcggaat	taaaaccaac	cgcatctacc	gcattcctgga	gctgaacggc	1020
tacgaccctg	cctacgccgc	ctccgtcttt	ctcggctggg	cccagaaaacg	gttcgggaaag	1080
cgcaacacca	tctggctgtt	tgggcccggc	accacgggca	agaccaacat	cgcggaagcc	1140
atcgcccacg	ccgtgccctt	ctacggctgc	gtcaactgga	ccaatgagaa	ctttcccttc	1200
aacgattgcg	tcgacaagat	ggtgatctgg	tgggaggagg	gcaagatgac	ggccaaggtc	1260
gtggagtccg	ccaaggccat	tctcggcggc	agcaagggtc	gcgtggacca	aaagtgcgaag	1320
tcgtccgccc	agatcgatcc	cacccccgtg	atcgtcacct	ccaacaccaa	catgtgcgcc	1380
gtgattgacg	ggaacagcac	caccttcgag	caccagcagc	cgttgcagga	ccggatgttc	1440
aaatttgaac	tcacccgccg	tctggagcat	gacttttgga	aggtgacaaa	gcaggaagtc	1500
aaagagttct	tccgtgggc	gcaggatcac	gtgaccgagg	tggcgcatga	gttctacgtc	1560
agaaagggtg	gagccaacaa	aagacccgcc	cccgatgacg	cggataaaaag	cgagcccaag	1620
cgggcctgcc	cctcagtcgc	ggatccatcg	acgtcagacg	cggaaaggagc	tccggtggac	1680
tttgccgaca	ggtaccaaaa	caaattgttct	cgtcacgcgg	gcattgcttca	gatgctgttt	1740
ccctgcaaga	catgcgagag	aatgaatcag	aatttcaaca	tttgcttcac	gcacgggacc	1800

140140433P1.TXT

agagactggt	cagaatgttt	ccccggcgtg	tcagaatctc	aaccgggtcgt	cagaaaaagg	1860
acgtatcggg	aactctgtgc	gattcatcat	ctgctggggc	gggctcccga	gattgcttgc	1920
tcggcctgcg	atctgggtcaa	cgtggacctg	gatgactgtg	tctctgagca	ataaatgact	1980
taaaccaggt	atggctgccg	atggttatct	tccagattgg	ctcaggagca	acctctctga	2040
gggcattcgc	gagtggtggg	acttgaacc	tggagccccg	aaacccaaag	ccaaccagca	2100
aaagcaggac	gacggccggg	gtctggtgct	tcctggctac	aagtacctcg	gaccttcaaa	2160
cggactcgac	aagggggagc	ccgtcaacgc	ggcggacgca	gcggccctcg	agcacgacaa	2220
ggcctacgac	cagcagctca	aagcgggtga	caatccgtac	ctgcggtata	accacgccga	2280
cgccgagttt	tccagagcgtc	tgcaagaaga	tacgtctttt	gggggcaacc	tcgggcgagc	2340
agtcttccag	gccagaagc	gggttctcga	accttttggg	ctgggtgagg	aaggcgctaa	2400
gacggctcct	ggaaagaaac	gtccgggtaga	gcagtcgcca	caagagccag	actcctcctc	2460
gggcatcggc	aagacaggcc	agcagcccgc	taaaaagaga	ctcaattttg	gtcagactgg	2520
gactcagag	cagggtcccc	accacacaacc	tctcggagaa	cctccagcaa	cccccgctgc	2580
tgtgggacct	actacaatgg	cttcaggcgg	tggcgaccca	atggcagaca	ataacgaagg	2640
cggcgacgga	gtgggtaatg	cctcaggaaa	ttggcattgc	gattccacat	ggctgggcga	2700
cagagtcac	accaccagca	cccgcacctg	ggccttgccc	acctacaata	accacctcta	2760
caagcaaatc	tcagtgctt	caacgggggc	cagcaacgac	aaccactact	tcggctacag	2820
cacccccctg	gggtattttg	atttcaacag	attccactgc	cactttttac	cgctgactg	2880
gcagcgactc	atcaacaaca	attggggatt	ccggcccaag	agactcaact	tcaagctctt	2940
caacatccaa	gtcaaggagg	tcacgacgag	tgatggcgtc	acaaccatcg	ctaataacct	3000
taccagcacg	gttcaagtct	tctcggactc	ggagctaccg	cttccgtacg	tcctcggctc	3060
tgccgaccag	ggctgcctcc	ctccgttccc	ggcggacgtg	ttcatgattc	cgcaatacgg	3120
ctacctgacg	ctcaacaatg	gcagccaaagc	cgtgggacgt	tcattccttt	actgcctgga	3180
atatttccct	tctcatagtc	tgagaacggg	caacaacttt	accttcagct	acacctttga	3240
ggaagtgcct	ttccacagca	gctacgcgca	cagccagagc	ctggaccggc	tgatgaatcc	3300
tctcatcgac	caatacctgt	attacctgaa	cagaactcaa	aatcagtcctg	gaagtgccta	3360
aaacaaggac	ttgctgttta	gccgtgggtc	tccagctggc	atgtctgttc	agcccaaaaa	3420
ctggctacct	ggagcctgtt	atcggcagca	gcgcgtttct	aaaacaaaaa	caggcaacaa	3480
caacagcaat	tttacctgga	ctgggtgctt	aaaatataac	ctcaatgggc	atgaatccat	3540
catcaaccct	ggcactgcta	tggcctcaca	caaagacgac	gaagacaagt	tctttcccat	3600
gagcgggtgtc	atgatttttg	gaaaagagag	cgccggagct	tcaaacactg	cattggacaa	3660
tgctcatgatt	acagacgaag	aggaaattaa	agccactaac	cctgtggcca	ccgaaagatt	3720
tgggaccgtg	gcagtcgaat	tccagagcag	cagcacacac	cctgcgaccg	gagatgtgca	3780
tggtatggga	gcattacctg	gcatgggtgtg	gcaagataga	gacgtgtacc	tgacgggtcc	3840
catctggggc	aaaatttcctc	acacagatgg	acactttcac	ccgtctcctc	ttatgggcgg	3900
ctttggactc	aagcaccgcg	ctcctcagat	cctcatcaaa	aacacgcctg	ttcctgcgaa	3960
tccttcggcg	gagttttcag	ctacaaagtt	tgcttcattc	atcacccaat	actccacagg	4020
acaagtgagt	gtggaaattg	aatgggagct	gcagaaagaa	aacagcaagc	gctggaatcc	4080
cgaagtgcag	tacacatcca	attatgcaaa	atctgccaac	gttgatttta	ccgtggacaa	4140
caatggactt	tatactgagc	ctcgcctcat	tggcaccgtg	taccttacc	gtccctgta	4200
attacgtgtt	aatcaataaa	cgggttgatt	cgtttcagtt	gaactttggt	ctcctgtcc	4259

<210> 2

<211> 4305

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 2

accctcacta	aagggactag	tcctgcaggt	ttaaacgaat	tcgccctttg	cgacattttg	60
cgacaccacg	tggccattca	gggtatata	ggccgagtga	gcgagcagga	tccccatttt	120
gaccgcgaaa	tttgaacgag	cagcagccat	gccgggcttc	tacgagatcg	tgatcaagggt	180
gccgagcgac	ctggacgagc	acctgccggg	catttctgac	tcgtttgtga	actgggtggc	240
cgagaaggaa	tgggagctgc	ccccggattc	tgacatggat	ctgaatctga	ttgagcaggc	300
acccttgacc	gtggccgaga	agctgcagcg	cgacttcctg	gtccaatggc	gccgcgtgag	360
taaggccccg	gaggccctct	tctttgttca	gttcgagaag	ggcagtcctt	acttccacct	420
ccatattctg	gtggagacca	cgggggtcaa	atccatgggt	ctgggcccgt	tcttgagtca	480
gattagggag	aagctgggtg	agaccatcta	ccgcgggatc	gagccgaccc	tgcccaactg	540
gttcgcgggtg	accaagacgc	gtaatggcgc	cggagggggg	aacaaggtgg	tgacgagtg	600
ctacatcccc	aactacctcc	tgcccaagac	tcagcccag	ctgcagtggg	cgtggactaa	660

140140433P1.TXT

catggaggag	tatataagcg	cgtgtttgaa	cctggccgag	cgcaaacggc	tcgtggcgca	720
gcacctgacc	cacgtcagcc	agacccagga	gcagaacaag	gagaatctga	accccaattc	780
tgacgcgcct	gtcatccggt	caaaaacctc	cgcgcgctac	atggagctgg	tcgggtggct	840
ggtaggaccg	ggcatcacct	ccgagaagca	gtggatccag	gaggaccagg	cctcgtacat	900
ctccttcaac	gccgcctcca	actcgcggtc	ccagatcaag	gccgctctgg	acaatgccgg	960
caagatcatg	gcgctgacca	aatccgcgcc	cgactacctg	gtaggccccg	ctcctccccg	1020
ggacattaaa	accaaccgca	tctaccgcat	cctggagctg	aacggctacg	accctgccta	1080
cgccggctcc	gtctttctcg	gctgggcccc	gaaacggttc	gggaagcgca	acaccatctg	1140
gctgtttggg	ccggccacca	cgggcaagac	caacatcgcg	gaagccatcg	cccacgccgt	1200
gcccttctac	ggctgcgtca	actggacca	tgagaacttt	cccttcaacg	attgcgtcga	1260
caagatgggt	atcttggtgg	aggagggcaa	agggtcggtg	aaggtcggtg	agtcgccaa	1320
ggccattctc	ggcggcagca	agggtgcggt	ggaccaaaag	tgcaagtcgt	ccgccagat	1380
cgatcccacc	cccgtgatcg	tcacctccaa	caccaacatg	tgccgctgta	ttgacgggaa	1440
cagcaccacc	ttcagacacc	agcagccgtt	gcaggaccgg	atgttcaaat	ttgaactcac	1500
ccgccgtctg	gagcatgact	ttggcaaggt	gacaaagcag	gaagtcaaa	agttcttcg	1560
ctgggcgag	gatcacgtga	ccgaggtggc	cgatgaagtc	tacgtcagaa	aggggtggagc	1620
caacaaaaga	cccgcctccg	atgacgcgga	taaaagcgag	cccaagcggg	cctgccccctc	1680
agtcgcggat	ccatcgacgt	cagacgcgga	aggagctccg	gtggactttg	ccgacaggta	1740
ccaaaacaaa	tgcttctcgt	acgcgggcat	ctgtcagatg	ctgtttccct	gcaagacatg	1800
cgagagaatg	aatcagaatt	tcaacatttg	cttcacgcac	gggaccagag	actgttcaga	1860
atgtttcccc	ggcgtgtcag	aatctcaacc	ggtcgtcaga	aaaaggacgt	atcggaaact	1920
ctgtgcgatt	catcatctgc	tggggctggc	tcccagagatt	gcttgctcgg	cctgcgatct	1980
ggtaacgtgc	gacttggaag	actgtgtctc	tgagcaataa	atgacttaaa	ccaggtatgg	2040
ctgccgatgg	ttatcttcca	gattggctcg	aggacaacct	ctctgagggc	attcgcgagt	2100
ggtagggact	gaaacctgga	gccccgaaac	ccaaagccaa	ccagcaaaag	caggacgacg	2160
gccggggctc	ggtgcttctc	ggctacaagt	acctcggaac	cttcaacgga	ctcgacaagg	2220
gggagccctg	caacgcggcg	gacgcagcgg	ccctcgagca	cgacaaggcc	tacgaccagc	2280
agctcaaaag	gggtgacaa	ccgtacctgc	ggtataacca	cgccgacgcc	gagtttcagg	2340
agcgtctgca	agaagatacg	tcttttgggg	gcaacctcgg	gcgagcagtc	ttccaggcca	2400
agaagcgggt	tctcgaacct	tttggtctgg	ttgaggaagg	cgctaagacg	gctcctggaa	2460
agaaacgtcc	ggtagctcgc	tcgccacaag	agccagactc	ctcctcgggc	atcggcaaga	2520
caggccagca	gcccgcataa	aagagactca	attttggtca	gactggcgac	tcagagtcag	2580
tccccgaccc	acaacctctc	ggagaacctc	cagcaacccc	cgctgctgtg	ggacctacta	2640
caatggcttc	aggcgggtgg	gcaccaatgg	cagacaataa	cgaaaggcgc	gacggagtgg	2700
gtaatgccct	gggattctgg	cattgcgatt	ccactgggct	gggcgacaga	gtcatcacca	2760
ccagcacccg	cacctggggc	ttgccacctc	acaataacca	cctctacaag	caaatctcca	2820
gtgcttcaac	ggggggccagc	aacgacaacc	actactcgg	ctacagcacc	ccctgggggt	2880
attttgattt	caacagattc	cactgccact	tttaccgcg	tgactggcag	cgactcatca	2940
acaacagtgg	gggattccgg	cccaagagac	gctcttcaac	gctcttcaac	atccaagtca	3000
aggaggtcac	gacgagtgat	ggcgtcaca	ccatcgctaa	taaccttacc	agcacggttc	3060
aagtcttctc	ggactcggag	taccagcttc	cgtaagctct	cggtctctcg	caccagggtc	3120
gcctccctcc	gttcccggcg	gacgtgttca	tgattccgca	atacggctac	ctgacgtcga	3180
acaatggcag	ccaagccgtg	ggacgttcat	ctgtttactg	cctggaatat	ttcccttctc	3240
agatgctgag	aacgggcaac	aactttacct	tcagctacac	ctttgaggaa	gtgcctttcc	3300
acagcagcta	cgcgcacagc	cagagcctgg	accggctgat	gaatcctctc	atcgaccaat	3360
acctgtatta	cctgaacaga	actcaaaatc	agtcgggaag	tgcccaaaac	aaggacttgc	3420
tgtttagccg	tggtgtctca	gctggcatgt	ctgttcagcc	caaaaactgg	ctacctggac	3480
cctgttatcg	gcagcagcgc	gtttctaaaa	caaaaacagg	caacaacaac	agcaatttta	3540
cctggactgg	tgcttcaaaa	tataacctca	atgggcatga	atccatcatc	aaccctggca	3600
ctgctatggc	ctcacacaaa	gacgacgaag	acaagtcttt	tcccatgagc	ggtgtcatga	3660
tttttgaaa	agagagcgcc	ggagcttcaa	acactgcatt	ggacaatgtc	atgattacag	3720
acgaagagga	aattaaagcc	actaacctcg	tggccaccga	aagatttggg	accgtggcag	3780
tcaatttcca	gagcagcagc	acacaccctg	cgaccggaga	tgtagcatgtt	atgggagcat	3840
tacctggcat	ggtgtggcaa	gatagagacg	tgtacctgca	gggtcccatc	tgggcaaaaa	3900
ttcctcacac	agatggacac	tttcacccgt	ctccttttat	gggcgggcttt	ggactcaagc	3960
acccgcctcc	tcagatcttc	atcaaaaaaca	cgctgtttcc	tgcaaatcct	ccggcgaggt	4020
tttcagctac	aaagtgtgct	tcattcatca	cccaatactc	caaggacaa	gtgagtgtgg	4080
aaattgaatg	ggagctgcag	aaagaaaaaca	gcaagcgctg	gaatcccga	gtgcagtaca	4140
catccaatta	tgcaaaatct	gccaacgttg	attttaccgt	ggacaacaat	ggactttata	4200
ctgagcctcg	ccccattggc	acccgttacc	ttaccgcgtc	cctgtaatta	cgtgttaatc	4260
aataaaccgg	ttgattcgtt	tcagttgaac	tttggctctc	tgctcc		4305

140140433P1.TXT

<211> 4196

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<221> misc_feature

<222> 745, 826, 845, 932, 960, 1003

<223> N can be A, C, G, or T

<400> 3

ccgcgagtga	gcgaaccagg	agctccattt	tgcccgcgaa	ttttgaacga	gcagcagcca	60
tgccgggatt	ctacgagatt	gtcctgaagg	tgcccagcga	cctggacgag	cacctgcctg	120
gcattttctga	ctcttttgta	aactgggtgg	cggagaagga	atgggagctg	ccgccggatt	180
ctgacatgga	tctgaatctg	attgagcagg	caccctaac	cgtggccgaa	aagctgcaac	240
gcgaattcct	ggtcgagtgg	cgccgcgtga	gtaaggcccc	ggaggccctc	ttctttgttc	300
agttcgagaa	gggggacagc	tacttccacc	tacacattct	ggtggagacc	gtgggcgtga	360
aatccatggt	ggtgggcccgc	tacgtgagcc	agattaaaga	gaagctggtg	acccgcatct	420
accgcggggt	cgagccgcag	cttccgaact	ggttcgcggt	gaccaagacg	cgtaatggcg	480
ccggaggcgg	gaacaagggtg	gtggacgact	gctacatccc	caactacctg	ctccccaaga	540
cccagcccga	gtctccagtgg	gcgtggacta	atatggacca	gtatttaagc	gcctgtttga	600
atctcgcggt	gcgtaaacgg	ctggtggcgc	agcatctgac	gcacgtgtcg	cagacgcagg	660
agcagaacaa	agagaaccag	aaccnaattc	tgacgcgcgg	gtgattcgat	caaaacctcc	720
gcgaggtaca	tggagctggt	cgggtggctg	gtggaccnng	ggatcncgtc	agaaaagcaa	780
tggantccag	gaggaccagg	cctctttacat	ctccttcaac	gccgcctcca	actcgcggtc	840
acaaatcaag	gccgcactgg	acaatgcctc	cnaaattatg	agcctgacaa	aaacggctcc	900
ggactacctg	gtgggaaaca	acccgccgga	ggacattact	canaaccgga	tctacaaaat	960
cctcgagatg	aacgggtacg	atccgcagta	cgcgccctcc	gtcttctctg	gctgggcgca	1020
aaagaagttc	gggaagagga	acaccatctg	gctcttttgg	ccggccacga	cgggtaaaaa	1080
caacatcggt	gaagctatcg	cccacgccgt	ttccctttac	ggctgcgtga	actggaccaa	1140
tgagaacttt	ccgttcaacg	attgcgctga	caagatgggtg	atctgggtgg	aggagggcaa	1200
gatgacggcc	aaggtcgtgg	agtccgccaa	ggccattctg	ggcggaagca	aggtgcgcgt	1260
ggaccaaaag	tgcaagtcac	cggcccagat	cgacccaact	cccgtcatcg	tcacctccaa	1320
caccaatcgt	tgccgcggtca	tccagcggaa	ttccaccacc	ttcgaagcacc	aacaaccact	1380
ccaagaccgg	atgttcaagt	tccagctcac	caagcgcctg	gagcacgact	ttggcaagggt	1440
caccaagcag	gaagtcaagg	actttttccg	gtgggcgtca	gatcacgtga	ctgaggtgtc	1500
tacagagttt	tacgtcagaa	aggggtggagc	tagaaaagagg	cccgcctcca	atgacgcaga	1560
ataatcgtag	cccacgcggg	cctgtccgtc	agttggcgca	ccatcgacgt	cagacgcgga	1620
agctccgggt	gactacgcgg	acaggtacca	aaacaaatgt	tctcgtcacg	tgggcatgaa	1680
tctgatgctt	tttccctgcc	ggcaatgcga	gagaatgaat	cagaatgtgg	acatttgcct	1740
cacgcacggg	gtcatggact	gtgccgagtg	cttccccgtg	tcagaatctc	aaccctgttc	1800
tgctgctcaga	aagcggacat	atcagaaact	gtgtccgatt	catcacatca	tggggagggc	1860
gcccagaggtg	gcttggttcg	cctgcatctt	ggccaatgtg	gacttggatg	actgtgacat	1920
ggagcaataa	atgactcaaa	ccagatatga	ctgacgggtt	ccttccagat	tggttagagg	1980
acaacctctc	tgaaggcggt	cgagagtgggt	gggcgctgca	acctggagcc	cctaaaccca	2040
aggcaaatca	acaacatcag	gacaacgcctc	ggggtcttgt	gcttccgggt	tacaaatacc	2100
tcggaccctg	caacggactt	gacaaggggg	aaccctgcaa	cgcagcggac	gcggcagccc	2160
tcgaacacga	caaggcctac	gaccagcagc	tcaaggccgg	tgacaacccc	tacctcaagt	2220
acaaccacgc	cgacgccgag	tttcaggagc	gtcttcaaga	agatacgtct	tttgggggca	2280
acctcggacg	agcagtcctt	caggccaaaa	agagatcctt	tgagcctctg	ggtctgggtg	2340
aggaagcggc	taagacggct	cctggaaaaa	agagacctgt	agagcaatct	ccagcagaac	2400
cggactcctc	ttcgggcatc	ggcaaatcag	gccagcagcc	cgtagaaaaa	agactgaatt	2460
ttggtcagac	tgggcagaca	gagtcagtc	cagacctca	accactcgga	caacctccc	2520
cagccccctc	tgggtgtggga	tctactacaa	tggtcttcagg	cgggtggcgca	ccaatggcag	2580
acaataacga	gggtgccgat	ggagtgggta	attcctcagg	aaattggcat	tgcgattccc	2640
aatgggtggg	cgacagagtc	atcaccacca	gcacccgcac	ctgggcccctg	cccacctaca	2700
acaatcacct	ctacaagcaa	atctccagcc	aatcaggagc	caccaacgac	aaccactact	2760
ttggctacag	caccccctgg	gggtattttg	acttcaacag	attccactgc	cacttttcac	2820
cacgtgactg	gcaaagactc	atcaacaaca	actggggatt	ccgacccaag	agactcaact	2880
tcaagctctt	taacattcaa	gtcaaagagg	tcacgcagaa	tgacgggtacg	acgacgattg	2940
ccaataacct	taccagcacg	gttcagggtg	ttactgactc	cgagtaccag	ctcccgtacg	3000

140140433P1.TXT

tcctcggctc	ggcgcatcag	ggatgcctcc	cgccgttccc	agcagacgtc	ttcatggctc	3060
caagatattg	atacctcacc	ctgaacaacg	ggagtcaggc	ggtaggacgc	tcttcctttt	3120
actgcctgga	gtactttcct	tctcagatgc	tgctgactgg	aaacaacttt	cagtttagct	3180
acacttttga	agacgtgcct	ttccacagca	gctacgtctc	cagccaaagt	ctggaccgtc	3240
tcatgaatcc	tctgatcgac	cagtacctgt	actatctgaa	caggacacaa	acagccagtg	3300
gaactcagca	gtctcggcta	ctgttttagc	aagctggacc	caccagtatg	tctcttcaag	3360
ctaaaaactg	gctgcctgga	ccttgctaca	gacagcagcg	tctgtcaaag	caggcaaacg	3420
acaacaacaa	cagcaacttt	ccctggactg	gtgccaccaa	atatcatctg	aatggccggg	3480
actcattggt	gaaccgggc	cctgctatgg	ccagtcacaa	ggatgacaaa	gaaaagtgtt	3540
tccccatgca	tggaaacctg	atatttggtg	aagaagggaac	aaatgccaac	aacgcggatt	3600
tggaaaatgt	catgattaca	gatgaagaag	aaatccgcac	caccaatccc	gtggctacgg	3660
agcagtagtg	gactgtgtca	aataatttgc	aaaactcaaa	cgctgggtcca	actactggaa	3720
ctgtcaatca	ccaaggagcg	ttacctggtg	tgggtgtggca	ggatcgagac	gtgtacctgc	3780
agggacccat	ttgggccaag	attcctcaca	ccgatggaca	ctttcatcct	tctccactga	3840
tgggaggttt	tgggctcaaa	caccgcctc	ctcagatcat	gatcaaaaaac	actcccgttc	3900
cagccaatcc	tcccacaac	tttagtgcg	caaagtgtgc	ttccttcac	acacagtact	3960
ccacggggca	ggtcagcggt	gagatcgagt	gggagctgca	gaaggagaac	agcaaacgct	4020
ggaaatcccg	aattcagtag	acttccaact	acaacaaatc	tgtaaatgtg	gactttactg	4080
tggacactaa	tgggtgtgat	tcagagcctc	gccccattgg	caccagatac	ctgactcgta	4140
atctgtaatt	gcttgtaatt	caataaaacc	gttgattcgt	ttcagttgaa	ctttgg	4196

<210> 4

<211> 3005

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 4

tgggtgggagg	agggcaagat	gacggccaag	gtcgtggagt	ccgccaaggc	cattctcggc	60
ggcagcaagg	tgcgcgtgga	ccaaaagtgc	aagtctgtcc	ccagatcga	tcccaccccc	120
gtgatcgtca	cctccaacac	caacatgtgc	gccgtgattg	acgggaacag	caccaccttc	180
gagcaccagg	agccgttgca	ggaccggatg	ttcaaatgtg	aactcacccg	ccgtctggag	240
catgactttg	gcaaggtgac	aaagcaggaa	gtcaaaagat	tcttcgctg	ggcgaggat	300
cacgtgaccg	aggtggcgca	tgagtcttac	gtcagaaagg	gtggagccaa	caaaagaccc	360
gcccccgatg	acgcggataa	aagcagagcc	aagcgggcct	gccccctagt	cgcggaacca	420
tccagctcag	acgcggaagg	agctccgggt	gactttgccg	acaggtacca	aaacaaatgt	480
tctcgtcacg	cgggcatgct	tcagatgctg	tttccctgca	agacatgcga	gagaatgaat	540
cagaatttca	acatttgctt	cacgcacggg	accagagact	gttcagaatg	tttccccggc	600
gtgtcagaat	ctcaaccggg	cgtcagaaaa	aggacgtatc	ggaaactctg	tgcgattcat	660
catctgctgg	ggcgggctcc	cgagattgct	tgctcggcct	gcgatctggt	caacgtggac	720
ctggatgact	gtgtctctga	gcaataaatg	acttaaacca	ggtatggctg	ccgatgggta	780
tcttcagat	tggctcgagg	acaacctctc	tgagggcatt	cgcgagtggg	gggacttgaa	840
acctggagcc	ccgaaaccca	aagccaacca	gcaaaagcag	gacgacggcc	ggggctcggg	900
gcttcctggc	tacaagtacc	tcggaccctt	caacggactc	gacaaggggg	agcccgtcaa	960
cgcggcggac	gcagcggccc	tcgagcacga	caaggcctac	gaccagcagc	tcaaagcggg	1020
tgacaatccg	tacctgcggg	ataaccacgc	cgacgcggag	tttcaggagc	gtctgcaaga	1080
agatacgtct	tttggggggc	acctcggggc	agcagtcctc	caggccaaga	agcgggttct	1140
cgaacctttt	ggtctgggtg	aggaaggcgc	taagacggct	cctggaaaga	aacgtccggg	1200
agagcagctg	ccacaagagc	cagactcctc	ctcgggcata	ggcaagacag	gccagcagcc	1260
cgctaaaaag	agactcaatt	ttggtcagac	tggcgactca	gagtcagtcc	ccgaccaca	1320
acctctcgga	gaacctccag	caacccccgc	tgctgtggga	cctactacaa	tggcttcagg	1380
cggtggcgca	ccaatggcag	acaataacga	aggcgccgac	ggagtgggta	atgcctcagg	1440
aaattggcat	tgcgattcca	catggctggg	cgacagagtc	atcaccacca	gcacccgcac	1500
ctgggccttg	cccacctaca	ataaccacct	ctacaagcaa	atctccagtg	cttcaacggg	1560
ggccagcaac	gacaaccact	acttcgggta	cagcaccctc	tgggggtatt	ttgatttcaa	1620
cagattccac	tggcactttt	caccacgtga	ctggcagcga	ctcatcaaca	acaattgggg	1680
attccggccc	aagagactca	acttcaagtc	cttcaacatc	caagtcaagg	aggtcacgac	1740
gaatgatggc	gtcacaacca	tcgctaataa	ccttaccagc	acggttcaag	tcttctcgga	1800
ctcggagtag	cagcttccgt	acgtcctcgg	ctctgcgcac	cagggtctgc	tcctccgtt	1860
cccggcggac	gtgttcatga	ttccgcaata	cggctacctg	acgtcaaca	atggcagcca	1920

140140433P1.TXT

agccgtggga	cgttcatcct	tttactgcct	ggaatatttc	ccttctcaga	tgctgagaac	1980
gggcaacaac	tttaccttca	gctacacctt	tgaggaagt	cctttccaca	gcagctacgc	2040
gcacagccag	agcctggacc	ggctgatgaa	tcctctcatc	gaccaatacc	tgtattacct	2100
gaacagaact	caaaatcagt	ccggaagtgc	ccaaaacaag	gacttgctgt	ttagccgtgg	2160
gtctccagct	ggcatgtctg	ttcagcccaa	aaactggcta	cctggaccct	gttatcggca	2220
gcagcgcggt	tctaaaacaa	aaacagacaa	caacaacagc	aattttacct	ggactgggtc	2280
ttcaaaatat	aacctcaatg	ggcgtgaatc	catcatcaac	cctggcactg	ctatggcctc	2340
acacaaaagac	agagaaagaca	agtcttttcc	catgagcggg	gtcatgattt	ttggaaaaga	2400
gagcgccgga	gcttcaaaca	ctgcattgga	caatgtcatg	attacagacg	aagaggaaat	2460
taaagccact	aaccctgttg	ccaccgaaag	atttgggacc	gtggcagtc	atttccagag	2520
cagcagcaca	gaccctgcga	ccggagatgt	gcatgttatg	ggagcattac	ctggcatggg	2580
gtggcaagat	agagacgtgt	acctgcagg	tcccatctgg	gccaaaattc	ctcacacaga	2640
tggacacttt	cacccgtctc	ctcttatggg	cggcttttga	ctcaagcacc	cgctctctca	2700
gctcctcatc	aaaaacacgc	ctgttcctgc	gaatcctccg	gcggagtttt	cagctacaaa	2760
gtttgcttca	ttcatcacc	aatactccac	aggacaagt	agtgtgga	ttgaatggga	2820
gtgacagaaa	gaaaacagca	agcgctggaa	tcccgaagt	cagtacacat	ccaattatgc	2880
aaaatctgcc	aacgttgatt	ttaccgtgga	caacaatgga	ctttatactg	agcctcgccc	2940
cattggcacc	cgttacctta	cccgtcccct	gtaattacgt	gttaatcaat	aaaccgtttm	3000
attcg						3005

<210> 5

<211> 3014

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<221> misc_feature

<222> 6

<223> N can be A, C, G, or T (U)

<400> 5

atgctnatgt	gggtgggagga	gggcaagatg	acggccaagg	tcgtggagtc	cgccaaggcc	60
attctcggcg	gcagcaaaagt	gcgcgtggac	caaaagtgc	agtcgtccgc	ccagatcgat	120
cccacccccg	tgatcgtcac	ctccaacacc	aacatgtgcg	ccgtgattga	cgggaaacagc	180
accaccttctg	agcaccagca	gccgttgacg	gaccggatgt	tcaaatttga	actcaccgcg	240
cgtctggagc	atggatttgg	caagggtgaca	aaacagggaag	tcaaagagtt	cttccgctgg	300
gcgcaggatc	acgtgaccga	ggtagcgcat	gagttctacg	tcagaaaggg	tggagccaac	360
aagagacccg	ccccgatga	cgcggaataa	agcgagccca	agcgggtctg	cccctcagtc	420
gcggatccat	cgacgtcaga	cgcggaagga	gttccgggtg	actttgccga	caggatccaa	480
aacaaatggt	ctcgtcacgc	gggcatgctt	cagatgctgt	ttccctgcaa	aacatgagag	540
agaatgaatc	agaatttcaa	catttgcttc	acgcacggga	ccagagactg	ttcagaatgt	600
ttccccggcg	tgtcagaatc	tcaaccggtc	gtcagaaaaa	ggacgtatcg	gaaactctgt	660
gccattcatc	atctgctggg	gcgggctccc	gagattgctt	gctcggcctg	cgatctggtc	720
aacgtggacc	tggatgactg	tgtttctgag	caataaatga	cttaaaccag	gtatggctgc	780
cgatgggttat	cttccagatt	ggctcgagga	caacctctct	gagggcattc	gcaagtgggtg	840
ggacttgaaa	cctggagccc	cgaaacccaa	agccaaccag	caaaagcagg	acgacggccg	900
gggtctgggtg	cttcctggct	acaagtacct	cggacccttc	aacggactcg	acaaggggga	960
gcccgtaac	gcggcggaag	cagcgccctc	cgagcagcac	aaggcctacg	accagcagct	1020
caaagcgggt	gacaatccgt	acctgcggta	taaccacgcc	gacgccgagt	ttcaggagcg	1080
tctgcaagaa	gatacgtctt	ttgggggcaa	cctcgggaga	gcagtcttcc	aggccaagaa	1140
gcgggttctc	gaaccttttg	gtctggttga	ggaaggcgct	aagacggctc	ctggaaagaa	1200
acgtccggta	gagcagtcgc	cacaagagcc	agactcctcc	tcgggcatcg	gcaagacagg	1260
ccagcagccc	gctaaaaaga	gactcaatct	tggtcagact	ggcgactcag	agtcagtcct	1320
cgacccacaa	cctctcggag	aacctccagc	aacccccgct	gctgtgggac	ctactacaat	1380
ggcttcaggc	ggtggcgcac	caatggcaga	caataacgaa	ggcgccgacg	gagtggttaa	1440
tgctccagga	aattggcatt	gcgattccac	atgggtgggc	gacagagtca	tcaccaccag	1500
cacccgcacc	tgggcttggc	ccacctacaa	taaccacctc	tacaagcaaa	tctccagtgc	1560
ttcaacgggg	gccagcaacg	acaaccacta	cttcggctac	agcaccctct	gggggtatct	1620
tgatttcaac	agattccact	gccacttttc	accacgtgac	tggcagcgac	tcatcaacaa	1680
caattgggga	ttccggccca	agagactcaa	cttcaagctc	ttcaacatcc	aagtcaagga	1740

140140433P1.TXT

ggtcacgacg	aatgatggcg	tcacaacccat	cgctaataac	cttaccagca	cggttcaagt	1800
cttctcggac	tcggagtacc	agcttccgta	cgctctcggc	tctgcgacc	agggctgcct	1860
ccctccgttc	ccggcggacg	tggtcatgat	tccgcaatac	ggctacctga	cgctcaacaa	1920
tggcagccaa	gccgtgggac	gttcatcctt	ttactgcctg	gaatatttcc	cttctcagat	1980
gctgagaacg	ggcaacaact	ttaccttcag	ctacaccttt	gaggaagtgc	ctttccacag	2040
cagctacgag	cacagccaga	gcctggaccg	gctgatgaat	cctctcatcg	accaatacct	2100
gtattacctg	aacagaactc	aaaatcagtc	cgggaagtgc	caaaacaagg	acttgctgtt	2160
tagccgtggg	tctccagctg	gcatgtctgt	tcagcccaaa	aactggctac	ctggaccctg	2220
ttatcggcag	cagcgcgttt	ctaaaacaaa	aacagacaac	aacaacagca	attttacctg	2280
gactgggtgt	tcaaaatata	acctcaatgg	gcgtgaatcc	atcatcaacc	ctggcactgc	2340
tatggcctca	cacaaagacg	acaagacaa	gttctttccc	atgagcgggt	tcatgatttt	2400
tggaaaagag	agcgccggag	cttcaaacac	tgcattggac	aatgtcatga	ttacagacga	2460
agaggaaaatt	aaagccacta	accctgtggc	caccgaaaga	tttgggaccg	tggcagtcga	2520
tttccagagc	agcagcacag	accctgcgac	cggagatgtg	catgttatgg	gagcattacc	2580
tggcatggtg	tggcaagata	gagacgtgta	cctgcagggg	cccatttggg	ccaaaatttc	2640
tcacacagat	ggacactttc	accggtctcc	tcttatgggc	ggctttggac	tcaagcacc	2700
gcctcctcag	atctctcatca	aaaacacacc	tggtcctgcg	aatcctccgg	cggagttttc	2760
agctacaaag	tttgcttcat	tcatacccca	atactccaca	ggacaagtga	gtgtggaaat	2820
tgaatgggag	ctgcagaaag	aaaacagcaa	gcgttggaat	cccgaagtgc	agtacacatc	2880
caattatgca	aaatctgcc	acgttgattt	taccgtggac	aacaatggac	tttatactga	2940
gcctcgcccc	attggcacc	gttaccttac	ccgtccccctg	taattacgtg	ttaatcaata	3000
aaccgkthh	ttcg					3014

<210> 6

<211> 3010

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 6

tgatttggtg	ggaggagggc	aagatgacgg	ccaaggtcgt	ggagtccgcc	aaagccattc	60
tcggcggcag	caaggtgcgc	gtggaccaaa	agtgcagtc	gtccgcccrg	atcgatccca	120
cccccgtag	cgctacctcc	aacaccaaca	tgtgcgccgt	gattgacggg	aacagcacca	180
ctttcgagca	ccagcagccg	ttgcaggacc	ggatgttcaa	atttgaactc	accgcgctc	240
tggagcatga	ctttggcaag	gtgacaaagc	aggaagtcaa	agagttcttc	cgctgggcgc	300
aggatcacgt	gaccgaggtg	gcgcgatgag	tctacgtcag	aaaggggtgga	gccaacaaaa	360
gaccgcccc	cgatgacgcg	gataaaagcg	agcccaagcg	ggcctgcccc	tcagtcgagg	420
atccatcgac	gtcagacgcg	gaaggagctc	gtgtggactt	tgccgacagg	taccaaaca	480
aatgttctcg	tcacgcgggc	atgcttcaga	tgtgtttcc	ctgcaagaca	tgcgagagaa	540
tgaatcagaa	tttcaacatt	tgcttcacgc	acgggaccag	agactgttca	gaatgtttcc	600
ccggcgtgtc	agaatctcaa	ccggtcgtca	gaaaaaggac	gtatcgaaa	ctctgtgcga	660
ttcatcatct	gctggggcgg	gctcccagaa	ttgcttgctc	ggcctgcgat	ctggtcaacg	720
tggacctgga	tactgtgtgc	tctgagcaat	aatgactta	aaccagggtat	ggctgccgat	780
ggttatcttc	cagattggct	cgaggacaac	ctctctgagg	gcattcgcga	gtggtgggac	840
ttgaaacctg	gagccccgaa	acccaaagcc	aaccagcaaa	agcaggacaa	cggccggggg	900
ctggtgcttc	ctggctacaa	gtacctcgga	cccttcaacg	gactcgacaa	gggggagccc	960
gtcaacgcgg	cggacgcagc	ggccctcgag	cacgacaagg	cctacgacca	gcagctcaaa	1020
gcgggtgaca	atccgtacct	gcggtataac	cacgcccagc	ccgagtttca	ggagcgtctg	1080
caagaagata	cgtcttttgg	gggcaacctc	gggcgagcag	tcttccaggc	caagaagcgg	1140
gttctcgaac	cttttgggtc	gggtgaggaa	ggcgctaaga	cggctcctgg	aaagaaacgt	1200
ccggtagagc	agtcgccaca	agagccagac	tcctcctcgg	gcatcgccaa	gacaggccag	1260
cagcccgtca	aaaagagact	caattttggt	cagactggcg	actcagagtc	agtcctccgc	1320
ccacaacctc	tcggagaacc	tccagcaacc	cccgtgctg	tgggacctac	tacaatggct	1380
tcaggcggtg	gcgcaccaat	ggcagacaat	aacgaaggcg	ccgacggagt	gggtaatgcc	1440
tcaggaaatt	ggcattgcga	ttccacatgg	ctgggcgaca	gagtcatcac	caccagcacc	1500
cgcacctggg	ccttgcctcc	ctacaataac	cacctctaca	agcaaatctc	cagtgtctta	1560
acggggggcca	tcaacgacaa	ccactacttc	ggctacagca	ccccctgggg	gtattttgat	1620
ttcaacagat	tccactgcc	cttttacc	cgtgactggc	agcgactcat	caacaacaat	1680
tggggattcc	ggcccaagag	actcaacttc	aagctcttca	acatccaagt	caaggaggct	1740
acgacgaatg	atggcgctac	aacctatcgt	aataacctta	ccagcacggt	tcaagtcttc	1800

140140433P1.TXT

tcggactcgg	agtaccagct	tccgtacgtc	ctcggctctg	cgcaccaggg	ctgcctccct	1860
ccgttccccg	cggacgtgtt	catgattccg	caatacggct	acctgacgct	caacaatggc	1920
agccaagccg	tgggacgttc	atcctttttac	tgcttggaat	atttcccttc	tcagatgctg	1980
agaacgggca	acaactttac	cttcagctac	acctttgagg	aagtgccttt	ccacagcagc	2040
tacgcgcaca	gccagagcct	ggaccggctg	atgaatcctc	tcacgcacca	atacctgtat	2100
tacctgaaca	gaactcaaaa	tcagtccgga	agtgcctcaa	acaaggactt	gctgttttagc	2160
cgtgggtctc	cagctggcat	gtctgttcag	cccaaaaact	ggctacctgg	accctgttat	2220
cggcagcagc	gcgtttctaa	aacaaaaaca	gacaacaaca	acagcaattt	tacctggact	2280
ggtgcttcaa	aataataacct	caatgggcgt	gaatccatca	tcaaccctgg	cactgctatg	2340
gcctcacaca	aagacgacga	agacaagttc	tttcccatga	gcgggtgcat	gatttttgga	2400
aaagagagcg	ccggagcttc	aaacactgca	ttggacaatg	tcattgattac	agacgaagag	2460
gaaattaaag	ccactaacc	tgtggccacc	gaaagatttg	ggaccgtggc	agtcaatttc	2520
cagagcagca	gcacacaccc	tgcgaccgga	gatgtgcatg	ttatgggagc	attacctggc	2580
atggtgtggc	cgtgtacctg	caggttccca	tcgtggccaa	aattcctcac	2640	
acagatggac	actttcacc	gtctcctctt	atgggcggct	ttggactcaa	gcacccgcct	2700
cctcagatcc	tcataaaaa	cacgcctgtt	cctgcgaatc	ctccggcgga	gttttcagct	2760
acaaagtttg	cttcattcat	cacccaatac	tccacaggac	aagtgagtgt	ggaaattgaa	2820
tgggagctgc	agaaaagaaa	cagcaagcgc	tgggattccc	aagtgcagta	cacatccaat	2880
tatgcaaat	ctgccaacgt	tgattttacc	gtggacaaca	atggacttta	tactgagcct	2940
cgccccattg	gcacccgtta	ccttaccctg	cccctgtaat	tacgtgttaa	tcaataaacc	3000
gtttyattcg						3010

<210> 7

<211> 3008

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 7

atytggtggg	aggagggcaa	gatgacggcc	aaggtcgtgg	agtccgccaa	ggccattctc	60
ggcggcagca	aggtgcgctg	ggaccaaag	tgcaagtcgt	ccgccagat	cgatcccacc	120
cccgtgatcg	tcacctcaa	caccaacatg	tgcgccgtga	ttgacgggaa	cagcaccacc	180
ttcagacacc	agcagccgtt	gcaggaccgg	atgttcaaat	ttgaactcac	ccgccgtctg	240
gagcagcact	ttggcaaggt	gacaaagcag	gaagtcaaa	agttcttccg	ctgggcgcag	300
gatcacgtga	ccgaggtggc	gcatgagttc	tacgtcagaa	aggggtggagc	caacaagaga	360
cccgcccccg	atgacgcgga	taaaagcgag	cccaagcggg	cctgccccctc	agtcgcggat	420
ccatcgacgt	cagacgcgga	aggagctccg	gtggactttg	ccgacaggta	ccaaaacaaa	480
tgttctcgtc	acgcgggcat	gcttcagatg	gttttccct	gcaaaacatg	cgagagaatg	540
aatcagaatt	tcaacatttg	cttcacgcac	gggaccagag	actgttcaga	gtgctttccc	600
ggcgtgtcag	aatctcaacc	ggtcgtcaga	aaaaggacgt	atcggaact	ctgtgccatt	660
catcatctgc	tggggcgggc	tcccagatt	gcttgctcgg	cctgcgatct	ggtcaacgtg	720
gacatggatg	rcgtgttttc	tgagcaataa	atgacttaaa	ccaggatagg	ctgccgatgg	780
ttatcttcca	gattggctcg	aggacaacct	ctctgagggc	attcgcgagt	ggtgggactt	840
gaaacctgga	gccccgaac	ccaaagcaa	ccagcaaaag	caggacgacg	gccggggctt	900
ggtgcttctt	ggctacaagt	acctcgagcc	cttcaacgga	ctcgacaagg	gggagcccgt	960
caacgcggcg	gacgcagcgg	ccctcgagca	cgacaaggcc	tacgaccagc	agctcaaagc	1020
gggtgacaat	ccgtacctgc	gggtataacca	cgccgacgcc	gagtttcagg	agcgtctgca	1080
agaagatacg	tcittttggg	gcaacctcgg	gcgagcagtc	ttccaggcca	aaaagcgggt	1140
tctcgaacct	tttggtctgg	ttgaggaagg	cgctaagacg	gctcctggaa	agaaacgtcc	1200
ggtagagcag	tcgccacaag	agccagactc	ctcctcgggc	atcggcaaga	caggccagca	1260
gccccgtaaa	aagagactca	attttgggtca	gactggcgac	tcagagtcag	tccccgaccc	1320
acaacctctc	ggagaacctc	cagcaacccc	cgctgctgtg	ggacctacta	caatggcttc	1380
aggcgtgtgc	gcaccaatgg	cagacaataa	cgaaggcgcc	gacggagtgg	gtaatgcctc	1440
aggaaattgg	cattgcgatt	ccacatggct	gggcgacaga	gtcatcacca	ccagcaccgc	1500
cacctggggc	ttgcccacct	acaataacca	ctcttacaag	caaactctca	gtgcttcaac	1560
ggggggccagc	aacgacaacc	actacttcgg	ctacagcacc	ccctgggggt	attttgattt	1620
caacagattc	cactgccact	tttcaccacg	tgactggcag	cgactcatca	acaacaattg	1680
gggattccgg	cccaagagac	tcaacttcaa	gtcttcaac	atccaagtca	aggaggtcac	1740
gacgaatgat	cccgtcacaa	cctatcgtaa	taaccttacc	agcacgggtc	aagtcttctc	1800
ggactcggag	taccagcttc	cgtacgtcct	cggctctcgg	caccaggggt	gcctccctcc	1860

140140433P1.TXT

gttcccggcg	gacgtgttca	tgattccgca	atagcgctac	ctgacgctca	acaatggcag	1920
ccaagccgtg	ggacgttcat	cctttttattg	cctggaatat	ttcccatcgc	agatgctgag	1980
aacgggcaat	aactttacct	tcagctacac	ctttgaggac	gtgcctttcc	acagcagcta	2040
cgcgacagc	cagagcctgg	accggctgat	gaatcctctc	atcgaccagt	acctgtatta	2100
cctgaacaga	actcagaacc	agtccggaag	tgcccaaac	aaggacttgc	tgtttagccg	2160
gggggtctcca	gctggcatgt	ctgttcagct	caaaaactgg	ctacctggac	cctgttatcg	2220
gcagcagcgc	gtttctaaaa	caaaaacaga	caacaacaac	agcaatttta	cctggactgg	2280
tgcttcaaaa	tataacctta	atgggcgtga	atccatcatc	aaccctggca	ctgctatggc	2340
ctcacacaaa	gacgacgaag	acaagtctct	tcccatgagc	ggtgtcatga	tttttgaaa	2400
agagagcgcc	ggagcttcaa	acactgcatt	ggacaatgtc	atgattacag	acgaagagga	2460
aattaaagcc	actaaccttg	tggccaccga	aagatttggg	accgtggcag	tcaattttcca	2520
gagcagcagc	acagaccctg	cgaccggaga	tgtgatgttt	atgggagcat	tacctggcat	2580
ggtgtggcaa	gatagagacg	tgtacctgca	gggtcccatt	tgggccaaaa	ttcctcacac	2640
agatggacac	tttcaaccgt	ctcctcttat	ggcgcgcttt	ggactcaaac	accgcctcc	2700
tcagatcctc	atcaaaaaca	cacctgttcc	tgcgaatcct	ccggcggagt	tttcagctac	2760
aaagtgtgct	tattcatca	cccaatactc	cacaggaaca	gtgagcggtg	aaattggaatg	2820
ggagctgcag	aaagaaaaca	gcaagcgctg	gaatcccga	gtgcagtaca	catccaatta	2880
tgcaaatctt	gccaacgttg	attttacgtt	ggacaacaat	ggactttata	ctgagcctcg	2940
ccccattggc	acccggtacc	ttaccctgct	cctgtaatta	cgtgttaatc	aataaaccgk	3000
ttaattcg						3008

<210> 8

<211> 3021

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 8

atgctdatgt	ggtgggagga	gggcaagatg	acggccaagg	tcgtggagtc	cgccaaggcc	60
attctcggcg	gcagcaaagt	gcgcgtggac	caaaagtga	agtcgtccgc	ccagatcgac	120
cccacccccg	tcatcgtcac	ctccaacacc	aacatgtgcg	ccgtgattga	cgggaaacagc	180
accaccttcg	agcaccagca	gccgttgacg	gaccggatgt	tcaaatttga	actcaccgcg	240
cgtctggagc	acgacttttg	caagggtgac	aagcaggaag	tcaaagagtt	cttcacttgg	300
gcgcaggatc	acgtgaccga	ggtggcgcat	gagttctacg	tcagaaaggg	tggagccaac	360
aagagacccg	cccccgatga	cgcggaataa	agcgagccca	agcgggcctg	cccctcagtc	420
gcggatccat	cgagctcaga	cgcggaagga	gctcgggtgg	actttgccga	caggtaccaa	480
aacaaatggt	ctcgtcacgc	gggcattgctt	cagatgtctg	ttccctgcaa	aacatgcbag	540
agaatgaatc	agaatttcaa	catttgcttc	acgcacggga	ccagagactg	ttcagaatgt	600
ttccccggcg	tgtcagaatc	tcaaccggtc	gtcagaaaaa	agacgtatcg	gaaactctgt	660
gccattcatc	atctgctggg	gcgggctccc	gagattgctt	gctcggcctg	cgatctgggt	720
aatgtggacc	tggatgactg	tgtttctgag	caataaatga	cttaaaccag	gtatggctgc	780
cgatggttat	cttcagattt	ggctcgagga	caacctctct	gagggcattc	gcgagtgggt	840
ggacttgaaa	cctggagccc	cgaaacccaa	agccaaccag	caaaagcagg	acgacggccg	900
gggtctgggt	cttcctgggt	acaagtacct	cggacccttc	aacggactcg	acaaggggga	960
gcccgtcaac	gcgcgggacg	cagcggccct	cgagcacgac	aaggccctacg	accagcagct	1020
caaagcgggt	gacaatccgt	acctgcggta	taaccacgcc	gacgccgagt	ttcaggagcg	1080
tctgcaagaa	gatactctt	ttgggggcaa	cctcgggcga	gcagtcttcc	aggccaagaa	1140
gcgggttctc	gaaccttttg	gtctggttga	ggaagggtgt	aagacggctc	ctggaaagaa	1200
gagaccggta	gagcagtcgc	cccaagaacc	agactcctca	tcgggcacatg	gcaaatcagg	1260
ccagcagccc	gctaaaaaga	gactcaattt	tggtcagact	ggcgactcag	agtcagtccc	1320
cgaccacaaa	cctctcggag	aacctccagc	aacccccgct	gctgtgggac	ctactacaat	1380
ggcttcaggc	ggtggcgcac	caatggcaga	caataacgaa	ggcgccgacg	gagtgggtaa	1440
tgcttcagga	aattggcatt	gcgattccac	atggctgggc	gacagagtca	ttaccaccag	1500
caccgaacc	tgggcccctg	ccacctataa	caaccacctc	tacaaacaaa	tctccagcgc	1560
ttcaacgggg	gccagcaacg	acaaccacta	cttcggctac	agcacccttc	gggggtattt	1620
tgattttaac	agattccact	gccacttctc	accacgtgac	tggcagcgac	tcatacaaaa	1680
caattgggga	ttccggccca	cttcaagctc	ttcaacatcc	aagtcaagga	cggttcaagt	1740
ggtcacgacg	aacgatggcg	tcacgaccat	cgctaataac	cttaccagca	cggttcaagt	1800
cttctcggac	tcggagtacc	agttgccgta	cgtctcgggc	tctgcgcacc	agggctgcct	1860
ccctccgttc	cggcgagacg	tgttcatgat	tccgcagtac	ggctacctaa	cactcaacaa	1920

140140433P1.TXT

tggcagccag	gccgtgggac	gttcacccctt	ttactgcctg	gaatatattcc	catcgcagat	1980
gctgagaacg	ggcaataaact	ttaccttcag	ctacacattc	gaggacgtgc	ctttccacag	2040
cagctacgcg	cacagccaaa	gcctggaccg	gctgatgaat	cctctcatcg	accagtactt	2100
gtattaccta	aacagaactc	aaaatcagtc	cggaagtgcc	caaaacaagg	acttgctgtt	2160
tagccggggg	tctccagctg	gcatgtctgt	tcagcccaaa	aactgggtac	ctggaccctg	2220
ttatcggcag	cagcgcgttt	ctaaaacaaa	aacagacaac	aacaacagca	actttacctg	2280
gactggtgct	tcaaaatata	accttaattg	gcgtgaatct	ataatcaacc	ctggcactgc	2340
tatggcttca	cacaaagacg	acgaagacaa	gttctttcca	atgagcgggt	tcatgatttt	2400
tggcaaggag	agcgcgggag	cttcaaacac	tgcattggac	aatgtcatga	ttacagacga	2460
agaggaaatt	aaagccacta	accctgtggc	caccgaaaga	tttgggaccg	tggcagtcaa	2520
tttccagagc	agcagcacag	accctgcgac	cggagatgtg	catgttatgg	gagcattacc	2580
tggatgggat	tggcagtgta	cctgcagggt	cctgcagggt	ccaatttggg	ccaaaattcc	2640
tcacacagat	ggacactttc	accgtctccc	ctttatgggc	ggctttggac	ttaagcacc	2700
gcctcctcag	atcctcatca	aaaacacgcc	tgctcctgcg	aatcctccgg	cagagttttc	2760
ggctacaaag	tttgcttcat	tcatcaccca	gtattccaca	ggacaagtga	gtgtggaaat	2820
tgaatgggag	ttgcagaaag	aaaacagcaa	gcgttggaa	cccgaagtgc	agtacacatc	2880
taattatgca	aaatctgcca	acgttgattt	cactgtggac	aacaatggac	tttatactga	2940
gcctgcctcc	attggcaccc	gttacctcac	ccgtcccctg	taattacttg	ttaatcaata	3000
aaccgtgtha	ttcgtgtcag	t				3021

<210> 9

<211> 4222

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 9

ttgcgacatt	ttgcgacacc	atgtggccat	tcagggtata	tatggccgag	tgagcgagca	60
ggatctccat	tttgaccgcg	aaatttgaac	gagcagcagc	catgccgggc	ttctacgaga	120
tcgtgatcaa	ggtgccgagc	gacctggacg	agcacctgcc	gggcatttct	gactcgtttg	180
tgaactgggt	ggccgagaag	gaatgggagc	tgcccccgga	ttctgacatg	gatctgaatc	240
tgattgagca	ggcaccctctg	accgtggccg	agaagctgca	gcgcgacttc	ctggtccaat	300
ggcgccgcgt	gagtaaggcc	ccggaggccc	tcttctttgt	tcagttcgag	aagggcgagt	360
cctactttca	cctccatatt	ctgggtggaga	ccacgggggt	caaattccatg	gtgctgggcc	420
gcttcctgag	tcagattagg	gacaagctgg	tgagaccat	ctaccgcggg	atcgagccga	480
ccctgccccaa	ctgggttcgag	gtgaccaaga	cgcgtaattg	cgccggaggg	gggaacaagg	540
tggtaggagca	gagtaagcac	cccaactacc	tcttgcccaa	gactcagccc	gagctgcagt	600
ggcgctggac	taacatggag	gagtatataa	gcgcgtgttt	gaacctggcc	gagcgcaaac	660
ggctcgtggc	gcagcacctg	acccacgtca	gccagacca	ggagcagaac	aaggagaatc	720
tgaacccgaa	ttctgacgcg	cctgtcatcc	ggtcaaaaac	ctccgcgcgc	tacatggagc	780
tggtcgggtg	gctggtggac	cggggcatca	cctccgagaa	gcagtggatc	caggaggacc	840
aggcctcgta	catctccttc	aacgcccgcct	ccaactcgcg	gtcccagatc	aaggccgctc	900
tggacaatgc	cggcaagatc	atggcgctaa	ccaaatccgc	gccccgactac	ctggtaggcc	960
ccgtccgccc	cgcggacatt	aaaaccaacc	gcatttaccg	catcctggag	ctgaacggct	1020
acgaccctgc	ctacgcgggc	tccgtctttc	tcggctgggc	ccagaaaagg	ttcgggaagc	1080
gcaacacccat	ctggctgttt	gggcccggcca	ccacggggaa	gaccaacatc	gcggaagcca	1140
tcgcacacgc	cgtgcccttc	tacggctgcg	tcaactggac	caatgaaaac	tttcccttca	1200
acgactgcgt	cgacaagatg	gtgatctggg	gggaggaggg	caagatgacg	gccaaggctg	1260
tggagtcgag	caaggccatt	ctcggcggca	gcaagggtcg	cgtggaccaa	aagtgcaggt	1320
cgtccgcccc	gatcgatccc	accccgtga	tcgtcacctc	caacaccaac	atgtgcgcgg	1380
tgattgacgg	gaacagcacc	accttcgagc	accagcagcc	gttgaggagc	cggatgttca	1440
aatttgaact	caccgcgcgt	ctggagcagc	actttggcaa	ggtgacaaag	caggaagtca	1500
aagagtcttt	ccgctgggag	caggatcacg	tgaccgaggt	ggcgcatgag	ttctacgtca	1560
gaaaggggtg	agccaaacaag	agacccgccc	ccgatgacgc	ggataaaaagc	gagcccaagc	1620
gggtctgccc	ctcagtcgag	gatccatcga	cgtcagacgc	ggaaggagct	ccggtggact	1680
ttgccgacag	gtaccaaacc	aaatgtttct	gtcacgcggg	catgtctcag	atgtgtttc	1740
cctgcaaaac	atgcgagaga	atttcaacat	atttcaacat	ttgcttcacg	cacgggacca	1800
gagactgttc	agaatgtttc	ccggcggtgt	cagaatctca	accggtcgtc	agaaaaagga	1860
cgtatcgga	actctgtgcc	attcatcatc	tgctggggcg	ggctcccagag	attgcttgct	1920
cggcctgcga	tctggtcaac	gtggacctgg	atgactgtgt	ttctgagcaa	taaatgactt	1980

140140433P1.TXT

```

aaaccaggta tggctgccga tggttatctt ccagattggc tgcaggacaa cctctctgag 2040
ggcattcgcg agtgggtggga cttgaaacct ggagcccaga aaccacaaagc caaccagcaa 2100
aagcaggacg acggccgggg tctgggtgctt cctgggtaca agtacctcgg acccttcaac 2160
ggactcgaca agggggagcc cgtcaacgcg gcggacgcag cggccctcga gcacgacaag 2220
gcctacgacc agcagctcaa agcgggtgac aatccgtacc tgcggtataa ccacgccgac 2280
gccgagtttc aggcagctct gcaagaagat acgtcttttg ggggcaacct cgggcgagca 2340
gtcttcaggg ccaagaagag ggtttctcga ccttttggtc tggttgagga aggtgctaag 2400
acggctcctg gaaagaaacg tccggtagag cagtcacccc aagaaccaga ctctctctcg 2460
ggcattggca aatcaggcca gcagcccgct aaaaagagac tcaatttttg tcagactggc 2520
gactcagagt cagtcaccga cccacaacct ctcggagaa cctccagaa ccccgctgct 2580
ttgggacctt ctacaatggc ttcaggcggt ggcgcaccaa tggcagacaa taacgaaggc 2640
gccgctcctg tgggtaatgc ctcaggaat cgcattgag attccatg gctgggcgac 2700
agagtcatca ccaccagcac ccgcacctgg gcccgtggca cctacaataa ccacctctac 2760
aagcaaatct ccagtgtctt aacggggggc agcaacga ea accactactt cggctacagc 2820
acccctggg ggtattttga tttcaacaga ttccactgcc atttctcacc acgtgactgg 2880
cagcgactca tcaacaacaa ctggggattc cggccaaga gactcaactt caagctcttc 2940
aacatccaag tcaaggaggt cacgacgaac gatggcgta cgacctcgc taataacctt 3000
accagcacgg ttcaagtctt ctcggactcg gagtaccagc ttccgtacgt cctcggctct 3060
gcgcaccagg gctgcctccc tccgttccc ggcgacgtgt tcatgattcc gcagtacggc 3120
tacctgacgc tcaaatgg cagcaaaagg gtgggacgtt catcctttta ctgcctggaa 3180
tatttccctt ctcagatgct gagaacgggc aacaacttta ccttcagcta cacttttgag 3240
gaagtgcctt tccacagcag ctacgcgcac agccagagcc tggaccggct gatgaatcct 3300
ctcatcgacc aatacctgta ttacctgaac agaactcaaa atcagtccgg aagtgcccaa 3360
aacaaggact tgctgtttag ccgtgggtct ccagctggca tgtctgttca gcccaaaaac 3420
tggctacctg gacctgttta tcggcagcag cgcgtttcta aaacaaaaac agacaacaac 3480
aacagcaatt ttacctggac tgggtgttca aaatataacc tcaatgggag tgaatccatc 3540
atcaaccctg gcaactgctat ggccctcacac aaagacgacg aagacaagtt ctttcccatg 3600
agcgtgtgca tgatttttgg aaaagagagc gccggagcgt caaacactgc attggacaat 3660
gtcatgatta cagacgaaga ggaaattaaa gccactaacc ctgtggccac cgaaagattt 3720
gggaccgtgg cagtcaattt ccagagcagc agcacagacc ctgcgaccgg agatgtgcat 3780
gttatgggag cattacctgg catggtgtgg caagatagag acgtgtacct gcagggtccc 3840
atttgggcca aaatttcctca cacggatgga cactttcacc cgtctcctct tatggggcgc 3900
tttgactca agcaccgcc tctcagatc ctcataaaaa acacacctgt tcttcgaat 3960
cctccggcag agttttcggc tacaagttt gcttcattca taccagga ctccacagga 4020
caagtgcg tggaaattga atgggagttg cagaaagaaa acagtaagcg ctggaatccc 4080
gaagtgcagt acacatctaa ttatgcaaaa tctgccaaag ttgacttcac tgtggacaac 4140
aatggacttt atactgagcc tcgccccatt ggcaccggtt acctcaccgc tcccctgtaa 4200
ttacttgta atcaataaac cg 4222

```

<210> 10

<211> 4213

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 10

```

ttgcgacagt ttgcgacacc atgtgggtcac aagagggtata taaccgcgag tgagccagcg 60
aggagctcca ttttggccgc gaagtttgaa cgagcagcag ccatgccggg gttctacgag 120
gtgggtgatca aggtgcccag cgacctggac gagcacctgc ccggcatttc tgactccttt 180
gtgaactggg tggccgagaa ggaatgggag ttgcccccg attctgacat ggatcagaat 240
ctgattgagc aggcacccct gaccgtggcc gagaagctgc agcgcgagtt cctggtggaa 300
tggcgccgag tgagtaaat tctggaggcc aagtttttg tgcagtttga aaagggggac 360
tcgtactttc atttgcatat tctgattgaa attaccggcg tgaaatccat ggtggtggc 420
cgctacgtga gtcagattag ggataaactg atccagcgca tctaccgcgg ggtcgagccc 480
cagctgcccc actggttcgc ggtcacaagg acccgaaatg gcgcccggag cgggaacaag 540
gtgggtggac agtgctacat cccaactac ctgtcctcca aggtccagc cgagcttcag 600
tggcggtgga ctaacatgga ggagtatata agcgcctgtt tgaacctcgc ggagcgtaaa 660
cggctcgtgg cgcagcacct gacgcacgtc tccagaccc agggggcgca caaggagaat 720
ctgaacccga attctgacgc gccggtgatc cgggtcaaaa cctccgccag gtacatggag 780
ctggtcgggt ggctggtgga caagggcatc acgtccgaga agcagtggat ccaggaggac 840

```


140140433P1.TXT

caggcctcgt	acatctcctt	caacgcggcc	tccaactccc	ggtcgcagat	caaggcggcc	900
ctggacaatg	cctccaaaat	catgagcctc	acccaaacgg	ctccggacta	tctcatcggg	960
cagcagcccc	tgggggacat	taccaccaac	cggatctaca	aaatcctgga	actgaacggg	1020
tacgaccccc	agtacgccgc	ctccgtcttt	ctcggctggg	cccagaaaaa	gtttggaag	1080
cgcaacacca	tctggctggt	tgggcccggc	accaccggca	agaccaacat	cgcggaagcc	1140
atcgcccacg	cgggtcccctt	ctacggctgc	gtcaactgga	ccaatgagaa	ctttcccttc	1200
aacgactgcg	tgcacaaaat	ggtgatttgg	tgggaggagg	gcaagatgac	cgccaagggtc	1260
gtagagtccg	ccaaggccat	tctggggcgc	agcaagggtg	gcgtggacca	aaaatgcaag	1320
gcctctgcg	agatcgaccc	cacccccgtg	atcgtcacct	ccaacaccaa	catgtgcgcc	1380
gtgattgacg	ggaacagcac	caccttcgag	caccagcagc	ccctgcagga	ccggatgttc	1440
aagtttgaac	taccccgccg	cctcgaccac	gactttggca	agggtcacca	gcagggaagtc	1500
aaggactttt	tccggtgggc	ggctgatcac	gtgactgacg	tgggtcatga	gttttactgc	1560
acaaagggtg	agtctaagaa	aaggcccggc	ccctctgacg	aggatataag	cgagcccaag	1620
cgccgcgcgc	tgtcatttgc	gcagccggag	acgtcagacg	cggaagctcc	cgagacttcc	1680
gccgacaggt	accaaaacaa	atgttctcgt	cacgcgggta	tgctgcagat	gctctttccc	1740
tgcaagacgt	gcgagagaat	gaatcagaat	tccaacgtct	gcttcacgca	cggtcagaaa	1800
gattgcgggg	agttctttcc	cggtcagaa	tcttcaaccg	tttctgtcgt	cagaaaaacg	1860
tatcagaaac	tgtgcatcct	tcatcagctc	cggggggcac	ccgagatcgc	ctgctctgct	1920
tgcgaccaac	tcaacccccg	tttggacgat	tgccaatttg	agcaataaat	gactgaaatc	1980
aggtatggct	gctgacgggt	atcttccaga	tgggtcagag	gacaacctct	ctgaaggcat	2040
tcgcgagttg	tggttgccga	aacctggagc	tccaacacc	aaggccaacc	aacagcatca	2100
ggacaacggc	aggggtcttg	tgcttctctg	gtacaagtac	ctcggaccct	tcaacggact	2160
cgacaaggga	gagccgggtca	acgaggcaga	cgccgcggcc	ctcgagcacg	acaaggccta	2220
cgacaagcag	ctcgagcagg	gggacaaccc	gtatctcaag	tacaaccacg	ccgacgccga	2280
gttccagcag	cgcttgccga	ccgacacctc	ttttgggggc	aacctcgggc	gagcagctct	2340
ccaggccaaa	aagaggattc	tcgagcctct	gggtctgggt	gaagaggggc	ttaaaacggc	2400
tcttgaaaag	aaacgcccct	tagaaaagac	tccaaatcgg	ccgaccaacc	cggtactctg	2460
gaaggccccc	gccaaagaaa	agcaaaaaga	cggcgaacca	gccgactctg	ctagaaggac	2520
actcgagttt	gagcagctct	gagcagcaga	cgacccccct	gagggatcat	cttccggaga	2580
aatgtctcat	gatgctgaga	tgctgctggc	gccaggcgga	aatgctgtcg	aggcgggaca	2640
aggtgcccgt	ggagtgggta	atgcctccgg	tgattggcat	tgcgattcca	cctgggtcaga	2700
gggcccagtc	accaccacca	gcacccgaac	tggggtccta	cccacgtaca	acaaccacct	2760
gtacctgcga	atcggaacaa	gcgccaacag	caacggattc	aacggattct	ccacccccct	2820
gggatacttt	gactttaacc	gcttccactg	ccacttttcc	ccacgcgact	ggcagcgact	2880
catcaacaac	aactggggac	tcaggccgaa	atcgatgcgt	gttaaaatct	tcaacataca	2940
ggtcaaggag	gtcacgacgt	caaacggcga	gactacggtc	gctaataacc	ttaccagcac	3000
ggttcagatc	tttgcggatt	cgacgtatga	actcccatac	gtgatggacg	ccggtcagga	3060
ggggagcttt	cctccgtttc	ccaacgacgt	ctttatgggt	ccccaatacg	gatactgcgg	3120
agttgtcact	ggaaaaaacc	agaaccagac	agacagaaat	gccttttact	gcctggaata	3180
ctttccattt	caaatgctaa	gaactggcaa	caattttgaa	gtcagttacc	aatttgaaaa	3240
agttcctttc	catccaatgt	acgcgcacag	ccagagcctg	gacagaatga	tgaatccttt	3300
actggatcag	tacctgtggc	atctgcaatc	gaccactacc	ggaaattccc	ttaatcaagg	3360
aacagctacc	accacgtacg	ggaaaattac	cactggagac	tttgcctact	acaggaaaaa	3420
ctggttgcct	ggagcctgca	ttaaacaaca	aaaattttca	agaatgccca	atcaaaacta	3480
caagattccc	gccagcgggg	gagacgcctt	tttaaagtat	gacacgcata	ccactctaaa	3540
tgggcatggt	agtaacatgg	ctcctggacc	tccaatggca	accgcagggtg	ccggggactc	3600
ggattttagc	aacagccagc	tgatctttgc	cggaaccaat	ccgagcggta	acacgaccac	3660
atcttcaaac	aatttgggtg	ttacctcaga	agaggagatt	gccacaacaa	acccacgaga	3720
cacggacatg	tttggacaga	ttgcagataa	taatcaaaat	gccaccaccg	cccctcacat	3780
cgctaacctg	gacgctatgg	gaattgttcc	cggaatgggt	tggcaaaaaca	gagacatcta	3840
ctaccagggc	cctatttggg	ccaaggtccc	tcacacggac	ggacactttc	acccttcgcc	3900
gctgatggga	ggatttggac	tgaaacaccc	gcctccacag	attttcatca	aaaacacccc	3960
cgtacccgcc	aatcccaata	ctacctttag	cgctcgaagg	attaattctt	ttctgacgca	4020
gtacagcacc	ggacaagttg	ccgttcagat	cgactgggaa	attcagaagg	agcattccaa	4080
acgctggaat	cccgaagttc	aatttacttc	aaactacggc	actcaaaatt	ctatgctgtg	4140
ggctcccgcg	aatgctggca	actaccacga	actccgggct	attgggtccc	gtttcctcac	4200
ccaccacttg	taa					4213

<210> 11

<211> 2211

<212> DNA

<213> Artificial Sequence

140140433P1.TXT

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 11

atggctgccc	atggttatct	tccagattgg	ctcaggagaca	acctctctga	gggcattcgc	60
gagtgggtggg	acttgaaacc	tggagccccg	aaacccaaag	ccaaccagca	aaagcaggac	120
gacggccggg	gtctgggtgct	tcctgggtac	aagtacctcg	gaccttcaa	cggactcgac	180
aagggggagc	ccgtcaacgc	ggcggacgca	gcggccctcg	agcacgacaa	ggcctacgac	240
cagcagctca	aagcgggtga	caatccgtac	ctgcggtata	accacgccga	cgccgagttt	300
caggagcgtc	tgcaagaaga	tacgtctttt	gggggcaacc	tcgggcgagc	agtcttcag	360
gccaagaagc	gggttctcga	accttttggg	ctggttgagg	aaggcgctaa	gacggctcct	420
ggaaagaaac	gtccggtaga	gcagtcgcca	caagagccag	actcctcctc	gggcatcggc	480
aagacaggcc	agcagcccgc	taaaaagaga	ctcaattttg	gtcagactgg	cgactcagag	540
tcagtccccg	accacaacc	tctcggagaa	cctccagcaa	cccccgctgc	tgtgggacct	600
actacaatgg	cttcaggcgg	tggcgacca	atggcagaca	ataacgaagg	cgccgacgga	660
gtgggtaatg	cctcaggaaa	tggcattg	gattccacat	ggctgggcca	cagagtcac	720
accaccagca	cccgcacctg	ggccttgccc	acctacaata	accactcta	caagcaaatc	780
tccagtgtct	caacgggggc	cagcaacgac	aacctact	tcggctacag	cacccctgg	840
gggtattttg	atttcaacag	attccactgc	cacttttcac	cgctgactg	gcagcgactc	900
atcaacaaca	attggggatt	ccggcccaag	agactcaact	tcaagctctt	caacatccaa	960
gtcaaggagg	tcacgacgag	tgatggcgtc	acaaccatcg	ctaataacct	taccagcacg	1020
gttcaagtct	tctcggactc	ggagtaccag	cttcctgtag	tcctcggtc	tgcgaccag	1080
ggctgctccc	ctccgttccc	ggcggacgtg	ttcatgattc	cgcaatacgg	ctacctgacg	1140
ctcaacaatg	gcagccaagc	cgtgggacgt	tcatcctttt	actgcctgga	atatttccct	1200
tctcagatgc	tgagaacggg	caacaacttt	accttcagct	acaccttga	ggaagtgcct	1260
ttccacagca	gctacgcgca	cagccagagc	ctggaccggc	tgatgaatcc	tctcatcgac	1320
caataacctg	attacctgaa	cagaactcaa	aatcagtcgg	gaagtgccca	aaacaaggac	1380
ttgctgttta	gccgtgggtc	tccagctggc	atgtctgttc	agcccaaaaa	ctggctacct	1440
ggaccctgtt	atcggcgaca	gcgcgtttct	aaaacaaaaa	caggcaacaa	caacagcaat	1500
tttacctgga	ctggtgcttc	aaaatataac	ctcaattggc	atgaatccat	catcaacctt	1560
ggcactgcta	tggcctcaca	caaagacgac	gaagacaagt	tctttcccat	gagcgggtgc	1620
atgatttttg	gaaaagagag	cgccggagct	tcaaacactg	cattggacaa	tgctatgatt	1680
acagacgaag	aggaaattaa	agccactaac	cctgtggcca	ccgaaagatt	tgggaccgtg	1740
gcagtcaatt	tccagagcag	cagcacacac	cctgcgaccg	gagatgtgca	tgttatggga	1800
gcattacctg	gcattggtgtg	gcaagataga	gacgtgtacc	tgacgggtcc	catctgggccc	1860
aaaattcctc	acacagatgg	acactttcac	ccgtctcctc	ttatgggcgg	ctttggactc	1920
aagcaccgcg	ctcctcagat	cctcatcaaa	aacacgcctg	ttcctgcgaa	tcctccggcg	1980
gagttttcag	ctacaaagt	tgcttcattc	atcacccaat	actccacagg	acaagtggat	2040
gtggaaattg	aatgggagct	gcagaaagaa	aacagcaagc	gctggaatcc	cgaagtgcag	2100
tacacatcca	attatgcaaa	atctgccaac	gttgatttta	ccgtggacaa	caatggacct	2160
tatactgagc	ctcgccccat	tggcaccctg	taccttacc	gtccccctga	a	2211

<210> 12

<211> 2211

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 12

atggctgccc	atggttatct	tccagattgg	ctcaggagaca	acctctctga	gggcattcgc	60
gagtgggtggg	acttgaaacc	tggagccccg	aaacccaaag	ccaaccagca	aaagcaggac	120
gacggccggg	gtctgggtgct	tcctgggtac	aagtacctcg	gaccttcaa	cggactcgac	180
aagggggagc	ccgtcaacgc	ggcggacgca	gcggccctcg	agcacgacaa	ggcctacgac	240
cagcagctca	aagcgggtga	caatccgtac	ctgcggtata	accacgccga	cgccgagttt	300
caggagcgtc	tgcaagaaga	tacgtctttt	gggggcaacc	tcgggcgagc	agtcttcag	360
gccaagaagc	gggttctcga	accttttggg	ctggttgagg	aaggcgctaa	gacggctcct	420
ggaaagaaac	gtccggtaga	gcagtcgcca	caagagccag	actcctcctc	gggcatcggc	480
aagacaggcc	agcagcccgc	taaaaagaga	ctcaattttg	gtcagactgg	cgactcagag	540
tcagtccccg	accacaacc	tctcggagaa	cctccagcaa	cccccgctgc	tgtgggacct	600

140140433P1.TXT

actacaatgg	cttcaggcgg	tggcgaccca	atggcagaca	ataacgaagg	cgccgacgga	660
gtgggtaatg	cctcaggaaa	ttggcattgc	gattccacat	ggctgggcca	cagagtcac	720
accaccagca	cccgcacctg	ggccttgccc	acctacaata	accacctcta	caagcaaatc	780
tccagtgctt	caacgggggc	cagcaacgac	aaccactact	tcggctacag	cacccctgg	840
gggtattttg	atttcaacag	attccactgc	cacttttcac	cgcgtagctg	gcagcgactc	900
atcaacaaca	attggggatt	ccggcccaag	agactcaact	tcaagctctt	caacatccaa	960
gtcaaggagg	tcacgacgag	tgatggcgct	acaaccatcg	ctaataacct	taccagcacg	1020
gttcaagtct	tctcggactc	ggagtaccag	cttcctgtag	tcctcggctc	tgcgaccag	1080
ggctgccttc	ctccgttccc	ggcggacgtg	ttcatgattc	cgcaatacgg	ctacctgacg	1140
ctcaacaatg	gcagccaagc	cgtgggacgt	tcattccttt	actgcctgga	atatttccct	1200
tctcagatgc	tgagaacggg	caacaacttt	accttcagct	acacctttga	ggaagtgcct	1260
ttccacagca	gctacgcgca	cagccagagc	ctggaccggc	tgatgaatcc	tctcatcgac	1320
caattacctg	attacctgaa	cagaactcaa	aatcagtcgg	gaagtgccta	aaacaaggac	1380
ttgctgttta	gccgtgggtc	tccagctggc	atgtctgttc	agcccaaaaa	ctggctacct	1440
ggaccctgtt	atcggcgaca	gcgcgtttct	aaaacaaaaa	caggcaacaa	caacagcaat	1500
tttacctgga	ctggtgcttc	aaaatataac	ctcaatgggc	atgaatccat	catcaacctt	1560
ggcactgcta	tgccctcaca	caaagacgag	gaagacaagt	tctttcccat	gagcgggtgt	1620
atgatttttg	gaaaagagag	cgccggagct	tcaaacactg	cattggacaa	tgcatgatt	1680
acagacgaag	aggaaattaa	agccactaac	cctgtggcca	ccgaaagatt	tggaaccgtg	1740
gcagtcaatt	tccagagcag	cagcacacac	cctgcgaccg	gagatgtgca	tggtatggga	1800
gcattacctg	gcatgggtgt	gcagataga	gacgtgtacc	tgcaagggtc	catctggggt	1860
aaaattcctc	acacagatgg	acactttcac	ccgtctcctc	ttatgggcgg	ctttggactc	1920
aagcaccgcg	ctcctcagat	cctcatcaaa	aacacgcctg	ttcctgcgaa	tcctccggcg	1980
gagttttcag	ctacaaagtt	tgcttcattc	atcacccaat	actccacagg	acaagtgaat	2040
gtggaaattg	aatgggagct	gcagaaagaa	aacagcaagc	gctggaatcc	cgaagtgcag	2100
tacacatcca	attatgcaaa	atctgccaac	gttgatttta	ccgtggacaa	caatggactt	2160
tatactgagc	ctcgcctcat	tgccacccgt	taccttacc	gtccctgtga	a	2211

<210> 13

<211> 2202

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 13

atgactgacg	gttaccttcc	agattggcta	gaggacaacc	tctctgaagg	cgttcgagag	60
tggtggggcg	tgcaacctgg	agccccataa	cccaaggcaa	atcaacaaca	tcaggacaac	120
gctcgggggtc	ttgtgcttcc	gggttacaaa	tacctcggac	ccggcaacgg	acttgacaag	180
ggggaacccg	tcaacgcagc	ggacgcggca	gccctcgaac	acgacaaggc	ctacgaccag	240
cagctcaagg	ccggtgacaa	cccctacctc	aagtacaacc	acgccgacgc	cgagtttcag	300
gagcgtcttc	aagaagatac	gtcttttggg	ggcaacctcg	gacgagcagt	cttccaggcc	360
aaaaagagga	tccttgagcc	tctgggtctg	gttgaggaag	cggtctaaag	ggctcctgga	420
aaaaagagac	ctgtagagca	atctccagca	gaaccggact	cctcttcggg	catcggaaca	480
tcaggccagc	agcccgctag	aaaagactg	aattttgggt	agactggcga	cacagagtca	540
gtcccagacc	ctcaaccact	cggacaacct	cccgcagccc	cctctggtgt	gggatctact	600
acaatggctt	caggcggtgg	cgaccaatg	gcagacaata	acgaggggtg	cgatggagtg	660
ggtaattcct	caggaaattg	gcattgcgat	tcccaatggc	tgggcgacag	agtcattacc	720
accagcacc	gcacctgggc	cctgcccacc	tacaacaatc	acctctacaa	gcaaattctc	780
agccaatcag	gagccaccaa	cgacaaccac	tactttgggt	acagcacc	ctgggggtat	840
tttgacttca	acagattcca	ctgccacttt	tcaccacgtg	actggcaaa	actcatcaac	900
aacaactggg	gattccgacc	caagagactc	aacttcaagc	tctttaacat	tcaagtcaaa	960
gaggtcacgc	agaatgacgg	tacgacgacg	attgccaata	accttaccag	cacggttcag	1020
gtgtttactg	actccgagta	ccagctcccg	tacgtcctcg	gctcggcgca	tcagggtatg	1080
ctcccggcgt	tcccagcaga	cgtcttcctg	gtcccacagt	atggatacct	cacctgaac	1140
aacgggagtc	aggcggtagg	acgctcttcc	ttttactgcc	tgagtagact	tccttctcag	1200
atgctgcgta	ctggaacaaa	ctttcagttt	agctacactt	ttgaagacgt	gcctttccac	1260
agcagctacg	ctcacagcca	aagtctggac	cgtctcatga	atcctctgat	cgaccagtac	1320
ctgtactatc	tgaacaggac	acaaacagcc	agtggaactc	agcagctctg	gctactgttt	1380
agccaagctg	gacccaccag	tatgtctctt	caagctaaaa	actggctgcc	tggaaccttg	1440
tacagacagc	agcgtctgtc	aaagcaggca	aacgacaaca	acaacagcaa	ctttccctgg	1500

140140433P1.TXT

actggtgcc	ccaaatatca	tctgaatggc	cgggactcat	tggatgaacc	gggccctgct	1560
atggccagtc	acaaggatga	caaagaaaag	tttttcccca	tgcattggaac	cctgatattt	1620
ggtaaaagaag	gaacaaatgc	caacaacgcg	gatttggaaa	atgtcatgat	tacagatgaa	1680
gaagaaatcc	gcaccacca	tcccgtggct	acggagcagt	acgggactgt	gtcaaataat	1740
ttgcaaaact	caaacgctgg	tccaactact	ggaactgtca	atcaccaagg	agcgttacct	1800
gggtatggtgt	ggcaggatcg	agacgtgtac	ctgcagggac	ccatttgggc	caagattcct	1860
cacaccgatg	gacactttca	tccttctcca	ctgattgggag	gttttgggct	caaacacccg	1920
cctcctcaga	tcatgatcaa	aaacactccc	gttccagcca	atcctccac	aaactttagt	1980
gcggcaaaagt	ttgcttcctt	catcacacag	tactccacgg	ggcagggtcag	cgtggagatc	2040
gagtgggagc	tgagaaagga	gaacagcaaa	cgctggaatc	ccgaaattca	gtacacttcc	2100
aactacaaca	aatctgttaa	tgtggacttt	actgtggaca	ctaattggtgt	gtattcagag	2160
cctcgcccca	ttggcaccag	atacctgact	cgtaatctgt	aa		2202

<210> 14

<211> 2211

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 14

atggctgccc	atggttatct	tccagattgg	ctcaggagaca	acctctctga	gggcattcgc	60
gagtgggtggg	acttgaacc	tggagccccg	aaacccaaag	ccaaccagca	aaagcaggac	120
gacggccggg	gtctgggtgt	tcctgggtac	aagtacctcg	gaccttcaa	cggactcgac	180
aagggggagc	ccgtcaacgc	ggcggacgca	gcggccctcg	agcacgacaa	ggcctacgac	240
cagcagctca	aagcgggtga	caatccgtac	ctgcgggtata	accacgccga	cgccgagttt	300
caggagcgtc	tgaagaaga	tacgtctttt	gggggcaacc	tcgggcgagc	agtcttcag	360
gccaaagaagc	gggttctcga	accttttgggt	ctggttgagg	aaggcgctaa	gacggctcct	420
ggaaagaaac	gtccggtaga	gcagtcgcca	caagagccag	actcctcctc	gggcatcggc	480
aagacaggcc	agcagcccgc	taaaaagaga	ctcaattttg	gtcagactgg	cgactcagag	540
tcagtccccg	accacaacc	tctcggagaa	cctccagcaa	cccccgctgc	tgtgggacct	600
actacaatgg	cttcaggcgg	tggcgaccca	atggcagaca	ataacgaagg	cggcgacgga	660
tggggtaatg	cctcaggaaa	ttggcattgc	gattccacat	ggctgggcga	cagagtcac	720
accacagtc	cccgccctg	ggccttgccc	acctacaata	accacctcta	caagcaaatc	780
tccagtgcct	caacgggggc	cagcaacgac	aaccactact	tcggctacag	caccccttgg	840
gggtattttg	atttcaacag	attccactgc	cacttttcac	cacgtgactg	gcagcgactc	900
atcaacaaca	attggggatt	ccggcccaag	agactcaact	tcaagctctt	caacatccaa	960
tcaaggaggc	tcacagcgaa	tgatggcgct	acaactatcg	ctaataacct	taccagcag	1020
gttcaagtct	tctcggactc	ggagtaccag	cttcctgacg	tcctcggctc	tgcgaccag	1080
ggctgcctcc	ctccgttccc	ggcggacgtg	ttcatgattc	cgcaatacgg	ctacctgacg	1140
ctcaacaatg	gcagccaagc	cgtgggacgt	tcattctttt	actgcctgga	atatttccct	1200
tctcagatgc	tgagaacggg	caacaacttt	accttcagct	acaccttga	ggaagtgcct	1260
ttccacagca	gctacgcgca	cagccagagc	ctggaccggc	tgatgaatcc	tctcatcgac	1320
caatacctgt	attacctgaa	cagaactcaa	aatcagtcgg	gaagtgccca	aaacaaggac	1380
ttgctgttta	gccgtgggtc	tccagctggc	atgtctgttc	agcccaaaaa	ctggctacct	1440
ggaccctgtt	atcggcagca	gcgcgtttct	aaaacaaaaa	cagacaacaa	caacagcaat	1500
tttacctgga	ctggtgtctc	aaaatataac	ctcaatgggc	gtgaatccat	catcaaccct	1560
ggcactgcta	tggcctcaca	caaagacgac	gaagacaagt	tctttcccat	gagcgggtgc	1620
atgatttttg	gaaaagagag	cgccggagct	tcaaactatg	cattggacaa	tgtcatgatt	1680
acagacgaag	aggaaattaa	agccactaac	cctgtggcca	ccgaaagatt	tgggaccgtg	1740
gcagtcaatt	tccagagcag	cagcacagac	cctgcgaccg	gagatgtgca	tgttatggga	1800
gcattacctg	gcatggtgtg	gcaagataga	gacgtgtacc	tgcagggtcc	catctgggac	1860
aaaattcctc	acacagatgg	acactttcac	ccgtctcctc	ttatgggctg	ctttggactc	1920
aagcacccgc	ctcctcagat	cctcatcaaa	aacacgcctg	ttcctgcgaa	tcctccggcg	1980
gagttttcag	ctacaaagtt	tgtttcattc	atcacccaat	actccacagg	acaagtgcag	2040
gtggaaattg	aatgggagct	gcagaaagaa	aacagcaagc	gctggaatcc	cgaagtgcag	2100
tacacatcca	attatgcaaa	atctgccaac	gttgatttta	ccgtggacaa	caatggactt	2160
tatactgagc	ctcgcccat	tggcaccctg	taccttacct	gtccctgta	a	2211

<210> 15

<211> 2211

140140433P1.TXT

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 15

atggctgccc	atggttatct	tccagattgg	ctcgaggaca	acctctctga	gggcattcgc	60
aaagtggg	acttgaaacc	tggagcccc	aaacccaaag	ccaaccagca	aaagcaggac	120
gacggccggg	gtctggtgct	tcctggctac	aagtacctcg	gacccttcaa	cggactcgac	180
aaagggggagc	ccgtcaacgc	ggcggacgca	gcggccctcg	agcacgacaa	ggcctacgac	240
cagcagctca	aagcgggtga	caatccgtac	ctgcggtata	accacgccga	cgccgagttt	300
caggagcgctc	tgcaagaaga	tacgtctttt	gggggcaacc	tcgggagagc	agtcttccag	360
gccaaagaagc	gggttctcga	accttttggt	ctggttgagg	aaggcgctaa	gacggctcct	420
ggaaagaaac	gtccggtaga	gcagtgcgca	caagagccag	actcctcctc	gggcatcggc	480
aagacagcca	agcagcccc	taaaaagaga	ctcaattttg	gtcagactgg	cgactcagag	540
tcagtccccg	accacaacc	tctcggagaa	cctccagcaa	cccccgctgc	tgtgggacct	600
actacaatgg	cttcaggcgg	tggcgacca	atggcagaca	ataacgaagg	cgccgacgga	660
gtgggtaatg	cctcaggaaa	ttggcattgc	gattccacat	ggctgggcga	cagagtcac	720
accaccagca	cccgcacctg	ggccttgccc	acctacaata	accacctcta	caagcaaata	780
tccagtgtct	caacgggggc	gagcaacgac	aacctact	tcggctacag	caccccttgg	840
gggtattttg	atttcaacag	attccactgc	cacttttcac	cacgtgactg	gcagcgactc	900
atcaacaaca	attgggggatt	ccggcccaag	agactcaact	tcaagctctt	caacatccaa	960
gtcaaggagg	tcacgacgaa	tgatggcgct	acaaccatcg	ctaataacct	taccagcacg	1020
gttcaagtct	tctcggactc	ggagtaccag	cttcggtacg	tcctcggctc	tgcgaccacg	1080
ggctgcctcc	ctccgttccc	ggcggacgtg	ttcatgattc	cgcaatacgg	ctacctgacg	1140
ctcaacaatg	gcagccaagc	cgtaggacgt	tcacctcttt	actgcctgga	atatttccct	1200
tctcagatgc	tgagaacggg	caacaacttt	accttcagct	acacctttga	ggaagtgcct	1260
ttccacagca	gtacgcgca	cagccagagc	cctgaccggc	tgatgaatcc	tctcatcgac	1320
caatacctgt	attacctgaa	cagaactcaa	aatcagtcgg	gaagtgccca	aaacaaggac	1380
ttgtctgtta	gccgtgggtc	tccagctggc	atgtctgttc	agcccaaaaa	ctggctacct	1440
ggaccctggt	atcggcagca	gcgcgtttct	aaaacaaaaa	cagacaacaa	caacagcaat	1500
tttacctgga	ctgggtgctt	aaaatataac	ctcaatgggc	gtgaatccat	catcaacctt	1560
ggcactgcta	tggcctcaca	caaagacgac	aaagacaagt	tctttcccat	gagcgggtgtc	1620
atgatttttg	gaaaagagag	cgccggagct	tcaaacactg	cattggacaa	tgcatgatt	1680
acagacgaag	aggaaattaa	agccactaac	ctgtggcca	ccgaaagatt	tgggaccgtg	1740
gcagtcaatt	tccagagcag	cagcacagac	cctgcgaccg	gagatgtgca	tggtatggga	1800
gcattacctg	gcattggtgtg	gcaagataga	gacgtgtacc	tgagggttcc	catttggggc	1860
aaaattcctc	acacagatgg	acactttcac	cgctctcctc	ttatgggagg	ctttggactc	1920
aagcaccgcg	ctcctcagat	cctcatcaaa	aacacacctg	ttcctgcgaa	tcctccggcg	1980
gagttttcag	ctacaaagtt	tgcttcattc	atcacccaat	actccacagg	acaagtgagt	2040
gtggaaattg	aatgggagct	gcagaaagaa	aacagcaagc	gctggaatcc	cgaagtgcag	2100
tacacatcca	attatgcaaa	atctgccaac	gttgatttta	ccgtggacaa	caatggactt	2160
tatactgagc	ctcgccccat	tggcaccctg	taccttacc	gtcccctgta	a	2211

<210> 16

<211> 2211

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 16

atggctgccc	atggttatct	tccagattgg	ctcgaggaca	acctctctga	gggcattcgc	60
gagtggtggg	acttgaaacc	tggagcccc	aaacccaaag	ccaaccagca	aaagcaggac	120
aacggccggg	gtctggtgct	tcctggctac	aagtacctcg	gacccttcaa	cggactcgac	180
aaagggggagc	ccgtcaacgc	ggcggacgca	gcggccctcg	agcacgacaa	ggcctacgac	240
cagcagctca	aagcgggtga	caatccgtac	ctgcggtata	accacgccga	cgccgagttt	300
caggagcgctc	tgcaagaaga	tacgtctttt	gggggcaacc	tcgggagagc	agtcttccag	360
gccaaagaagc	gggttctcga	accttttggt	ctggttgagg	aaggcgctaa	gacggctcct	420

140140433P1.TXT

ggaaagaaac	gtccggtaga	gcagtcgcca	caagagccag	actcctcctc	gggcatcggc	480
aagacaggcc	agcagcccgc	taaaaagaga	ctcaattttg	gtcagactgg	cgactcagag	540
tcagtccccg	accacaacc	tctcggagaa	cctccagcaa	cccccgctgc	tgtgggacct	600
actacaatgg	cttcaggcgg	tggcgaccca	atggcagaca	ataacgaagg	cgccgacgga	660
gtgggtaatg	cctcaggaaa	ttggcattgc	gattccacat	ggctgggcca	cagagtcatc	720
accaccagca	cccgcacctg	ggccttgccc	acctacaata	accacctcta	caagcaaadc	780
tccagtgcct	caacgggggc	cagcaacgac	aaccactact	tcggctacag	cacccctggg	840
gggtattttg	atttcaacag	attccactgc	cacttttcac	cacgtgactg	gcagcgactc	900
atcaacaaca	attgggggatt	ccggcccaag	agactcaact	tcaagctctt	caacatccaa	960
gtcaaggagg	tcacgacgaa	tgatggcgct	acaaccatcg	ctaataacct	taccagcacg	1020
gttcaagtct	tctcggactc	ggagtaccag	cttcggtacg	tcctcggctc	tgcgcaccag	1080
ggctgcctcc	ctccgttccc	ggcggacgtg	ttcatgattc	cgcaatacgg	ctacctgacg	1140
ctcaacaatg	gcagccaagc	cgtgggacgt	tcattcctttt	actgcctgga	atatttccct	1200
tctcagatgc	tgagaacggg	caacaacttt	accttcagct	acacctttga	ggaagtgcct	1260
ttccacagca	gctacgcgca	cagccagagc	ctggaccggc	tgatgaatcc	tctcatcgac	1320
caatacctgt	attacctgaa	cagaactcaa	aatcagtcctg	gaagtgccca	aaacaaggac	1380
ttgctgttta	gccgtgggtc	tccagctggc	atgtctgttc	agcccaaaaa	ctggctacct	1440
ggaccctggt	atcggcagca	gcgcgtttct	aaaacaaaaa	cagacaacaa	caacagcaat	1500
tttacctgga	ctggtgcttc	aaaatataac	ctcaatgggc	gtgaatccat	catcaaccct	1560
ggcactgcta	tggcctcaca	caaagacgac	gaagacaagt	tccttcccat	gagcgggtgc	1620
atgatttttg	gaaaagagag	cgccggagct	tcaaacactg	cattggacaa	tgatcatgatt	1680
acagacgaag	aggaaattaa	agccactaac	cctgtggcca	ccgaaagatt	tgggaccgtg	1740
gcagttcaat	tccagagcag	cagcacacac	cctgcgaccg	gagatgtgca	tggttatgga	1800
gcattacctg	gcatgggtgtg	gcaagataga	gacgtgtacc	tgagggttcc	catctgggac	1860
aaaattcctc	acacagatgg	acactttcac	ccgtctcctc	ttatgggagg	ctttggactc	1920
aagcaccgcg	ctcctcagat	cctcatcaaa	aacacgcctg	ttcctgcgaa	tcctccggcg	1980
gagttttcag	ctacaaagtt	tgcttcattc	atcaccctaa	actccacagg	acaagtgaat	2040
gtggaaattg	aatgggagct	gcagaaagaa	aacagcaagc	gctggaatcc	cgaagtgcag	2100
tacacatcca	attatgcaaa	atctgccaac	gttgatttta	ccgtggacaa	caatggactt	2160
tatactgagc	ctcgcccat	tggcaccctg	taccttacc	gtcccctgta	a	2211

<210> 17

<211> 2211

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 17

atggctgccc	atggttatct	tccagattgg	ctcgaggaca	acctctctga	gggcattcgc	60
gagtggtggg	acttgaacc	tggagccccg	aaacccaaag	ccaaccagca	aaagcaggac	120
gacggccggg	gtctggtgct	tcctggctac	aagtacctcg	gaccttcaa	cggactcgac	180
aagggggagc	ccgtcaacgc	ggcggacgca	gcggccctcg	agcacgacaa	ggcctacgac	240
cagcagctca	aagcgggtga	caatccgtac	ctgcggtata	accacgccga	cgccgagttt	300
caggagcgtc	tgcaagaaga	tacgtctttt	ggggggcaac	tcgggcgagc	agtcttcag	360
gccaaaaagc	gggttctcga	accttttggt	ctggttgagg	aaggcgctaa	gacggctcct	420
ggaaagaaac	gtccggtaga	gcagtcgcca	caagagccag	actcctcctc	gggcatcggc	480
aagacaggcc	agcagcccgc	taaaaagaga	ctcaattttg	gtcagactgg	cgactcagag	540
tcagtccccg	accacaacc	tctcggagaa	cctccagcaa	cccccgctgc	tgtgggacct	600
actacaatgg	cttcaggcgg	tggcgaccca	atggcagaca	ataacgaagg	cgccgacgga	660
gtgggtaatg	cctcaggaaa	ttggcattgc	gattccacat	ggctgggcca	cagagtcatc	720
accaccagca	cccgcacctg	ggccttgccc	acctacaata	accacctcta	caagcaaadc	780
tccagtgcct	caacgggggc	cagcaacgac	aaccactact	tcggctacag	cacccctggg	840
gggtattttg	atttcaacag	attccactgc	cacttttcac	cacgtgactg	gcagcgactc	900
atcaacaaca	attgggggatt	ccggcccaag	agactcaact	tcaagctctt	caacatccaa	960
gtcaaggagg	tcacgacgaa	tgatggcgct	acaaccatcg	ctaataacct	taccagcacg	1020
gttcaagtct	tctcggactc	ggagtaccag	cttcggtacg	tcctcggctc	tgcgcaccag	1080
ggctgcctcc	ctccgttccc	ggcggacgtg	ttcatgattc	cgcaatacgg	ctacctgacg	1140
ctcaacaatg	gcagccaagc	cgtgggacgt	tcattcctttt	attgcctgga	atatttccca	1200
tcgcagatgc	tgagaacggg	caataacttt	accttcagct	acacctttga	ggacgtgcct	1260
ttccacagca	gctacgcgca	cagccagagc	ctggaccggc	tgatgaatcc	tctcatcgac	1320

140140433P1.TXT

cagtacctgt	attacctgaa	cagaactcag	aaccagtccg	gaagtgccca	aaacaaggac	1380
ttgctgttta	gccgggggtc	tccagctggc	atgtctgttc	agctcaaaaa	ctggctacct	1440
ggaccctgtt	atcggcagca	gcgcgtttct	aaaacaaaaa	cagacaacaa	caacagcaat	1500
tttacctgga	ctggtgcttc	aaaatataac	cttaatgggc	gtgaatccat	catcaaccct	1560
ggcactgcta	tggcctcaca	caaagacgac	gaagacaagt	tctttcccat	gagcgggtgc	1620
atgatttttg	gaaaagagag	cgccggagct	tcaaactctg	cattggacaa	tgtcatgatt	1680
acagacgaag	aggaaattaa	agccactaac	cctgtggcca	ccgaaagatt	tgggaccgtg	1740
gcagtcaatt	tccagagcag	cagcacagac	cctgcgaccg	gagatgtgca	tgttatggga	1800
gcattacctg	gcattggtgtg	gcaagataga	gacgtgtacc	tgcagggtcc	catttgggac	1860
aaaatttcctc	acacagatgg	acactttcac	ccgtctcctc	ttatgggcgg	ctttggactc	1920
aaacacccgc	ctcctcagat	cctcatcaaa	aacacacctg	ttcctgcgaa	tcctccggcg	1980
gagttttcag	ctacaaagtt	tgcttcattc	atcacccaat	actccacagg	acaagtgaag	2040
gtggaaattg	aatgggagct	gcagaaagaa	aacagcaagc	gctggaatcc	cgaagtgcag	2100
tacacatcca	attatgcaaa	atctgccaac	gttgatttta	ccgtggacaa	caatggactt	2160
tatactgagc	ctcgcccat	tggcaccctg	taccttacc	gtcccctgta	a	2211

<210> 18

<211> 2211

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 18

atggctgccg	atggttatct	tccagattgg	ctcaggagca	acctctctga	gggcattcgc	60
gagtgggtgg	acttgaaacc	tggagccccg	aaacccaaag	ccaaccagca	aaagcaggac	120
gacggccggg	gtctggtgct	tcctggctac	aagtacctcg	gaccttcaa	cggactcgac	180
aagggggagc	ccgtcaacgc	ggcggacgca	gcggccctcg	agcacgacaa	ggcctacgac	240
cagcagctca	aagcgggtga	caatccgtac	ctgcggtata	accacgccga	cgccgagttt	300
caggagcgtc	tgcaagaaga	tacgtctttt	gggggcaacc	tcgggcgagc	agtcctccag	360
gccaagaagc	gggttctcga	accttttggg	ctggttgagg	aaggtgctaa	gacggctcct	420
ggaaaagaaga	gaccggtaga	gcagtcgccc	caagaaccag	actctcatc	gggcatcggc	480
aaatcaggcc	agcagccgc	taaaaagaga	ctcaattttg	gtcagactgg	cgactcagag	540
tcagtccccg	acccacaacc	tctcggagaa	cctccagcaa	cccccgctgc	tgtgggacct	600
actacaatgg	cttcaggcgg	tggcgacaca	atggcagaca	ataacgaagg	cgccgacgga	660
gtgggttaatg	cttcaggaaa	ttggcattgc	gattccacat	ggctgggcga	cagagtcatt	720
accaccagca	cccgaacctg	ggccctgccc	acctataaca	accacctcta	caaacaaatc	780
tccagcgctt	caacgggggc	cagcaacgac	aaccactact	tcggctacag	caccccttgg	840
gggtattttg	attttaacag	attccactgc	cacttctcac	cacgtgactg	gcagcgactc	900
atcaacaaca	attggggatt	ccggcccaag	agactcaact	tcaagctctt	caacatccaa	960
gtcaaggagg	tcacgacgaa	cgatggcgct	acgaccatcg	ctaataacct	taccagcacg	1020
gttcaagtct	tctcggactc	ggagtaccag	ttgccgtacg	tcctcggctc	tgcgcaccag	1080
ggctgcctcc	ctccgttccc	ggcggacgtg	ttcatgattc	cgcagtacgg	ctacctaaca	1140
ctcaacaatg	gcagccaggc	cgtagggacgt	tcattccttt	actgcctgga	atatttccca	1200
tcgcagatgc	tgagaacggg	caataacttt	accttcagct	acacattcga	ggacgtgcct	1260
ttccacagca	gctacgcgca	cagccaaagc	ctggaccggc	tgatgaatcc	tctcatcgac	1320
cagtacttgt	attacctaaa	cagaactcaa	aatcagtcgg	gaagtgccca	aaacaaggac	1380
ttgctgttta	gccgggggtc	tccagctggc	atgtctgttc	agcccaaaaa	ctggctacct	1440
ggaccctgtt	atcggcagca	gcgcgtttct	aaaacaaaaa	cagacaacaa	caacagcaac	1500
tttacctgga	ctggtgcttc	aaaatataac	cttaatgggc	gtgaatctat	aatcaaccct	1560
ggcactgcta	tggcttcaca	caaagacgac	gaagacaagt	tctttccaat	gagcgggtgc	1620
atgatttttg	gcaaggagag	cgccggagct	tcaaactctg	cattggacaa	tgtcatgatt	1680
acagacgaag	aggaaattaa	agccactaac	cctgtggcca	ccgaaagatt	tgggaccgtg	1740
gcagtcaatt	tccagagcag	cagcacagac	cctgcgaccg	gagatgtgca	tgttatggga	1800
gcattacctg	gcattggtgtg	gcaagataga	gacgtgtacc	tgcagggtcc	aatttgggac	1860
aaaatttcctc	acacagatgg	acactttcac	ccgtctcctc	ttatgggcgg	ctttggactt	1920
aagcaccgc	ctcctcagat	cctcatcaaa	aacacgcctg	ttcctgcgaa	tcctccggca	1980
gagttttcgg	ctacaaagtt	tgcttcattc	atcacccagt	attccacagg	acaagtgaag	2040
gtggaaattg	aatgggagtt	gcagaaagaa	aacagcaagc	gttggaaatcc	cgaagtgcag	2100
tacacatcta	attatgcaaa	atctgccaac	gttgatttca	ctgtggacaa	caatggactt	2160
tatactgagc	ctcgcccat	tggcaccctg	tacctcacc	gtcccctgta	a	2211

140140433P1.TXT

<210> 19
<211> 2211
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 19
atggctgccc atggttatct tccagattgg ctgaggaca acctctctga gggcattcgc 60
gagtgggtgg acttgaaacc tggagccccg aaacccaaag ccaaccagca aaagcaggac 120
gacggccggg gtctgggtct tcctggctac aagtacctcg gacccttcaa cggactcgac 180
aagggggagc ccgtcaacgc ggcgagcgca gcggccctcg agcagacaa ggcctacgac 240
cagcagctca aagcgggtga caatccgtac ctgcggtata accacgccga cgccgagttt 300
caggagcgtc tgcaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttcag 360
gccagaaga gggttctcga accttttggg ctggttgagg aagggtctaa gacggctcct 420
ggaaagaaac gtccggtaga gcagtcaccc caagaaccag actcctcctc gggcattggc 480
aaatcaggcc agcagccgc taaaaagaga ctcaattttg gtcagactgg cgactcagag 540
tcagtcctcc caaccacaac tctcggagaa cctccagcaa ccccgctgc tttgggacct 600
actacaatgg ctccaggcgg tggcgacca atggcagaca ataacgaagg cgccgacgga 660
gtgggtaatg cctcaggaat ttggcattgc gattccacat gggtggcgca cagagtcac 720
accaccagca cccgcacctg ggccttgccc acctacaata accacctcta caagcaaatc 780
tcagtgctt caacgggggc cagcaacgac aaccactact tcggctacag caccctctgg 840
gggtattttg atttcaacag attccactgc catttctcac cactgtactg gcagcgactc 900
atcaacaaca actggggatt ccggcccaag agactcaact tcaagctctt caacatccaa 960
gtcaaggagg tcacgacgaa cgatggcgct acgacctcgc ctaataacct taccagcacg 1020
gttcaagtct tctcggactc ggagtaccag ctccgtagc tcctcggctc tgcgcaccag 1080
ggctgcctcc ctccgttccc ggcgagcgtg ttcatgattc cgagtagcgg ctacctgacg 1140
ctcaacaatg gcagcaaagc cgtgggacgt tcatcctttt actgcctgga atatttcctt 1200
tctcagatgc tgagaacggg caacaacttt accttcagct acaccttga ggaagtgcct 1260
ttccacagca gctacgcgca cagccagagc ctggaccggc tgatgaatcc tctcatcgac 1320
caatacctgt attacctgaa cagaactcaa aatcagtcgg gaagtgccca aaacaaggac 1380
ttgctgttta gccgtgggtc tccagctggc atgtctgttc agcccaaaaa ctggctacct 1440
ggaccctggt atcggcagca gcgcgtttct aaaacaaaaa cagacaacaa caacagcaat 1500
tttacctgga ctggtgcttc aaaatataac ctcaatgggc gtgaatccat catcaacctt 1560
ggcactgcta tggcctcaca caaagacgac gaagacaagt tctttcccat gagcgggtgtc 1620
atgatttttg gaaaagagag cgccggagct tcaaacactg cattggacaa tgtcatgatt 1680
acagacgaag aggaaattaa agccactaac cctgtggcca cgaagagatt tgggaccgtg 1740
gcagtcgaatt tcagagcag cagcacagac cctgcgaccg gagatgtgca tgttatggga 1800
gcattacctg gcatggtgtg gcaagataga gacgtgtacc tgcagggtcc catttgggccc 1860
aaaattcctc acacggatgg acactttcac ccgtctcctc ttatgggcgg ctttggactc 1920
aagcaccgcg ctctcagat cctcatcaaa aacacacctg ttcctgcgaa tcctccggca 1980
gagttttcgg ctacaaagtt tgcttcattc atcacccagt actccacagg acaagtgcgc 2040
gtggaaattg aatgggagtt gcagaaagaa aacagtaagc gctggaatcc cgaagtgcag 2100
tacacatcta attatgcaaa atctgccaac gttgacttca ctgtggacaa caatggactt 2160
tatactgagc ctgcgcccat tggcaccctg tacctcaccg gtcccctgta a 2211

<210> 20
<211> 2970
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 20
agatgaccgc caaggtcgtg gagtccgcca aggccattct gggcggcagc aaggtgcgcg 60
tggaacaaaa atgcaaggcc tctgcgcaga tcgacccac ccccgtagtc gtcacctcca 120
acaccaacat gtgcgcggtg attgacggga acagaccac ctctgagcac cagcagcccc 180
tgaggaccg gatgttcaag tttgaactca cccgcgcgct cgactacgac tttggcaagg 240

140140433P1.TXT

```

tcaccaagca ggaagtcaag gactttttcc ggtgggaggc tgatcacgtg actgacgtgg 300
ctcatgagtt ttacgtcaca aaggggtggag ctaagaaaag gcccgcccc tctgacgagg 360
atataagcga gcccaagcgg ccgcgcgtgt catttgcgca gccggagacg tcagacgcgg 420
aagctcccg agacttcgcc gacaggtacc aaaacaaatg ttctcgtcac gcgggtatgc 480
tgcagatgct ctttccctgc aagacgtgcg agagaatgaa tcagaattcc aacgtctgct 540
tcacgcacgg tcagaaagat tgcggggagt gctttcccgg gtcagaatct caaccggttt 600
ctgtcgtcag aaaaactgat cagaaactgt gcatccttca tcagctccgg ggggcacccg 660
agatcgctcg acctcgttgc gaccaactca accccgattt ggacgattgc caatttgagc 720
aataaatgac tgaatcagg tatggctgct gacgggtatc ttccagattg gctcaggagc 780
aacctctctg aaggcattcg cgagtgggtg gcgctgaaac ctggagctcc acaaccacag 840
gccaaccaac agcatcagga caacggcagg ggtcttgtgc ttcttgggta caagtacctc 900
ggagggcgta aaacggcttc gacgaactca ccccgattt aggcagacgc cgcggccctc 960
gagcacgaca aggcctacga caagcagctc gacgaggggg acaacccgta tctcaagtac 1020
aacacggcg acgcccaggt ccagcagcgc ttggcgaccg acacctcttt tgggggcaac 1080
ctcgggagag cagctctcca ggccaaaaag aggattctcg agcctctggg tctggttgaa 1140
gagggcggtt aaacggcttc tggaaagaaa aaaagactcc aaatcgccg 1200
accaacccgg actctgggaa ggccccggcc aagaaaaagc aaaaagacgg cgaaccagcc 1260
gactctgcta gaaggacact cgactttgaa gactctggag caggagacgg accccctgag 1320
ggatcatctt ccggagaaat gtctcatgat gctgagatgc gtgcggcgcc aggcggaaat 1380
gctgtcgagg cgggacaagg tgccgatgga gtcgggtatg cctccggtga ttggcattgc 1440
gattccacct ggtcagaggg ccgagtcacc accaccagca cccgaacctg ggtcctaccc 1500
acgtacaaca accacctgta cctgcgaatc ggaacaacgg ccaacagcaa cacctacaac 1560
ggattctcca ccccttgggg atactttgac ttaaacgcgt tccactgcca cttttcccca 1620
cgcgactggc agcgactcat caacaacaac tggggactca ggccgaaatc gatgcgtgtt 1680
aaaatcttca acatacaggt caaggaggtc acgacgtcaa acggcgagac tacggtcgct 1740
aataacctta ccagcacggt tcagatcttt gcggattcga cgtatgaact cccatacgtg 1800
atggacggcg ctcaggaggg gagctttcct ccgtttccca acgacgtctt tatggttccc 1860
caatacggat actgcggagt tgtcactgga aaaaaccaga accagacaga cagaaatgcc 1920
ttttactgcc tggaaatact tccatcccaa atgctaagaa ctggcaacaa ttttgaagtc 1980
agttaccaat ttgaaaaagt tcttttccat tcaatgtacg cgcacagcca gagcctggac 2040
agaatgatga atcctttact ggatcagtag ctgtggcatc tgcaatcgac cactaccgga 2100
aattccctta atcaaggaa acgtaccacc agctacggga' aaattaccac tggagacttt 2160
gcctactaca ggaaaaactg gttgcctgga gcctgcatta aacaacaaaa attttcaaag 2220
aatgccaatc aaaactacaa gattcccggc agcgggggag acgccctttt aaagtatgac 2280
acgcatacca ctctaaatgg gcgatggagt aacatggctc ctggacctcc aatggcaacc 2340
gcaggtgccc gggactcgga ttttagcaac agccagctga tctttgcccg acccaatccg 2400
agcggtaaca cgaccacatc ttcaaacaat ttgttgttta cctcagaaga ggagattgcc 2460
acaacaaacc cacgagacac ggacatgttt ggacagattg cagataataa tcaaaatgcc 2520
accaccgccc ctcacatcgc taacctggac gctatgggaa ttgttcccgg aatggtctgg 2580
caaaacagag acatctacta ccagggccct atttgggcca aggtccctca cacggacgga 2640
cactttcacc cttcgccgct gatgggagga tttggactga aacacccgcc tccacagatt 2700
ttcatcaaaa acacccccgt acccgccaat cccaatacta cttttagcgc tgcaaggatt 2760
aattcttttc tgacgcagta cagcaccgga caagttgccg ttcagatcga ctgggaaatt 2820
cagaaggagc attccaaacg ctggaatccc ttacttcaaa ctacggcact 2880
caaaattcta tgctgtgggc tcccgacaat gctggcaact accacgaact ccgggctatt 2940
gggtcccgtt tcctcaccca ccacttgtaa

```

<210> 21

<211> 736

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 21

```

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1      5      10      15
Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
20      25      30
Lys Ala Asn Gln Gln Lys Gln Asp Gly Arg Gly Leu Val Leu Pro
35      40      45

```


140140433P1.TXT

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
 50 55 60
 Val Asn Ala Ala Asp Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
 65 70 75 80
 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
 85 90 95
 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
 100 105 110
 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
 115 120 125
 Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
 130 135 140
 Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
 145 150 155 160
 Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
 165 170 175
 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
 180 185 190
 Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly
 195 200 205
 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
 210 215 220
 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
 225 230 235 240
 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
 245 250 255
 Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His
 260 265 270
 Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
 275 280 285
 His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
 290 295 300
 Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
 305 310 315 320
 Val Lys Glu Val Thr Thr Ser Asp Gly Val Thr Thr Ile Ala Asn Asn
 325 330 335
 Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro
 340 345 350
 Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
 355 360 365
 Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
 370 375 380
 Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
 385 390 395 400
 Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe
 405 410 415
 Glu Glu Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
 420 425 430
 Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg
 435 440 445
 Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser
 450 455 460
 Arg Gly Ser Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro
 465 470 475 480
 Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Gly Asn
 485 490 495
 Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn
 500 505 510
 Gly His Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys
 515 520 525
 Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly
 530 535 540
 Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile

140140433P1.TXT

545 Thr Asp Glu Glu Glu 550 Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg
 Phe Gly Thr Val 565 Val Asn Phe Gln Ser Ser Thr His Pro Ala
 Thr Gly Asp Val 580 His Val Met Gly Ala Leu Pro Gly Met Val Trp Gln
 Asp Arg Asp Val Tyr Leu Gln 600 Gly Pro Ile Trp Ala Lys Ile Pro His
 Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
 Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr
 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn
 Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu
 Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu

<210> 22

<211> 736

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 22

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
 Lys Ala Asn Gln Gln Lys Gln Asp Gly Arg Gly Leu Val Leu Pro
 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
 Val Asn Ala Ala Asp Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
 Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
 Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
 Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
 Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly
 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile

140140433P1.TXT

225	Thr	Thr	Ser	Thr	Arg	230	Thr	Trp	Ala	Leu	Pro	235	Thr	Tyr	Asn	Asn	His	240	Leu
					245							250	Gly	Ala	Ser	Asn	Asp	255	His
	Tyr	Lys	Gln	Ile	Ser	Ser	Ala	Ser	Thr	265	Gly	265	Ala	Ser	Asn	Asp	270	Asn	His
				260		Thr	Pro	Trp	Gly	280	Tyr	Phe	Asp	Phe	Asn	Arg	285	Phe	
	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn	300		
	290						295					300							
	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	315	Leu	Phe	Asn	Ile	Gln	320	
	305					310						315							
	Val	Lys	Glu	Val	Thr	Thr	Ser	Asp	Gly	Val	Thr	Thr	Ile	Ala	Asn	Asn	335		
					325							330							
	Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Ser	Asp	Ser	Glu	Tyr	Gln	Leu	Pro	350		
					340							345							
	Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala	365		
					355														
	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly	380		
	370						375					380							
	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro	400		
	385					390					395								
	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Thr	Phe	Ser	Tyr	Thr	Phe	415		
					405						410								
	Glu	Glu	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp	430		
					420														
	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Asn	Arg	445		
					435														
	Thr	Gln	Asn	Gln	Ser	Gly	Ser	Ala	Gln	Asn	Lys	Asp	Leu	Leu	Phe	Ser	460		
	Arg	Gly	Ser	Pro	Ala	Gly	Met	Ser	Val	Gln	Pro	Lys	Asn	Trp	Leu	Pro	480		
	465					470					475								
	Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Lys	Thr	Lys	Thr	Gly	Asn	495		
					485						490								
	Asn	Asn	Ser	Asn	Phe	Thr	Trp	Thr	Gly	Ala	Ser	Lys	Tyr	Asn	Leu	Asn	510		
					500														
	Gly	His	Glu	Ser	Ile	Ile	Asn	Pro	Gly	Thr	Ala	Met	Ala	Ser	His	Lys	525		
					515														
	Asp	Asp	Glu	Asp	Lys	Phe	Phe	Pro	Met	Ser	Gly	Val	Met	Ile	Phe	Gly	540		
	Lys	Glu	Ser	Ala	Gly	Ala	Ser	Asn	Thr	Ala	Leu	Asp	Asn	Val	Met	Ile	560		
	545					550					555								
	Thr	Asp	Glu	Glu	Glu	Ile	Lys	Ala	Thr	Asn	Pro	Val	Ala	Thr	Glu	Arg	575		
					565						570								
	Phe	Gly	Thr	Val	Ala	Val	Asn	Phe	Gln	Ser	Ser	Ser	Thr	His	Pro	Ala	590		
					580														
	Thr	Gly	Asp	Val	His	Val	Met	Gly	Ala	Leu	Pro	Gly	Met	Val	Trp	Gln	605		
					595														
	Asp	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His	620		
	610						615												
	Thr	Asp	Gly	His	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu	640		
	625					630					635								
	Lys	His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala	655		
					645						650								
	Asn	Pro	Pro	Ala	Glu	Phe	Ser	Ala	Thr	Lys	Phe	Ala	Ser	Phe	Ile	Thr	670		
					660														
	Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	Leu	Gln	685		
					675														
	Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Val	Gln	Tyr	Thr	Ser	Asn	700		
							695												
	Tyr	Ala	Lys	Ser	Ala	Asn	Val	Asp	Phe	Thr	Val	Asp	Asn	Asn	Gly	Leu	720		
	705					710					715								
	Tyr	Thr	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	Pro	Leu	735		
					725														

140140433P1.TXT

<210> 23
 <211> 733
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note =
 synthetic construct

<400> 23
 Met Thr Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser Glu
 1 5 10 15
 Gly Val Arg Glu Trp Trp Ala Leu Gln Pro Gly Ala Pro Lys Pro Lys
 20 25 30
 Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro Gly
 35 40 45
 Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro Val
 50 55 60
 Asn Ala Ala Asp Ala Ala Leu Glu His Asp Lys Ala Tyr Asp Gln
 65 70 75 80
 Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp
 85 90 95
 Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly Asn
 100 105 110
 Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Ile Leu Glu Pro Leu
 115 120 125
 Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg Pro
 130 135 140
 Val Glu Gln Ser Pro Ala Glu Pro Asp Ser Ser Ser Gly Ile Gly Lys
 145 150 155 160
 Ser Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln Thr Gly
 165 170 175
 Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Gln Pro Pro Ala
 180 185 190
 Ala Pro Ser Gly Val Gly Ser Thr Thr Met Ala Ser Gly Gly Ala
 195 200 205
 Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser Ser
 210 215 220
 Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile Thr
 225 230 235 240
 Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr
 245 250 255
 Lys Gln Ile Ser Ser Gln Ser Gly Ala Thr Asn Asp Asn His Tyr Phe
 260 265 270
 Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys
 275 280 285
 His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly
 290 295 300
 Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val Lys
 305 310 315 320
 Glu Val Thr Gln Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu Thr
 325 330 335
 Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr Val
 340 345 350
 Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val
 355 360 365
 Phe Met Val Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln
 370 375 380
 Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln
 385 390 395 400
 Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Thr Phe Glu Asp
 405 410 415

140140433P1.TXT

Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu
 420 425 430
 Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg Thr Gln
 435 440 445
 Thr Ala Ser Gly Thr Gln Gln Ser Arg Leu Leu Phe Ser Gln Ala Gly
 450 455 460
 Pro Thr Ser Met Ser Leu Gln Ala Lys Asn Trp Leu Pro Gly Pro Cys
 465 470 475 480
 Tyr Arg Gln Gln Arg Leu Ser Lys Gln Ala Asn Asp Asn Asn Ser
 485 490 495
 Asn Phe Pro Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asp
 500 505 510
 Ser Leu Val Asn Pro Gly Pro Ala Met Ala Ser His Lys Asp Asp Lys
 515 520 525
 Glu Lys Phe Phe Pro Met His Gly Thr Leu Ile Phe Gly Lys Glu Gly
 530 535 540
 Thr Asn Ala Asn Asn Ala Asp Leu Glu Asn Val Met Ile Thr Asp Glu
 545 550 555 560
 Glu Glu Ile Arg Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr Gly Thr
 565 570 575
 Val Ser Asn Asn Leu Gln Asn Ser Asn Ala Gly Pro Thr Thr Gly Thr
 580 585 590
 Val Asn His Gln Gly Ala Leu Pro Gly Met Val Trp Gln Asp Arg Asp
 595 600 605
 Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly
 610 615 620
 His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro
 625 630 635 640
 Pro Pro Gln Ile Met Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro
 645 650 655
 Thr Asn Phe Ser Ala Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser
 660 665 670
 Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn
 675 680 685
 Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Asn Lys
 690 695 700
 Ser Val Asn Val Asp Phe Thr Val Asp Thr Asn Gly Val Tyr Ser Glu
 705 710 715 720
 Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
 725 730

<210> 24

<211> 736

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 24

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
 1 5 10 15
 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
 20 25 30
 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
 35 40 45
 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
 50 55 60
 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
 65 70 75 80
 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
 85 90 95

140140433P1.TXT

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
 100 105 110
 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
 115 120 125
 Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
 130 135 140
 Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
 145 150 155 160
 Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
 165 170 175
 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
 180 185 190
 Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly
 195 200 205
 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
 210 215 220
 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
 225 230 235 240
 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
 245 250 255
 Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His
 260 265 270
 Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
 275 280 285
 His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
 290 295 300
 Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
 305 310 315 320
 Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn
 325 330 335
 Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro
 340 345 350
 Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
 355 360 365
 Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
 370 375 380
 Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
 385 390 395 400
 Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe
 405 410 415
 Glu Glu Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
 420 425 430
 Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg
 435 440 445
 Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser
 450 455 460
 Arg Gly Ser Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro
 465 470 475 480
 Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn
 485 490 495 500
 Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn
 505 510
 Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys
 515 520 525
 Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly
 530 535 540
 Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile
 545 550 555 560
 Thr Asp Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg
 565 570 575
 Phe Gly Thr Val Ala Val Asn Phe Gln Ser Ser Ser Thr Asp Pro Ala
 580 585 590
 Thr Gly Asp Val His Val Met Gly Ala Leu Pro Gly Met Val Trp Gln

140140433P1.TXT

595 600 605
 Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
 610 615 620
 Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
 625 630 635 640
 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
 645 650 655
 Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr
 660 665 670
 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
 675 680 685
 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn
 690 695 700
 Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu
 705 710 715 720
 Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu
 725 730 735

<210> 25

<211> 736

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 25

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
 1 5 10 15
 Glu Gly Ile Arg Lys Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
 20 25 30
 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
 35 40 45
 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
 50 55 60
 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
 65 70 75 80
 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
 85 90 95
 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
 100 105 110
 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
 115 120 125
 Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
 130 135 140
 Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Gly Ile Gly
 145 150 155 160
 Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
 165 170 175
 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
 180 185 190
 Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly
 195 200 205
 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
 210 215 220
 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
 225 230 235 240
 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
 245 250 255
 Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His
 260 265 270
 Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe

140140433P1.TXT

His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn
275	290					280					285				
Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	Gln
305					310					315					320
Val	Lys	Glu	Val	Thr	Asn	Asp	Gly	Val	Thr	Thr	Ile	Ala	Asn	Asn	
				325				330						335	
Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Ser	Asp	Ser	Glu	Tyr	Gln	Leu	Pro
			340					345					350		
Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala
		355					360					365			
Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly
370						375					380				
Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro
385					390					395					400
Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Thr	Phe	Ser	Tyr	Thr	Phe
				405					410					415	
Glu	Glu	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp
			420					425					430		
Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Asn	Arg
		435					440					445			
Thr	Gln	Asn	Gln	Ser	Gly	Ser	Ala	Gln	Asn	Lys	Asp	Leu	Leu	Phe	Ser
		450				455					460				
Arg	Gly	Ser	Pro	Ala	Gly	Met	Ser	Val	Gln	Pro	Lys	Asn	Trp	Leu	Pro
465					470					475					480
Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Lys	Thr	Lys	Thr	Asp	Asn
				485					490					495	
Asn	Asn	Ser	Asn	Phe	Thr	Trp	Thr	Gly	Ala	Ser	Lys	Tyr	Asn	Leu	Asn
			500					505					510		
Gly	Arg	Glu	Ser	Ile	Ile	Asn	Pro	Gly	Thr	Ala	Met	Ala	Ser	His	Lys
		515					520					525			
Asp	Asp	Lys	Asp	Lys	Phe	Phe	Pro	Met	Ser	Gly	Val	Met	Ile	Phe	Gly
		530				535					540				
Lys	Glu	Ser	Ala	Gly	Ala	Ser	Asn	Thr	Ala	Leu	Asp	Asn	Val	Met	Ile
545					550					555					560
Thr	Asp	Glu	Glu	Glu	Ile	Lys	Ala	Thr	Asn	Pro	Val	Ala	Thr	Glu	Arg
				565					570					575	
Phe	Gly	Thr	Val	Ala	Val	Asn	Phe	Gln	Ser	Ser	Ser	Thr	Asp	Pro	Ala
			580					585					590		
Thr	Gly	Asp	Val	His	Val	Met	Gly	Ala	Leu	Pro	Gly	Met	Val	Trp	Gln
		595					600					605			
Asp	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His
		610				615					620				
Thr	Asp	Gly	His	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu
625					630					635					640
Lys	His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala
				645					650					655	
Asn	Pro	Pro	Ala	Glu	Phe	Ser	Ala	Thr	Lys	Phe	Ala	Ser	Phe	Ile	Thr
			660					665					670		
Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	Leu	Gln
		675					680					685			
Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Val	Gln	Tyr	Thr	Ser	Asn
		690				695					700				
Tyr	Ala	Lys	Ser	Ala	Asn	Val	Asp	Phe	Thr	Val	Asp	Asn	Asn	Gly	Leu
705					710					715					720
Tyr	Thr	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	Pro	Leu
				725					730					735	

<210> 26

<211> 736

<212> PRT

<213> Artificial Sequence

140140433P1.TXT

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 26

```

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1      5      10      15
Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
20      25      30
Lys Ala Asn Gln Gln Lys Gln Asp Asn Gly Arg Gly Leu Val Leu Pro
35      40      45
Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
50      55      60
Val Asn Ala Ala Asp Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65      70      75      80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
85      90      95
Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
100      105      110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115      120      125
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130      135      140
Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145      150      155      160
Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165      170      175
Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
180      185      190
Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly
195      200      205
Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
210      215      220
Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
225      230      235      240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245      250      255
Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His
260      265      270
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275      280      285
His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290      295      300
Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305      310      315      320
Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn
325      330      335
Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro
340      345      350
Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
355      360      365
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
370      375      380
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385      390      395      400
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe
405      410      415
Glu Glu Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420      425      430
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg
435      440      445
Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser
450      455      460

```

140140433P1.TXT

```

Arg Gly Ser Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro
465      470      475
Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn
      485      490      495
Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn
      500      505      510
Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys
      515      520      525
Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly
      530      535      540
Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile
545      550      555      560
Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg
      565      570      575
Phe Gly Thr Val Ala Val Asn Phe Gln Ser Ser Ser Thr His Pro Ala
      580      585      590
Thr Gly Asp Val His Val Met Gly Ala Leu Pro Gly Met Val Trp Gln
      595      600      605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
      610      615      620
Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
625      630      635      640
Lys His Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
      645      650      655
Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr
      660      665      670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
      675      680      685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn
      690      695      700
Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu
705      710      715      720
Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu
      725      730      735

```

<210> 27

<211> 736

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 27

```

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1      5      10      15
Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
      20      25      30
Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
      35      40      45
Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
      50      55      60
Val Asn Ala Ala Asp Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65      70      75      80
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
      85      90      95
Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
      100      105      110
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
      115      120      125
Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130      135      140

```

140140433P1.TXT

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
 145 150 155 160
 Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
 165 170 175
 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
 180 185 190
 Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly
 195 200 205
 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
 210 215 220
 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
 225 230 235 240
 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
 245 250 255
 Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His
 260 265 270
 Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
 275 280 285
 His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
 290 295 300
 Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
 305 310 315 320
 Val Lys Glu Val Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn
 325 330 335
 Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro
 340 345 350
 Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
 355 360 365
 Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
 370 375 380
 Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
 385 390 395 400
 Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe
 405 410 415
 Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
 420 425 430
 Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg
 435 440 445
 Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser
 450 455 460
 Arg Gly Ser Pro Ala Gly Met Ser Val Gln Leu Lys Asn Trp Leu Pro
 465 470 475 480
 Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn
 485 490 495
 Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn
 500 505 510
 Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys
 515 520 525
 Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly
 530 535 540
 Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile
 545 550 555 560
 Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg
 565 570 575
 Phe Gly Thr Val Ala Val Asn Phe Gln Ser Ser Ser Thr Asp Pro Ala
 580 585 590
 Thr Gly Asp Val His Val Met Gly Ala Leu Pro Gly Met Val Trp Gln
 595 600 605
 Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
 610 615 620
 Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
 625 630 635 640
 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala

140140433P1.TXT

645
 Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr
 660
 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
 675
 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn
 690
 Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu
 705
 Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu
 725
 730
 735

<210> 28

<211> 736

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 28

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
 1 5 10 15
 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
 20 25 30
 Lys Ala Asn Gln Gln Lys Gln Asp Gly Arg Gly Leu Val Leu Pro
 35 40 45
 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
 50 55 60
 Val Asn Ala Ala Asp Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
 65 70 75 80
 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
 85 90 95
 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
 100 105 110
 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
 115 120 125
 Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
 130 135 140
 Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
 145 150 155 160
 Lys Ser Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
 165 170 175
 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
 180 185 190
 Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly
 195 200 205
 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
 210 215 220
 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
 225 230 235 240
 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
 245 250 255
 Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His
 260 265 270
 Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
 275 280 285
 His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
 290 295 300
 Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
 305 310 315 320
 Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn
 Page 32

140140433P1.TXT

```

325          330          335
Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro
340          345          350
Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
355          360          365
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
370          375          380
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385          390          395          400
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe
405          410          415
Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420          425          430
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg
435          440          445
Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser
450          455          460
Arg Gly Ser Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro
465          470          475          480
Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn
485          490          495          500
Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn
505          510          515
Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys
520          525          530
Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly
535          540          545
Lys Gly Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile
550          555          560
Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg
565          570          575
Phe Gly Thr Val Ala Val Asn Phe Gln Ser Ser Ser Thr Asp Pro Ala
580          585          590
Thr Gly Asp Val His Val Met Gly Ala Leu Pro Gly Met Val Trp Gln
595          600          605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610          615          620
Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
625          630          635          640
Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645          650          655
Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr
660          665          670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675          680          685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn
690          695          700
Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu
705          710          715          720
Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu
725          730          735

```

<210> 29

<211> 736

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 29

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser

140140433P1.TXT

1	Glu	Gly	Ile	Arg	5	Glu	Trp	Trp	Asp	Leu	10	Lys	Pro	Gly	Ala	Pro	15	Lys	Pro
				20						25						30			
	Lys	Ala	Asn	Gln	Gln	Lys	Gln	Asp	Asp	Gly	Arg	Gly	Leu	Val	Leu	Pro			
			35					40						45					
	Gly	Tyr	Lys	Tyr	Leu	Gly	Pro	Phe	Asn	Gly	Leu	Asp	Lys	Gly	Glu	Pro			
			50				55					60							
	Val	Asn	Ala	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp			
	65				70						75					80			
	Gln	Gln	Leu	Lys	Ala	Gly	Asp	Asn	Pro	Tyr	Leu	Arg	Tyr	Asn	His	Ala			
				85						90					95				
	Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Gln	Glu	Asp	Thr	Ser	Phe	Gly	Gly			
			100						105					110					
	Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Val	Leu	Glu	Pro			
			115					120					125						
	Phe	Gly	Leu	Val	Glu	Glu	Gly	Ala	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg			
		130					135					140							
	Pro	Val	Glu	Gln	Ser	Pro	Gln	Glu	Pro	Asp	Ser	Ser	Ser	Gly	Ile	Gly			
	145					150					155					160			
	Lys	Ser	Gly	Gln	Gln	Pro	Ala	Lys	Lys	Arg	Leu	Asn	Phe	Gly	Gln	Thr			
				165						170					175				
	Gly	Asp	Ser	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Leu	Gly	Glu	Pro	Pro			
			180						185					190					
	Ala	Thr	Pro	Ala	Ala	Leu	Gly	Pro	Thr	Thr	Met	Ala	Ser	Gly	Gly	Gly			
			195					200					205						
	Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Asn	Ala			
		210					215					220							
	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	Trp	Leu	Gly	Asp	Arg	Val	Ile			
	225					230					235					240			
	Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	Leu			
				245						250					255				
	Tyr	Lys	Gln	Ile	Ser	Ser	Ala	Ser	Thr	Gly	Ala	Ser	Asn	Asp	Asn	His			
			260						265					270					
	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	Phe			
			275					280					285						
	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn			
		290					295					300							
	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	Gln			
		305				310					315					320			
	Val	Lys	Glu	Val	Thr	Thr	Asn	Asp	Gly	Val	Thr	Thr	Ile	Ala	Asn	Asn			
				325						330					335				
	Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Ser	Asp	Ser	Glu	Tyr	Gln	Leu	Pro			
			340						345					350					
	Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala			
			355					360					365						
	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly			
		370					375					380							
	Ser	Lys	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro			
		385				390					395					400			
	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Thr	Phe	Ser	Tyr	Thr	Phe			
				405						410					415				
	Glu	Glu	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp			
			420						425					430					
	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Asn	Arg			
			435					440					445						
	Thr	Gln	Asn	Gln	Ser	Gly	Ser	Ala	Gln	Asn	Lys	Asp	Leu	Leu	Phe	Ser			
		450					455					460							
	Arg	Gly	Ser	Pro	Ala	Gly	Met	Ser	Val	Gln	Pro	Lys	Asn	Trp	Leu	Pro			
		465				470					475					480			
	Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Lys	Thr	Lys	Thr	Asp	Asn			
				485						490					495				
	Asn	Asn	Ser	Asn	Phe	Thr	Trp	Thr	Gly	Ala	Ser	Lys	Tyr	Asn	Leu	Asn			
				500					505					510					

140140433P1.TXT

Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys
 515 520 525
 Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly
 530 535 540
 Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile
 545 550 555 560
 Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg
 565 570 575
 Phe Gly Thr Val Ala Val Asn Phe Gln Ser Ser Ser Thr Asp Pro Ala
 580 585 590
 Thr Gly Asp Val His Val Met Gly Ala Leu Pro Gly Met Val Trp Gln
 595 600 605
 Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
 610 615 620
 Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
 625 630 635 640
 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
 645 650 655
 Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr
 660 665 670
 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
 675 680 685
 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn
 690 695 700
 Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu
 705 710 715 720
 Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu
 725 730 735

<210> 30

<211> 742

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 30

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
 1 5 10 15
 Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro
 20 25 30
 Lys Ala Asn Gln Gln His Gln Asp Asn Gly Arg Gly Leu Val Leu Pro
 35 40 45
 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
 50 55 60
 Val Asn Glu Ala Asp Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
 65 70 75 80
 Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
 85 90 95
 Asp Ala Glu Phe Gln Gln Arg Leu Ala Thr Asp Thr Ser Phe Gly Gly
 100 105 110
 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Ile Leu Glu Pro
 115 120 125
 Leu Gly Leu Val Glu Glu Gly Val Lys Thr Ala Pro Gly Lys Lys Arg
 130 135 140
 Pro Leu Glu Lys Thr Pro Asn Arg Pro Thr Asn Pro Asp Ser Gly Lys
 145 150 155 160
 Ala Pro Ala Lys Lys Gln Lys Asp Gly Glu Pro Ala Asp Ser Ala
 165 170 175
 Arg Arg Thr Leu Asp Phe Glu Asp Ser Gly Ala Gly Asp Gly Pro Pro
 180 185 190

140140433P1.TXT

Glu Gly Ser Ser Ser Gly Glu Met Ser His Asp Ala Glu Met Arg Ala
 195 200 205
 Ala Pro Gly Gly Asn Ala Val Glu Ala Gly Gln Gly Ala Asp Gly Val
 210 215 220
 Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr Trp Ser Glu Gly
 225 230 235 240
 Arg Val Thr Thr Thr Ser Thr Arg Thr Trp Val Leu Pro Thr Tyr Asn
 245 250 255
 Asn His Leu Tyr Leu Arg Ile Gly Thr Thr Ala Asn Ser Asn Thr Tyr
 260 265 270
 Asn Gly Phe Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His
 275 280 285
 Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp
 290 295 300
 Gly Leu Arg Pro Lys Ser Met Arg Val Lys Ile Phe Asn Ile Gln Val
 305 310 315 320
 Lys Glu Val Thr Thr Ser Asn Gly Glu Thr Thr Val Ala Asn Asn Leu
 325 330 335
 Thr Ser Thr Val Gln Ile Phe Ala Asp Ser Thr Tyr Glu Leu Pro Tyr
 340 345 350
 Val Met Asp Ala Gly Gln Glu Gly Ser Phe Pro Pro Phe Pro Asn Asp
 355 360 365
 Val Phe Met Val Pro Gln Tyr Gly Tyr Cys Gly Val Val Thr Gly Lys
 370 375 380
 Asn Gln Asn Gln Thr Asp Arg Asn Ala Phe Tyr Cys Leu Glu Tyr Phe
 385 390 395 400
 Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Val Ser Tyr Gln
 405 410 415
 Phe Glu Lys Val Pro Phe His Ser Met Tyr Ala His Ser Gln Ser Leu
 420 425 430
 Asp Arg Met Met Asn Pro Leu Leu Asp Gln Tyr Leu Trp His Leu Gln
 435 440 445
 Ser Thr Thr Thr Gly Asn Ser Leu Asn Gln Gly Thr Ala Thr Thr Thr
 450 455 460
 Tyr Gly Lys Ile Thr Thr Gly Asp Phe Ala Tyr Tyr Arg Lys Asn Trp
 465 470 475 480
 Leu Pro Gly Ala Cys Ile Lys Gln Gln Lys Phe Ser Lys Asn Ala Asn
 485 490 495
 Gln Asn Tyr Lys Ile Pro Ala Ser Gly Gly Asp Ala Leu Leu Lys Tyr
 500 505 510
 Asp Thr His Thr Thr Leu Asn Gly Arg Trp Ser Asn Met Ala Pro Gly
 515 520 525
 Pro Pro Met Ala Thr Ala Gly Ala Gly Asp Ser Asp Phe Ser Asn Ser
 530 535 540
 Gln Leu Ile Phe Ala Gly Pro Asn Pro Ser Gly Asn Thr Thr Thr Ser
 545 550 555 560
 Ser Asn Asn Leu Leu Phe Thr Ser Glu Glu Glu Ile Ala Thr Thr Asn
 565 570 575
 Pro Arg Asp Thr Asp Met Phe Gly Gln Ile Ala Asp Asn Asn Gln Asn
 580 585 590
 Ala Thr Thr Ala Pro His Ile Ala Asn Leu Asp Ala Met Gly Ile Val
 595 600 605
 Pro Gly Met Val Trp Gln Asn Arg Asp Ile Tyr Tyr Gln Gly Pro Ile
 610 615 620
 Trp Ala Lys Val Pro His Thr Asp Gly His Phe His Pro Ser Pro Leu
 625 630 635 640
 Met Gly Gly Phe Gly Leu Lys His Pro Pro Gln Ile Phe Ile Lys
 645 650 655
 Asn Thr Pro Val Pro Ala Asn Pro Asn Thr Thr Phe Ser Ala Ala Arg
 660 665 670
 Ile Asn Ser Phe Leu Thr Gln Tyr Ser Thr Gly Gln Val Ala Val Gln
 675 680 685
 Ile Asp Trp Glu Ile Gln Lys Glu His Ser Lys Arg Trp Asn Pro Glu

140140433P1.TXT

690 695 700
 Val Gln Phe Thr Ser Asn Tyr Gly Thr Gln Asn Ser Met Leu Trp Ala
 705 710 715 720
 Pro Asp Asn Ala Gly Asn Tyr His Glu Leu Arg Ala Ile Gly Ser Arg
 725 730 735
 Phe Leu Thr His His Leu
 740

<210> 31
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note =
 synthetic construct

<400> 31
 gcgacakttt gcgacaccay gtgg 24

<210> 32
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note =
 synthetic construct

<221> misc_feature
 <222> 4-6
 <223> N can be a, g, c, or t (u)

<400> 32
 ccannnggaa tcgcaatgcc aat 23

<210> 33
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note =
 synthetic construct

<221> misc_feature
 <222> 4, 6, 9
 <223> N can be a, g, c, or t (u)

<400> 33
 atgntnatnt ggtgggagga ggg 23

<210> 34
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note =
 synthetic construct

<221> misc_feature
 <222> 6

140140433P1.TXT

<223> N can be a, g, c, or t (u)

<400> 34

cgaatnaamc ggtttattga ttaac

25

<210> 35

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 35

Asn Gly Arg Ala His Ala

1

5

<210> 36

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 36

Ser Ile Gly Tyr Pro Leu Pro

1

5

<210> 37

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 37

Lys Phe Asn Lys Pro Phe Val Phe Leu Ile

1

5

10

<210> 38

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 38

Asn Ile Ser Leu Asp Asn Pro Leu Glu Asn Pro Ser Ser Leu Phe Asp

1

5

10

15

Leu Val Ala Arg Ile Lys

20

<210> 39

<211> 26

<212> DNA

<213> Artificial Sequence

140140433P1.TXT

<220>
 <223> Description of Artificial Sequence: Note =
 synthetic construct

 <221> misc_feature
 <222> 14
 <223> N can be a, g, c, or t (u)

 <400> 39
 caataaaccg kkttnattcgt ktcagt 26

 <210> 40
 <211> 26
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Note =
 synthetic construct

 <221> misc_feature
 <222> 4-5, 21
 <223> N can be a, g, c, or t (u)

 <400> 40
 acannwgagt cagaaatkcc nggcag 26

 <210> 41
 <211> 640
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Note =
 synthetic construct

 <221> misc_feature
 <222> 608, 624
 <223> N can be a, g, c, or t (u)

 <400> 41
 gcgaattgaa tttagcggcc gcgaattcgc ctttcaataa accgtttgat tcgtgtcagt 60
 tgatctttgg cctacttgtc cttcttatct tatctggctg ccatggctgc gtagataagc 120
 agcttggtat gcgcttcgcg gttaatcatc aactacgcca aaccctagat gatggagtgg 180
 gccactccct ctatgcgcgc tcgctcgctc ggtggggccg gactgcccgg catttctgac 240
 tcctttgtga actgggtggc cctccgggct attgggtccc gtttcctcac ccaccacttg 300
 taacccttcc tggttaatca atgaaccggt taattcgttt cagttgatct ttggcctact 360
 tgtccttctt atcttatctg gttgccatgg ctgcgtagat aagcagcttg gtatgcgctt 420
 cgcggttaat catcaactac gccaaaccct agatgatgga gttggccact ccctctatgc 480
 gcgctcgctc gctcggtggg gccggactgc cgggcatttc tgactcactt gtaagggcga 540
 aattcgttta aacctgcagg actagtccct ttagtgaggg ttaattctga gcttggcgta 600
 atcatggnca tagctgtttc ctgnggaaaa tgttatccgc 640

 <210> 42
 <211> 248
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Note =
 synthetic construct

140140433P1.TXT

<400> 42
 tggaggggtg gagtcgtgrc gtgaattacg tcataggggtt agggaggtcc tgtattagag 60
 gtcacgtgag tgttttgcga cattttgcga caccatgtgg tcacgctggg tatttaagcc 120
 cgagtggwca cgcaggggtc ccatTTtgaa gcgggaggtt tgaacgcgca gccgccatgc 180
 cggggtttta cgagattgtg attaaggtcc ccagcgacct tgacgagcat ctgccaggaa 240
 ttctgac 248

<210> 43
 <211> 317
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note =
 synthethic construct

<400> 43
 gcccgggcgg cctcagttag cgagcgagcg cgcagagagg gagtggccaa ctccatcact 60
 aggggttcct ggaggggtgg agtcgtgacg tgaattacgt catagggtta gggaggtcct 120
 gtattagagg tcacgtgagt gttttgcgac attttgcgac accatgtggt cacgctgggt 180
 atttaagccc gagtgagcac gcaggggtctc catTTtgaag cgggaggttt gaacgcgcag 240
 ccgccatgcc ggggttttac gagattgtga ttaaggtccc cagcgacctt gacgagcatc 300
 tgcttgaat ttctgac 317

<210> 44
 <211> 157
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note =
 synthethic construct

<221> misc_feature
 <222> 33, 105, 141
 <223> N can be a, g, c, or t (u)

<400> 44
 gagtgagcga gcaggggtctc catTTtgacc gcnaaatttg aacgagcagc atccatgccg 60
 ggcttctacg agatcgtgat caaggtgccg agcgacctgg acgancacct gcctggcatt 120
 tctgactcaa ttgtaagggc naattcgttt aaacctg 157

<210> 45
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note =
 synthethic construct

<400> 45
 gcgacakttt gcgacaccay gtgg 24

<210> 46
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note =
 synthethic construct

140140433P1.TXT

<221> misc_feature
 <222> 4-6
 <223> N can be a, g, c, or t (u)

 <400> 46
 ccannnggaa tcgcaatgcc aat 23

 <210> 47
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Note =
 synthethic construct

 <221> misc_feature
 <222> 4, 6, 9
 <223> N can be a, g, c, or t (u)

 <400> 47
 atgntnatnt ggtgggagga ggg 23

 <210> 48
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Note =
 synthethic construct

 <221> misc_feature
 <222> 6
 <223> N can be a, g, c, or t (u)

 <400> 48
 cgaatnaamc ggtttattga ttaac 25

 <210> 49
 <211> 1872
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Note =
 synthethic construct

 <400> 49
 atgccgggct tctacgagat cgtgatcaag gtgccgagcg acctggacga gcacctgccg 60
 ggcatttctg actcgtttgt gaactgggtg gccgagaagg aatgggagct gcccccgat 120
 tctgacatgg atctgaatct gattgagcag gcacccctga ccgtggccga gaagctgcag 180
 cgcgacttcc tgggtccaatg gcgcccgcgtg agtaaggccc cggaggccct cttctttgtt 240
 cagttcgaga agggcgagtc ctacttcac ctccatattc tgggtggagac cacgggggtc 300
 aaatccatgg tgcctgggccg cttcttgagt cagattaggg acaagctggt gcagaccatc 360
 taccgcggga tcgagccgac cctgcccac tggttcgcgg tgaccaagac gcgtaatggc 420
 gccggagggg ggaacaaggt ggtggacgag tgctacatcc ccaactacct cctgcccag 480
 actcagcccc agctgcagtg ggcgtggact aacatggagg agtatataag cgctgtttg 540
 aacctggccg agcgcaaacg gctcgtggcg cagcacctga ccacgctcag ccagaccag 600
 gagcagaaca aggagaatct gaaccccaat tctgacgcgc ctgtcatccg gtcaaaaacc 660
 tccgcgcgct acatggagct ggtcgggttg ctgggtggacc ggggcatcac ctccgagaag 720
 cagtggatcc aggaggacca ggccctgtac atctccttca acgcccctc caactcgcg 780
 tcccagatca aggccgctct ggacaatgcc ggcaagatca tggcgctgac caaatccgcg 840

140140433P1.TXT

```

cccgactacc  tggtaggccc  cgctcctccc  gcggacatta  aaaccaaccg  catctaccgc  900
atccttgagc  tgaacggcta  cgaccctgcc  tacgccggct  ccgtctttct  cggctgggccc  960
cagaaacggg  tcgggaagcg  caacaccatc  tggctgtttg  ggccggccac  cacgggcaag  1020
accaacatcg  cgggaagccat  cgcccacgcc  gtgcccttct  acggctgcgt  caactggacc  1080
aatgagaact  ttcccttcaa  cgattgcgtc  gacaagatgg  tgatctggtg  ggaggagggc  1140
aagatgacgg  ccaaggtcgt  ggagtcggcc  aaggccattc  tcggcggcag  caaggtgcgc  1200
gtggaccaaa  agtgcaagtc  gtccgcccag  atcgatccca  ccccgtgat  cgtcacctcc  1260
aacaccaaca  tgtgcgccgt  gattgacggg  aacagcacca  ctttcgagca  ccagcagccg  1320
ttgcaggacc  ggatgttcaa  atttgaactc  acccgccgtc  tggagcatga  ctttggcaag  1380
gtgacaaagc  aggaagtcaa  agagtcttct  cgctgggccc  aggatcacgt  gaccgaggtg  1440
gcgcattgag  tctacgtcag  aaagggtgga  gccaacaaaa  gaccgcccc  cgatgacgcg  1500
gataaaagcg  agcccaagcg  ggcctgcccc  tcagtcgcgg  atccatcgac  gtcagacgcg  1560
gaaggagctc  cgttggaact  tgccgacagg  taccaaaaaca  aatgttctcg  tcacgcgggc  1620
atgcttcaga  tgctgtttcc  ctgcaagaca  tgcgagagaa  tgaatcagaa  tttcaacatt  1680
tgcttcacgc  acgggaccag  agactgttca  gaatgtttcc  ccggcgtgtc  agaattctca  1740
ccggtcgtca  gaaaaaggac  gtatcggaaa  ctctgtgcga  ttcatcatct  gctggggcgg  1800
gtccccgaga  ttgcttgctc  ggcctgcgat  ctggtcaacg  tggacctgga  tgactgtgtc  1860
tctgagcaat  aa

```

<210> 50

<211> 623

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 50

```

Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp
1      5      10      15
Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Asn Trp Val Ala Glu
20     25     30
Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile
35     40     45
Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg Asp Phe Leu
50     55     60
Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu Phe Phe Val
65     70     75     80
Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His Ile Leu Val Glu
85     90     95
Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe Leu Ser Gln Ile
100    105    110
Arg Asp Lys Leu Val Gln Thr Ile Tyr Arg Gly Ile Glu Pro Thr Leu
115    120    125
Pro Asn Trp Phe Ala Val Thr Lys Thr Arg Asn Gly Ala Gly Gly Gly
130    135    140
Asn Lys Val Val Asp Glu Cys Tyr Ile Pro Asn Tyr Leu Leu Pro Lys
145    150    155    160
Thr Gln Pro Glu Leu Gln Trp Ala Trp Thr Asn Met Glu Glu Tyr Ile
165    170    175
Ser Ala Cys Leu Asn Leu Ala Glu Arg Lys Arg Leu Val Ala Gln His
180    185    190
Leu Thr His Val Ser Gln Thr Gln Glu Gln Asn Lys Glu Asn Leu Asn
195    200    205
Pro Asn Ser Asp Ala Pro Val Ile Arg Ser Lys Thr Ser Ala Arg Tyr
210    215    220
Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys
225    230    235    240
Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala
245    250    255
Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys
260    265    270

```

140140433P1.TXT

Ile	Met	Ala	Leu	Thr	Lys	Ser	Ala	Pro	Asp	Tyr	Leu	Val	Gly	Pro	Ala
		275					280					285			
Pro	Pro	Ala	Asp	Ile	Lys	Thr	Asn	Arg	Ile	Tyr	Arg	Ile	Leu	Glu	Leu
	290					295					300				
Asn	Gly	Tyr	Asp	Pro	Ala	Tyr	Ala	Gly	Ser	Val	Phe	Leu	Gly	Trp	Ala
305					310					315					320
Gln	Lys	Arg	Phe	Gly	Lys	Arg	Asn	Thr	Ile	Trp	Leu	Phe	Gly	Pro	Ala
				325					330					335	
Thr	Thr	Gly	Lys	Thr	Asn	Ile	Ala	Glu	Ala	Ile	Ala	His	Ala	Val	Pro
			340					345					350		
Phe	Tyr	Gly	Cys	Val	Asn	Trp	Thr	Asn	Glu	Asn	Phe	Pro	Phe	Asn	Asp
		355					360					365			
Cys	Val	Asp	Lys	Met	Val	Ile	Trp	Trp	Glu	Glu	Gly	Lys	Met	Thr	Ala
	370					375					380				
Lys	Val	Val	Glu	Ser	Ala	Lys	Ala	Ile	Leu	Gly	Gly	Ser	Lys	Val	Arg
385					390					395					400
Val	Asp	Gln	Lys	Cys	Lys	Ser	Ser	Ala	Gln	Ile	Asp	Pro	Thr	Pro	Val
				405					410					415	
Ile	Val	Thr	Ser	Asn	Thr	Asn	Met	Cys	Ala	Val	Ile	Asp	Gly	Asn	Ser
		420						425					430		
Thr	Thr	Phe	Glu	His	Gln	Gln	Pro	Leu	Gln	Asp	Arg	Met	Phe	Lys	Phe
		435					440					445			
Glu	Leu	Thr	Arg	Arg	Leu	Glu	His	Asp	Phe	Gly	Lys	Val	Thr	Lys	Gln
	450					455					460				
Glu	Val	Lys	Glu	Phe	Phe	Arg	Trp	Ala	Gln	Asp	His	Val	Thr	Glu	Val
465					470					475					480
Ala	His	Glu	Phe	Tyr	Val	Arg	Lys	Gly	Gly	Ala	Asn	Lys	Arg	Pro	Ala
				485					490					495	
Pro	Asp	Asp	Ala	Asp	Lys	Ser	Glu	Pro	Lys	Arg	Ala	Cys	Pro	Ser	Val
			500					505					510		
Ala	Asp	Pro	Ser	Thr	Ser	Asp	Ala	Glu	Gly	Ala	Pro	Val	Asp	Phe	Ala
	515						520					525			
Asp	Arg	Tyr	Gln	Asn	Lys	Cys	Ser	Arg	His	Ala	Gly	Met	Leu	Gln	Met
	530					535					540				
Leu	Phe	Pro	Cys	Lys	Thr	Cys	Glu	Arg	Met	Asn	Gln	Asn	Phe	Asn	Ile
545					550					555					560
Cys	Phe	Thr	His	Gly	Thr	Arg	Asp	Cys	Ser	Glu	Cys	Phe	Pro	Gly	Val
				565					570					575	
Ser	Glu	Ser	Gln	Pro	Val	Val	Arg	Lys	Arg	Thr	Tyr	Arg	Lys	Leu	Cys
			580					585					590		
Ala	Ile	His	His	Leu	Leu	Gly	Arg	Ala	Pro	Glu	Ile	Ala	Cys	Ser	Ala
	595						600					605			
Cys	Asp	Leu	Val	Asn	Val	Asp	Leu	Asp	Asp	Cys	Val	Ser	Glu	Gln	
610						615					620				

<210> 51

<211> 1872

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 51

atgccgggct	tctacgagat	cgtgatcaag	gtgccgagcg	acctggacga	gcacctgccg	60
ggcattttctg	actcgtttgt	gaactgggtg	gccgagaagg	aatgggagct	gcccccgat	120
tctgacatgg	atctgaatct	gattgagcag	gcacccctga	ccgtggccga	gaagctgcag	180
cgcgacttcc	tgggtccaatg	gcgcgcgcgtg	agtaaggccc	cggaggccct	cttctttgtt	240
cagtttcgaga	agggcgagtc	ctactttccac	ctccatattc	tgggtggagac	cacgggggtc	300
aaatccatgg	tgtctgggccc	cttcctgagt	cagattaggg	acaagctggg	gcagaccatc	360
taccgcggga	tcgagccgac	cctgccccaac	tggttcgcgg	tgaccaagac	gcgtaatggc	420
gccggaggggg	ggaacaagg	gggtggacgag	tgctacatcc	ccaactacct	cctgcccgaag	480

140140433P1.TXT

```

actcagcccc agctgcagtg ggcgtggact aacatggagg agtatataag cgcgtgtttg 540
aacctggccc agcgcaaacg gctcgtggcg cagcacctga cccacgtcag ccagaccag 600
gagcagaaca aggagaatct gaacccgaat tctgacgcgc ctgtcatccg gtcaaaaacc 660
tccgcgcgct acatggagct ggtcgggtgg ctggtggacc ggggcatcac ctccgagaag 720
cagtggtatcc aggaggacca ggcctcgtac atctccttca acgcccctc caactcgcgg 780
tcccagatca aggccgctct ggacaatgcc ggcaagatca tggcgctaac caaatccgcg 840
cccgaactacc tggtaggcc ccctcgcgcc gcggacatta aaaccaaccg catttaccgc 900
atcctggagc tgaacggcta cgaccctgcc tacgccggct ccgtctttct cggctgggccc 960
cagaaaaggt tcgggaagcg caacaccatc tggctgtttg ggccggccac cacgggcaag 1020
accaacatcg cggaagccat cgcacacgcc gtgccccttct acggctgcgt caactggacc 1080
aatgaaaact ttcccttcaa cgactgcgtc gacaagatgg tgatctggtg ggaggagggc 1140
aagatgacgg ccaaggtcgt ggagtccgcc aaggccattc tcggcggcag caaggtgcgc 1200
gtggaccaaa agtgcaagtc gtccgcccag atcgatccca ccccgtgat cgtcacctcc 1260
aacaccaaca tgtgcgcgct gattgacggg aacagcacca ccttcgagca ccagcagccg 1320
ttgcaggacc ggatgttcaa atttgaactc acccgccgtc tggagcacga ctttggcaag 1380
gtgacaaagc aggaagtcaa agagtcttct cgctgggccc aggatcacgt gaccgaggtg 1440
gcgcatgagt ttacgtcag aaaggggtgga gccacaaga gaccgcccc cgatgacgcg 1500
gataaaagcg agcccaagcg ggtctgcccc tcagtgcgag atccatcgac gtcagacgcg 1560
gaaggagctc cgggtggactt tgccgacagg taccaaaaca aatgttctcg tcacgcgggc 1620
atgcttcaga tgcgttttcc ctgcaaaaca tgcgagagaa tgaatcagaa tttcaacatt 1680
tgcttcacgc acgggaccag agactgttca gaatgtttcc ccggcgtgtc agaattctcaa 1740
ccggtcgtca gaaaaaggac gtatcggaaa ctctgtgcca ttcacatct gctggggcgg 1800
gtccccgaga ttgcttgctc ggcctgcgat ctggtcaacg tggacctgga tgactgtgtt 1860
tctgagcaat aa

```

<210> 52
 <211> 623
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Note =
 synthetic construct

<400> 52
 Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp
 1 5 10 15
 Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Asn Trp Val Ala Glu
 20 25 30
 Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile
 35 40 45
 Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg Asp Phe Leu
 50 55 60
 Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu Phe Phe Val
 65 70 75 80
 Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His Ile Leu Val Glu
 85 90 95
 Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe Leu Ser Gln Ile
 100 105 110
 Arg Asp Lys Leu Val Gln Thr Ile Tyr Arg Gly Ile Glu Pro Thr Leu
 115 120 125
 Pro Asn Trp Phe Ala Val Thr Lys Thr Arg Asn Gly Ala Gly Gly Gly
 130 135 140
 Asn Lys Val Val Asp Glu Cys Tyr Ile Pro Asn Tyr Leu Leu Pro Lys
 145 150 155 160
 Thr Gln Pro Glu Leu Gln Trp Ala Trp Thr Asn Met Glu Glu Tyr Ile
 165 170 175
 Ser Ala Cys Leu Asn Leu Ala Glu Arg Lys Arg Leu Val Ala Gln His
 180 185 190
 Leu Thr His Val Ser Gln Thr Gln Glu Gln Asn Lys Glu Asn Leu Asn
 195 200 205
 Pro Asn Ser Asp Ala Pro Val Ile Arg Ser Lys Thr Ser Ala Arg Tyr
 210 215 220

140140433P1.TXT

Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys
 225 230 235 240
 Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala
 245 250 255
 Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys
 260 265 270
 Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala
 275 280 285
 Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu
 290 295 300
 Asn Gly Tyr Asp Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala
 305 310 315 320
 Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala
 325 330 335
 Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro
 340 345 350
 Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp
 355 360 365
 Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala
 370 375 380
 Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg
 385 390 395 400
 Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val
 405 410 415
 Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser
 420 425 430
 Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe
 435 440 445
 Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln
 450 455 460
 Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val
 465 470 475 480
 Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala
 485 490 495
 Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Val Cys Pro Ser Val
 500 505 510
 Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala
 515 520 525
 Asp Arg Tyr Gln Asn Lys Cys Ser Arg His Ala Gly Met Leu Gln Met
 530 535 540
 Leu Phe Pro Cys Lys Thr Cys Glu Arg Met Asn Gln Asn Phe Asn Ile
 545 550 555 560
 Cys Phe Thr His Gly Thr Arg Asp Cys Ser Glu Cys Phe Pro Gly Val
 565 570 575
 Ser Glu Ser Gln Pro Val Val Arg Lys Arg Thr Tyr Arg Lys Leu Cys
 580 585 590
 Ala Ile His His Leu Leu Gly Arg Ala Pro Glu Ile Ala Cys Ser Ala
 595 600 605
 Cys Asp Leu Val Asn Val Asp Leu Asp Asp Cys Val Ser Glu Gln
 610 615 620

<210> 53

<211> 2689

<212> DNA

<213> Artificial Sequence

<220>

 <223> Description of Artificial Sequence: Note =
 synthethic construct

<400> 53

 ttgcgacagt ttgcgacacc atgtggtcac aagaggtata taaccgcgag tgagccagcg
 aggagctcca ttttggccgc gaagtttgaa cgagcagcag ccatgccggg gttctacgag

60

120

140140433P1.TXT

gtggtgatca	aggtgcccag	cgacctggac	gagcacctgc	ccggcatttc	tgactccttt	180
gtgaactggg	tggccgagaa	ggaatgggag	ttgcccccg	attctgacat	ggatcagaat	240
ctgattgagc	aggcaccctt	gaccgtggcc	gagaagctgc	agcgcgagtt	cctgggtggaa	300
tggcgccgag	tgaagtaaatt	tctggaggcc	aagttttttg	tgagtttga	aaagggggac	360
tcgtactttc	atttgcataat	tctgattgaa	attaccggcg	tgaaatccat	ggtgggtgggc	420
cgctacgtga	gtcagattag	ggataaaactg	atccagcgca	tctaccgcgg	ggtcgaagccc	480
cagctgcccc	actggttcgc	ggtcacaaaag	acccgaaatg	gcgccggagg	cggaacacag	540
gtggtggacg	agtgtacat	ccccaaactac	ctgctcccca	aggtccagcc	cgagcttcag	600
tgggcgtgga	ctaacatgga	ggagtatata	agcgcctgtt	tgaacctcgc	ggagcgtaaa	660
cggctcgtgg	cgcagcacct	gacgcacgtc	tcccagaccc	aggagggcga	caaggagaat	720
ctgaaccgga	attctgacgc	gccgtgtatc	cggctcaaaa	cctccgccag	gtacatggag	780
ctggtcgggt	ggctgggtgga	caagggcatc	acgtccgaga	agcagtggag	ccaggaggac	840
caggcctcgt	acatctcctt	caacgcggcc	tccaactccc	ggtcgcagat	caaggcggcc	900
ctggacaatg	cctccaaaat	catgagcctc	acaaaaacgg	ctccggacta	tctcatcggg	960
cagcgacccg	tggggggacat	taccaccaac	cggatctaca	aaatcctgga	actgaacggg	1020
tacgaccccc	agtacgcgcg	ctccgtcttt	ctcggctggg	cccagaaaaa	gtttggaaag	1080
cgcaacacca	tctggctgtt	tgggcccgcg	accaccggca	agaccaacat	cgcggaagcc	1140
atcggcccag	cggtccccctt	ctacggctgc	gtcaactgga	ccaatgagaa	ctttcccttc	1200
aacgactcgc	gggtgatttgg	gtggaggagg	tgggaggagg	gcaagatgac	cgccaagggtc	1260
gtagagtcgg	ccaaggccat	tctgggcccgc	agcaagggtc	gcgtggacca	aaaatgcaag	1320
gcctctgcgc	agatcgaccc	cacccccgtg	atcgtcacct	ccaacaccaa	catgtgcgcc	1380
gtgattgacg	ggaacagcac	caccttcgag	caccagcagc	ccctgcagga	ccggatgttc	1440
aagtttgaac	tcaccccgccg	cctcgaccac	gacttttgca	aggtcaccaa	gcaggaagtc	1500
aaggactttt	tccggtgggc	ggctgatcac	gtgactgacg	tggctcatga	gttttacgtc	1560
acaaaggggtg	gagctaagaa	aaggcccgcg	ccctctgacg	aggatataag	cgagcccaag	1620
cggccgcgcg	tgtcatttgc	gcagccggag	acgtcagacg	cggaagctcc	cggagacttc	1680
gccgacagggt	acaaaaacaa	atgttctcgt	cacgcgggta	tgtctcagat	gctctttccc	1740
tgcaagacgt	gcgagagaat	gaatcagaat	tccaacgtct	gcttcacgca	cggtcagaaa	1800
gattgcgggg	agtgttttcc	cggttcagaa	tctcaaccgg	tttctgtcgt	cagaaaaacg	1860
tatcagaaac	tgtgcacctt	tcacagctc	cgggggggcac	ccgagatcgc	ctgctctgct	1920
tgcgaccaac	tcaaccccga	tttggaacgt	tggcaatttg	agcaataaat	gactgaaatc	1980
aggtatggct	gctgacgggt	atcttccaga	ttggctcgag	gacaacctct	ctgaaggcat	2040
tcgcgagtg	tgggctgta	aacctggagc	tccacaaccc	aaggccaacc	aacagcatca	2100
ggacaacggc	aggggtcttg	tgcttccctg	gtacaagtac	ctcggaccct	tcaacggact	2160
cgacaaggga	gagccgggtca	acgaggcaga	cgccgcggcc	ctcagcacg	acaaggccta	2220
cgacaagcag	ctcgaagcag	gggacaaccc	gtatctcaag	tacaaccacg	ccgacgccga	2280
gttccagcag	cgcttgccga	ccgacacctc	ttttgggggc	aacctcgggc	gagcagcttt	2340
ccaggccaaa	aagaggattc	tcgagcctct	gggtctggtt	gaagagggcg	ttaaaacggc	2400
tcctggaaaag	aaacgcccct	tagaaaaagc	tccaatctcg	ccgaccaacc	cggactctgg	2460
gaaggccccc	gccaaagaaa	agcaaaaaga	cggcgaacca	gccgactctg	ctagaaggac	2520
actcgacttt	gaagactctg	gagcaggaga	cggaccccct	gagggatcat	cttccggaga	2580
aatgtctcat	gatgctgaga	tgcgtgcggc	gccaggcgga	aatgctgtcg	aggcgggaca	2640
aggtgccgat	ggagtgggta	atgcctccgg	tgattggcat	tgcatattcc		2689

<210> 54

<211> 621

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Note =
synthetic construct

<400> 54

Met	Pro	Gly	Phe	Tyr	Glu	Val	Val	Ile	Lys	Val	Pro	Ser	Asp	Leu	Asp
1				5				10						15	
Glu	His	Leu	Pro	Gly	Ile	Ser	Asp	Ser	Phe	Val	Asn	Trp	Val	Ala	Glu
			20					25					30		
Lys	Glu	Trp	Glu	Leu	Pro	Pro	Asp	Ser	Asp	Met	Asp	Gln	Asn	Leu	Ile
		35					40					45			
Glu	Gln	Ala	Pro	Leu	Thr	Val	Ala	Glu	Lys	Leu	Gln	Arg	Glu	Phe	Leu
	50					55					60				
Val	Glu	Trp	Arg	Arg	Val	Ser	Lys	Phe	Leu	Glu	Ala	Lys	Phe	Phe	Val

140140433P1.TXT

65	Gln	Phe	Glu	Lys	Gly	Asp	Ser	Tyr	Phe	His	Leu	His	Ile	Leu	Ile	Glu
					85					90					95	
	Ile	Thr	Gly	Val	Lys	Ser	Met	Val	Val	Gly	Arg	Tyr	Val	Ser	Gln	Ile
				100					105					110		
	Arg	Asp	Lys	Leu	Ile	Gln	Arg	Ile	Tyr	Arg	Gly	Val	Glu	Pro	Gln	Leu
				115				120					125			
	Pro	Asn	Trp	Phe	Ala	Val	Thr	Lys	Thr	Arg	Asn	Gly	Ala	Gly	Gly	Gly
				130				135				140				
	Asn	Lys	Val	Val	Asp	Glu	Cys	Tyr	Ile	Pro	Asn	Tyr	Leu	Leu	Pro	Lys
	145					150					155				160	
	Val	Gln	Pro	Glu	Leu	Gln	Trp	Ala	Trp	Thr	Asn	Met	Glu	Glu	Tyr	Ile
					165					170					175	
	Ser	Ala	Cys	Leu	Asn	Leu	Ala	Glu	Arg	Lys	Arg	Leu	Val	Ala	Gln	His
				180					185					190		
	Leu	Thr	His	Val	Ser	Gln	Thr	Gln	Glu	Gly	Asp	Lys	Glu	Asn	Leu	Asn
				195				200					205			
	Pro	Asn	Ser	Asp	Ala	Pro	Val	Ile	Arg	Ser	Lys	Thr	Ser	Ala	Arg	Tyr
				210			215					220				
	Met	Glu	Leu	Val	Gly	Trp	Leu	Val	Asp	Lys	Gly	Ile	Thr	Ser	Glu	Lys
	225					230					235				240	
	Gln	Trp	Ile	Gln	Glu	Asp	Gln	Ala	Ser	Tyr	Ile	Ser	Phe	Asn	Ala	Ala
					245					250					255	
	Ser	Asn	Ser	Arg	Ser	Gln	Ile	Lys	Ala	Ala	Leu	Asp	Asn	Ala	Ser	Lys
				260					265					270		
	Ile	Met	Ser	Leu	Thr	Lys	Thr	Ala	Pro	Asp	Tyr	Leu	Ile	Gly	Gln	Gln
				275				280					285			
	Pro	Val	Gly	Asp	Ile	Thr	Thr	Asn	Arg	Ile	Tyr	Lys	Ile	Leu	Glu	Leu
				290			295					300				
	Asn	Gly	Tyr	Asp	Pro	Gln	Tyr	Ala	Ala	Ser	Val	Phe	Leu	Gly	Trp	Ala
	305					310					315				320	
	Gln	Lys	Lys	Phe	Gly	Lys	Arg	Asn	Thr	Ile	Trp	Leu	Phe	Gly	Pro	Ala
					325					330					335	
	Thr	Thr	Gly	Lys	Thr	Asn	Ile	Ala	Glu	Ala	Ile	Ala	His	Ala	Val	Pro
				340					345					350		
	Phe	Tyr	Gly	Cys	Val	Asn	Trp	Thr	Asn	Glu	Asn	Phe	Pro	Phe	Asn	Asp
				355				360					365			
	Cys	Val	Asp	Lys	Met	Val	Ile	Trp	Trp	Glu	Glu	Gly	Lys	Met	Thr	Ala
				370			375					380				
	Lys	Val	Val	Glu	Ser	Ala	Lys	Ala	Ile	Leu	Gly	Gly	Ser	Lys	Val	Arg
	385					390					395				400	
	Val	Asp	Gln	Lys	Cys	Lys	Ala	Ser	Ala	Gln	Ile	Asp	Pro	Thr	Pro	Val
					405					410					415	
	Ile	Val	Thr	Ser	Asn	Thr	Asn	Met	Cys	Ala	Val	Ile	Asp	Gly	Asn	Ser
				420					425					430		
	Thr	Thr	Phe	Glu	His	Gln	Gln	Pro	Leu	Gln	Asp	Arg	Met	Phe	Lys	Phe
				435				440					445			
	Glu	Leu	Thr	Arg	Arg	Leu	Asp	His	Asp	Phe	Gly	Lys	Val	Thr	Lys	Gln
				450			455					460				
	Glu	Val	Lys	Asp	Phe	Phe	Arg	Trp	Ala	Ala	Asp	His	Val	Thr	Asp	Val
	465					470					475				480	
	Ala	His	Glu	Phe	Tyr	Val	Thr	Lys	Gly	Gly	Ala	Lys	Lys	Arg	Pro	Ala
					485					490					495	
	Pro	Ser	Asp	Glu	Asp	Ile	Ser	Glu	Pro	Lys	Arg	Pro	Arg	Val	Ser	Phe
				500					505					510		
	Ala	Gln	Pro	Glu	Thr	Ser	Asp	Ala	Glu	Ala	Pro	Gly	Asp	Phe	Ala	Asp
				515				520					525			
	Arg	Tyr	Gln	Asn	Lys	Cys	Ser	Arg	His	Ala	Gly	Met	Leu	Gln	Met	Leu
							535					540				
	Phe	Pro	Cys	Lys	Thr	Cys	Glu	Arg	Met	Asn	Gln	Asn	Ser	Asn	Val	Cys
	545					550					555				560	
	Phe	Thr	His	Gly	Gln	Lys	Asp	Cys	Gly	Glu	Cys	Phe	Pro	Gly	Ser	Glu
					565					570					575	

140140433P1.TXT
Ser Gln Pro Val Ser Val Val Arg Lys Thr Tyr Gln Lys Leu Cys Ile
580 585 590
Leu His Gln Leu Arg Gly Ala Pro Glu Ile Ala Cys Ser Ala Cys Asp
595 600 605
Gln Leu Asn Pro Asp Leu Asp Asp Cys Gln Phe Glu Gln
610 615 620